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Microbes frequently rely on metabolites excreted by other bacterial species, but little is 
known about how this cross-feeding influences the effect of antibiotics. We 
hypothesized that when species rely on each other for essential metabolites, the 
minimum inhibitory concentration (MIC) for all species will drop to that of the "weakest 
link"— the species least resistant in monoculture. We tested this hypothesis in an 
obligate cross-feeding system that was engineered between Escherichia coli, Salmonella 
enterica, and Methylobacterium extorquens. The effect of tetracycline and ampicillin 
were tested on both liquid and solid media. In all cases, resistant species were inhibited 
at significantly lower antibiotic concentrations in the cross-feeding community than in 
monoculture or a competitive community. However, deviation from the "weakest link" 
hypothesis was also observed in cross-feeding communities apparently as a result of 
changes in the timing of growth and cross-protection. Comparable results were also 
observed in a clinically relevant system involving facultative cross-feeding between 
Pseudomonas aeruginosa and an anaerobic consortium found in the lungs of cystic 
fibrosis patients. P. aeruginosa was inhibited by lower concentrations of ampicillin 
when cross-feeding than when grown in isolation. These results suggest that cross-
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No bacterium is an island 
An estimated 1012 species of bacteria are predicted to exist worldwide (1, 2), from 
expected environments such as doorknobs to toilet seats on the international space 
station (3). Yet, even the very concept of a species in bacteria may be flawed, with the 
macroscopic species definitions of reproductive isolation and genetic dissimilarity 
falling apart at the microscopic level (4–6). Bacteria exist in a world defined not by a 
species concept but by their environment and by their interactions with each other; 
interspecies interactions have shaped selection for possibly billions of years longer than 
any anthropomorphic selection pressure. Even antibiotics, one of the great public health 
advances of the 20th century, likely originally evolved in bacteria as a mechanism of 
competition and possibly communication, as well as functioning as a carbon source (7–
9). The importance of considering the bacterial community around a focal species, 
therefore, cannot be overstated.  
Historically, microbiological research has been performed using a reductionist approach 
of studying a single species in isolation. Particularly in the study of infectious agents, 
these monoculture studies have proved both useful and essential in the development of 
effective treatments for various bacterial diseases. In the context of a human infection, 
Koch’s postulates state that an infection is caused by a single infectious agent which can 
be transmitted to a healthy person and cause the same disease (10). However, a growing 
body of evidence suggests that not only do many infectious diseases occur in the context 
of an existing microbial community, but many infections are polymicrobial in nature 
(11–15). Nowhere is this more evident than in cystic fibrosis, where communities of 





decreases in lung function (16–18). From dental plaque (19, 20), to Pseudomonas 
aeruginosa– Staphylococcus aureus co-infections in ulcers and burn wounds (21, 22), to 
polymicrobial interactions in urinary tract infections (15), polymicrobial infections are 
increasingly recognized as significant detriments to human health.  
The ways in which microbes interact, and the ecological sign of those interactions, are 
myriad in their complexity and are likely underappreciated in how they contribute to 
microbial ecology and evolution. Quorum sensing, which was originally noted as a way 
for bacteria to sense the population sizes of their own species, is now being identified as 
a mechanism for interspecies and even interkingdom signaling (23–25). Interspecies 
quorum signals are known to alter expression of virulence genes, toxins, motility genes, 
and even metabolic processing (23, 26, 27) — suggesting that community context is an 
important factor in bacterial behavior and physiology. Horizontal gene transfer, wherein 
species exchange and acquire genetic material from others, has obvious implications for 
the transfer of antibiotic resistance (28, 29) but may also impact metabolic flexibility 
and evolution of novel metabolic pathways (30–32). Interference competition through 
the production of antibiotics, toxins, and other effectors has been harnessed by humans 
as a method of biological control in a variety of contexts (33–35). The exclusion of 
competitors by resource competition for nutrients or space has also been extensively 
studied; this is thought to be one mechanism behind the success of fecal microbiome 
transplants, where native flora are thought to more successfully compete for nutrients in 
the colonic environment than a C. difficile invader (36). Similarly, siderophore 
production as a mechanism of iron competition has been shown to influence 





downregulation antibiotic production in Streptomyces species in competitive 
environments (38), and prevent swarming of Vibrio alginolyticus near the siderophore 
producer Shewanella algae (39). 
Despite the focus of much research on competitive interspecies interactions, cooperative 
interactions among bacteria are also common in natural communities (40–43). 
Interspecies cooperation is likely to especially manifest in the phenomenon of cross-
feeding, wherein one species provides an essential metabolite that another is unable to 
synthesize or derive from the environment (44, 45). Many cross-fed nutrients have 
relatively little cost to producer species, and may explain how biodiversity is higher than 
ecological theory would predict in nutrient-poor environments (46). The prevalence of 
cross-feeding may explain the difficulty in culturing bacteria from natural environments 
in the lab— even in supposedly rich growth medium, bacteria may be unable to obtain 
essential nutrients in the absence of co-evolved partners (40). Cross-feeding has been 
shown to maintain species diversity in microbial communities (47) and lowers the 
energetic costs of metabolic processes such as amino acid production (40, 41, 48). This 
latter phenomenon makes cross-feeding an attractive field of research for biotechnology 
applications. Indeed, cellulose degradation and biofuel production using a consortium of 
bacterial species, each with a specific enzymatic role, has proven much more efficient 
than a single species producing all necessary enzymes (49–51). These lowered energetic 
costs may explain why cross-feeding is so common in natural communities, and has 
implications for community stability over time. 
Community stability may be measured in terms of (but not limited to) species richness 





theory and experimentation have shown that cooperative interactions such as cross-
feeding stabilize species richness at the expense of biomass, and that competitive 
interactions stabilize total biomass (47, 53). The latter phenomenon is often driven by 
the concept of competitive release, wherein the removal of a competitor species by some 
environmental pressure frees the focal species and allows it to propagate in the 
environment (54, 55). This concept is crucial in the development of antibiotic treatment 
regimens, especially in cases where resistance is thought to be associated with a fitness 
cost. The duration and intensity of the environmental pressure (in this case, an antibiotic 
course) must be sufficient to eliminate both sensitive and resistant strains of a pathogen; 
otherwise, the antibiotic will eliminate only the sensitive strains, thereby removing any 
competitors of the resistant strain (56). C. difficile invasion is also thought to occur via 
competitive release— the long-term antibiotic exposure that many C. difficile patients 
have undergone decimates natural intestinal communities, allowing C. difficile to 
colonize without competition (36). Given that pathogens are often viewed as invading 
species, it makes sense that research on the community context of infectious diseases has 
focused on competition. However, with more and more infections being recognized as 
polymicrobial and at least somewhat cooperative in nature, more research must be done 
on the role of cooperation, and its ability to stabilize species richness at the cost of 
biomass, in pathogenic bacteria. 
Antibiotic resistance (or is it tolerance?): definitions and mechanisms 
In an interview following his 1945 Nobel Prize win for the discovery of penicillin, 
Alexander Fleming warned the scientific community of the potential for the rapid 





millions of lives globally; however, antibiotic-resistant infections currently kill 700,000 
people globally per year and are estimated to kill 10 million people a year by 2050 (58). 
The baffling speed with which bacteria evolve and spread resistance has stymied the 
global health community. This, coupled with the relatively slow and ultimately 
ineffectual development of novel antimicrobials, have resulted in the need for creative 
solutions to this issue. Much evolutionary theory and experimentation have resulted in a 
relatively clear understanding of how antibiotic resistance evolves and spreads within, 
and even between, species— horizontal gene transfer has proved an especially common 
mechanism by which high-level resistance is exchanged between proximal bacteria. The 
relative fitness costs to a bacterium of carrying a resistance element, both 
chromosomally and exogenously encoded, have also been well-studied— resistance is 
generally costly to a bacterium, and may be lost in non-selective environments (this is 
particularly true of resistance plasmids). Despite this, the problem remains— bacteria 
evolve resistance quickly, and the costs of resistance are insufficient to keep resistance 
from spreading in bacterial populations and communities. 
The terminology surrounding antibiotic resistance is often imprecise and terms such as 
resistance and tolerance are used interchangeably. However, throughout this thesis I will 
be using the following terminology based on recommendations from Brauner et al. (59). 
Antibiotic resistance is defined as a genetic mechanism which confers a heritable 
increased ability to grow and/or survive at increased antibiotic concentrations. Antibiotic 
tolerance, in contrast, may be considered a phenotypic trait describing the ability of a 
species to grow transiently at high antibiotic concentrations. A given population of 





environmental conditions (or vice versa). Tolerance is also a useful term for describing 
antibiotic responses at the community level. ‘Community tolerance’ (i.e. the ability of a 
community to grow in the presence of antibiotic) makes more sense than ‘community 
resistance’, which may incorrectly assume genetically encoded resistance mechanisms 
for each community member.  
Cellular mechanisms of antibiotic resistance have been described exhaustively elsewhere 
(60–66); I will provide a brief explanation here for context. Cellular-level resistance may 
be broken up into four main types: target modification, target bypass, efflux/ uptake, and 
antibiotic inactivation. The former two may generally be considered ‘private’ resistance 
mechanisms; that is, they confer resistance only on the cells which contain the requisite 
mutations. The latter two, however, have the potential to influence antibiotic effects on 
other cells in the population, with antibiotic inactivation even representing a mechanism 
of public-goods resistance. Target modification involves modifications to the target site 
of antibiotics which reduce antibiotic binding and/or inhibition of the target; notable 
examples include rpoB mutations in rifampicin resistance which prevent binding to 
RNA polymerase (67) and gyrA mutations which prevent fluoroquinolone binding and 
inhibition of gyrase (68). Target bypass involves expression of an alternate cellular 
pathway which decreases the cell’s dependence on an antibiotic-inhibited pathway. For 
example, resistance to trimethoprim, a folate biosynthesis inhibitor, often occurs via 
duplication or increased expression of dihydrofolate reductase, an essential enzyme in 
folate biosynthesis (69). Resistance-conferring porin mutations (via a change in type, 
expression, or function) are common but confer low levels of resistance on their own 





tends to confer high-level resistance to a broad spectrum of antibiotics (63). Enzymatic 
degradation of antibiotics is perhaps most commonly associated with β-lactamases 
which degrade β-lactam antibiotics such as penicillin; however, degradation enzymes 
also exist for a variety of other antibiotics (61, 70). These mechanisms are not mutually 
exclusive to an antibiotic or a species. β-lactam resistance, for example, may arise by 
any of these mechanisms: mutations in penicillin-binding proteins (PBPs) which 
decrease its affinity for β-lactam antibiotics; decreased cell wall permeability and/or 
efflux pump expression; β-lactamase degradation of the antibiotic, or expression of 
PBPs with low β-lactam binding affinity (71). Generally, resistance mutations which 
confer increased drug efflux/ decreased drug uptake confer lower levels of resistance 
than those that modify the drug or its target (72).  
In addition to the antibiotic class-specific mechanisms described above, bacteria can also 
evolve more generalized resistance through a more global modification of cellular 
functions such as stress response and growth rate. These mutations, which often occur in 
global stress response regulators such as the Mar, Sox, and Rob regulons in 
Enterobacteriaceae, often play a significant role in increasing broad-spectrum antibiotic 
resistance by inducing multidrug efflux pump expression, decreasing cell wall 
permeability, and inducing a protective dormant state (73–75). Modifications to cellular 
growth rate have long been known to increase phenotypic antibiotic tolerance; the 
phenomenon of persister cells, which are heterogeneously metabolically inactive but 
highly antibiotic tolerant (76), has proven challenging in eliminating pathogens such as 
Staphylococcus aureus, Mycobacterium tuberculosis, uropathogenic E. coli, and others 





rate of resistance evolution, as the pool of possible resistance mutations expands (78–
80); horizontal gene transfer (HGT) and genomic rearrangements can greatly increase 
mutation rates (72), as can antibiotics themselves (60, 80). 
Changes in cellular metabolism can also induce antibiotic tolerance (81, 82). Particularly 
for antibiotics which target specific cellular pathways, diversion of metabolic flux away 
from these pathways may diminish or eliminate the effectiveness of the antibiotic. In E. 
coli grown in rich medium, bleomycin application at low concentrations is lethal and 
induces a strong SOS response to repair double-stranded breaks induced by the drug. In 
minimal medium, however, E. coli are resistant to bleomycin and show fewer double-
stranded breaks; the authors speculate that the change in nutrient environment induced a 
transcriptomic shift that led to this increased tolerance (83). Increased nutrient 
availability can also induce tolerance: methionine antagonizes para-aminosalicylic acid 
killing of Mycobacterium tuberculosis (84), and addition of N and P increased 
Enterococcus faecalis resistance to a variety of antibiotics (85). In these cases, nutrient 
environment can greatly alter the costs and even the possibility of tolerance arising in a 
population. However, the difficulty in quantifying the specific metabolites available in 
infection sites, for example, has made this type of work challenging.  
One possible solution to the relative ease with which bacteria can induce tolerance is the 
use of multiple antibiotics to treat an infection. Combination therapy, wherein multiple 
antibiotics are administered at the same time, has two main goals. First, it may be 
clinically necessary in cases where a single drug is ineffective at tolerable concentrations 
(as is the case in tuberculosis) (86), or in cases where the most effective antibiotic is 





antibiotics synergize with each other; that is, they are more effective (and can be used in 
lower dosages) when administered together than when they act alone. Antibiotics may 
also antagonize each other, becoming less effective when used in combination than 
when used alone. A well-established example of this is the use of protein synthesis 
inhibitors such as tetracycline alongside DNA synthesis inhibitors such as ciprofloxacin. 
Use of a single drug causes a cellular imbalance in the DNA to protein ratio in cells 
which slows their growth; using both drugs in combination, however, restores the ratio 
and allows rapid growth to resume (88). 
The most widespread use of synergizing compounds in treatment of bacterial infections 
is the use of antibiotic adjuvants, compounds which alone have no antimicrobial activity 
but which potentiate the activity of antibiotics (89). For example, β-lactam antibiotics 
are often administered in conjunction with clavulanic acid or other β-lactamase 
inhibitors. These compounds covalently bind and inhibit the β-lactamases present in 
many clinically relevant pathogens such as Acinetobacter baumanii, and are currently 
the focus of much research (90, 91). Beyond adjuvant therapy, however, use of 
antibiotics in combination therapy in the clinic has had mixed success (92, 93). It also 
remains unclear how combination therapy affects microbial communities, as few 
antibiotic interaction studies have been performed using multispecies systems. One 
study, however, found that synergizing combinations of arginine and fluoride suppressed 
the growth of caries— inducing oral bacteria. In a mixed community of Streptococcus 
mutans, Streptococcus sanguinis, and Porphyromonas gingivalis, the arginine-fluoride 
combination suppressed the growth of acid-producing S. mutans growth and facilitated 





suppressed in the presence of arginine-fluoride, likely due to increased competition from 
the streptococci (94). However, in this study, the precise nature of the interspecies 
interactions was unknown, making such effects difficult to predict in other communities.  
Factors impacting antibiotic resistance evolution: a little nudge has a big effect 
It is well established that the context in which bacteria acquire resistance can have 
significant impacts on the type of resistance mechanism they evolve, as well as the 
fitness costs of resistance. The canonical view of antibiotic resistance evolution, or 
indeed of evolution in general, is that a selection pressure is required to make one 
genotype (in this case, a resistant genotype) more fit versus other genotypes. Over time, 
this genotype will spread in the population to some optimal frequency and remain as 
such until the environment shifts such that it is no longer the most fit. However, in the 
case of antibiotic resistance, many additional parameters factor into the biologically– 
and environmentally– dependent fitness costs of resistance.  
Predicting the evolutionary trajectory of antibiotic resistance evolution requires 
information about mutation rates, the level of resistance conferred by a given mutation, 
the fitness of the resistant mutant at a given antibiotic concentration, and the strength of 
the antibiotic selection pressure (60, 72). When mutation supplies are limited (due to 
small population sizes, low mutation rates, and/or small mutation target sizes), the most 
likely resistance mutation to be selected is the one which arises first or at all; if mutation 
supplies are less limited, clonal interference may cause the resistant mutant with the 
highest competitive fitness to be selected (72, 95). For example, a study of ciprofloxacin 





the few surviving resistant clones to do so with their competitive fitness relatively intact 
(68). Another study found that population size alters antibiotic tolerance and some 
changes in tolerance were associated with changes in extracellular pH during the 
exponential growth phase (96)— suggesting that population size may modulate 
environmental parameters affecting antibiotic tolerance. In clinical settings, the 
appearance and frequency of antibiotic resistance does not appear to be correlated with 
mutation rates; this is likely because bacterial population sizes in infection contexts are 
sufficiently high to supply pre-existing resistance mutations into an infected host, rather 
than relying on a high mutation rate to generate resistant mutants during the course of an 
infection (60, 72).  
Resistance mutations do not always carry fitness costs, particularly in competitive 
environments and in vivo models of infection (60, 97). For example, rifampicin and 
nalidixic acid resistance mutations in E. coli have been shown to increase fitness over 
non-resistant mutants in nutrient-limited antibiotic–free environments (98). In 
Pseudomonas putida genetically diverse colonies, selection for private mechanisms of 
resistance (e.g. rpsL mutations which modify the target site of streptomycin) occurs 
quickly and even at low concentrations of antibiotic (99). Even if resistance mutations 
are initially costly, subsequent rounds of evolution (in the clinic or in the natural 
environment) decreases these costs through compensatory mutations (97); for example, 
by making a costly resistance gene inducible only in the presence of an antibiotic (100). 
Identifying the context in which mutations are costly and where they are not, therefore, 
becomes critical in predicting where and when they will be selected. This makes it 





relevant scenarios, such as the polymicrobial nature of many infection contexts (11, 19, 
101), or in environmental microbial communities where high, sustained concentrations 
of antibiotics are unlikely (102). In these contexts, in conjunction with the fact that high-
fitness-cost resistance genes are expected to be lost in the absence of antibiotic selection, 
resistance genes which successfully spread in bacterial populations (including to 
pathogens) have also likely evolved to lower the fitness cost of carriage and expression 
(102). This phenomenon of low-cost resistance likely contributes to the difficulty in 
eliminating resistant pathogens in infection contexts, where antibiotic-sensitive 
competitors do not have the fitness advantage that they might otherwise have in, for 
example, an in vitro lab scenario where resistance has been newly introduced to a strain 
on a plasmid. It is therefore critical to identify novel resistance mechanisms as they 
evolve, and before they spread through a bacterial population alongside compensatory 
mutations that decrease their fitness costs.  
Genetic background and epistasis also impact the fitness costs and benefits of resistance 
mutations (60, 100). When streptomycin resistance was added to E. coli rifampicin-
sensitive and resistant genetic backgrounds evolved in the absence of antibiotics, the 
rifampicin-resistant backgrounds showed less of a fitness cost for streptomycin 
resistance than the rifampicin-sensitive background (103). This suggests that adaptation 
to a given environment by a previously resistant strain diminishes the cost of resistance 
to a new antibiotic. However, a phenomenon known as collateral sensitivity has also 
demonstrated the opposite effect— that high-level resistance to one antibiotic can result 
in sensitivity to many others (104–106). In an analysis of co-evolved polymorphisms in 





observed to be strongly epistatic, likely because PBPs are part of a multimeric complex 
(107). This epistasis is manifested in the observations that mutations in multiple PBPs 
are required to develop resistance, and in that fitness defects caused by mutations in one 
PBP are compensated for by mutations in other PBPs (108). Similar epistatic patterns 
have also been observed in Neisseria gonorrhoeae resistance to cephalosporins and 
penicillin (109). The genetic background and evolutionary history of a given species, 
therefore, is critical in understanding its present and future resistance profiles.  
Rates of resistance evolution are affected by a variety of factors and can have additional 
effects on the fitness costs of resistance mutations. Generally, high-dosage antibiotics 
are expected to select for high-cost, high-benefit resistance; however, as described 
above, there are many factors which might determine the specific costs and benefits of 
resistance (see (72) for a comprehensive review). Low-dose antibiotics, particularly 
sublethal antibiotics, are known to select for low-cost but often high-benefit resistance. 
In these cases, the distribution of mutations which allows for survival is larger, thereby 
increasing the possibility of acquiring a big-benefit, low cost mutation or a series of 
compounding low-cost, low benefit mutations (67, 99, 110–112). Modeling experiments 
have also shown that antibiotic gradients may alter the evolutionary trajectory of 
resistance, though the extent and precise effects are dependent on the mutational 
pathway of resistance development and the fitness effects of sequential mutations (113). 
If sequential mutations increase resistance monotonically, gradients can accelerate 
resistance evolution by increasing selection on the most resistant sub-population. If, 
however, there are epistatic interactions between resistance mutations leading to 





slow resistance evolution due to smaller effective population sizes of most fit/ most 
resistant mutants (113). In situations where resistance has a longer mutational pathway 
(i.e. a greater number of independent mutations required for high-level resistance), 
gradients also increase the rate of resistance evolution (113).  
Overall, antibiotic resistance evolution is highly complex and modulated by a variety of 
genetic and environmental factors. While most of these are beyond the scope of this 
work, it is important to mention them as it is likely, if not probable, that all of them are 
playing some role in the experiments described here. Despite the decades of research 
being done on antibiotic resistance, many questions remain as to how it arises and how 
best to mitigate its spread in human-impacted settings. My research focuses particularly 
on antibiotic resistance evolution and ecology in a microbial community, and the role of 
metabolic interactions on resistance manifestation and mechanisms. However, it is worth 
noting that this is only a tiny (if often overlooked) aspect of resistance evolution, and 
many other factors may be at play in my work than the ones that I discuss.  
One for all, and all for one: antibiotic resistance and tolerance in microbial 
communities 
The problem with only taking resistance mechanisms into account when studying, and 
trying to prevent the evolution of, antibiotic resistance, is that resistance mechanisms are 
often viewed in a single-cell or single-species context; they occur in, and benefit, only 
one cell at a time. However, antibiotic resistance frequently evolves and occurs in 
polymicrobial contexts— from periodontal disease to chronic wound infections to 





frequently more serious than mono-species infections (115–117). Polymicrobial 
infections are a great challenge in antimicrobial treatment— with multiple species 
present, will a narrow-spectrum antibiotic be an effective treatment? Or should a broad-
spectrum antibiotic be used, which increases the rate of resistance acquisition in other 
bacteria and potentially decimates the natural microbial communities in the host? In 
these infections, the ecology of the infection and the precise nature of the interactions 
between the species involved could prove essential in understanding the best treatment 
protocol. 
The concept of shared, or public-good, antimicrobial resistance is especially critical in 
polymicrobial infection contexts. In a monoculture, the fitness costs of target site 
modification (e.g. rpoB mutations in rifampicin resistance) might be less than that of 
enzymatic inactivation (e.g. production of a β-lactamase). However, if the resistant 
species is engaged in a mutualism with another sensitive species, the production of a 
publicly available resistance mechanism may be evolutionarily favorable. In this 
context, production of a β-lactamase functions as a public good — something that comes 
at a cost to the producer but that benefits the whole community. One would predict that 
public-goods resistance would be more likely to evolve in microbial communities with 
high levels of interdependence, but few studies have examined this. Conversely, the 
production of public-goods resistance might complicate the relationship between a 
pathogen and the native microbial communities with which it ostensibly completes 
during an infection. The evolutionary dynamics of an invader which competes for space 
and nutrients with native species but also protects them from antibiotic pressure remains 





Polymicrobial communities are particularly prevalent in biofilm-associated infections 
(114). Biofilms represent a growth phase of bacteria wherein they adhere to a surface 
and produce an exopolysaccharide matrix to maintain their position. This matrix serves a 
variety of functions, but mainly works to protect the bacteria from external 
environmental disturbances, such as mechanical disturbances, phage predators, and 
antimicrobials (118). Mixed-species biofilms are significantly more resistant to 
antibiotics than planktonic cultures or single-species biofilms, sometimes through the 
acquisition and transfer of resistance elements between species but also by minimizing 
exposure to antimicrobials though factors such as exopolysaccharide production (119), 
breakdown of antibiotics by one species which protects other sensitive species (120–
122), or induction of stress response genes in neighboring sensitive bacterial species 
(123–125). Biofilms also create spatially structured environments wherein different 
bacterial species can engage in beneficial cross-feeding interactions which would be 
impossible in a planktonic growth/ mass action environment. For example, in a synthetic 
community of Acinetobacter sp. Strain C6 and Pseudomonas putida strain R1, 
planktonic co-cultures competed for benzyl alcohol, their sole carbon and energy source. 
However, under biofilm conditions, these species grew synergistically, with 
Acinetobacter consuming the benzyl alcohol and excreting a benzoate intermediate 
where it is preferentially consumed by P. putida (126). Therefore, understanding the 
metabolic interactions between bacterial species is critical for assessing their response to 
external selection pressures such as antibiotics.  
Additionally, growth in a multispecies community has been demonstrated to protect 





signaling molecule indole has received great attention for its ability to modulate gene 
expression in recipient cells to increase their antibiotic tolerance. In an E. coli– 
Pseudomonas putida mixed-species community, indole production by E. coli induced 
expression of a multidrug efflux pump in P. putida, increasing its tolerance to a variety 
of antibiotics (125). Similarly, S. enterica tolerance to carbenicillin and ciprofloxacin 
increased when indole production from co-cultured E. coli resulted in induction of the S. 
enterica SOS response (123). Interspecies quorum sensing, which is widespread in 
interspecies communities (25), can induce expression of multidrug efflux pumps and 
subsequent increases in antibiotic tolerance (128, 129). These factors, in addition to 
those described above, clearly indicate that antibiotic resistance and tolerance can be 
modulated by interspecies interactions in myriad ways. One avenue of research that has 
been less explored, however, is how cooperative metabolic exchange might impact 
resistance ecology and evolution.  
The idea that metabolic interactions might modulate antibiotic resistance ecology and 
evolution has remained an outstanding question in both the microbial ecology and the 
microbiology fields. However, much research suggests that bacterial metabolism and 
antibiotic resistance are inexorably linked, raising some testable hypotheses as to the 
nature of these interactions. For example, mutations in rpoB conferring rifampicin 
resistance can have wide-ranging effects on bacterial growth phenotypes and pleiotropic 
effects on gene expression throughout the cell, as rpoB mutations modify the 
functionality of RNA polymerase and therefore may have a profound effect on global 
cellular transcription (130). rpoB mutations have also been shown to modify metabolic 





relationship between species and potentially change the fitness cost of resistance in 
monocultures vs. multispecies communities. Antibiotic resistance mutations have also 
been shown to cause metabolic network rearrangement (131), increase expression of 
secondary metabolism pathways (132), and modify substrate utilization capabilities 
(130). Generally, resistance mutations depress metabolic capabilities, but some 
pathways are also expressed only in the presence of resistance mutations (130, 132). 
This is one possible mechanism by which resistance evolution might differ between 
monocultures and multispecies systems. 
The research being performed on how competition impacts resistance evolution and 
ecology has yielded some interesting insights. Generally, competition increases 
resistance evolution— likely partially because competition may involve nutrient 
limitation, which can induce antibiotic tolerance as described above. One mathematical 
model suggests that resistance evolution is only prevented by high dosages of antibiotics 
if competition between resistant and sensitive species is minimal, or if the resistant 
species is a poor competitor. If the resistant strain is more fit, however, a moderate 
antibiotic dose is more effective as it allows the sensitive strain to better compete with 
the resistant strain (133). In a study of two species of Candida competing for a shared 
carbon source (glucose), changes in both antifungal concentration and nutrient 
availability were shown to drive different species of different resistance phenotypes to 
dominate the community. This effectively allowed resistant phenotypes to increase in 
frequency even if the antifungal was withdrawn (134). In a co-culture of Burkholdaria 
thailandensis and Chromobacterium violaceum, nutrient competition is mediated 





Additionally, C. violaceum quorum sensing allows it to upregulate an efflux pump to 
increase its resistance to B. thailandensis produced antimicrobials (129). Interspecies 
competition also drives Bacillus subtilis efflux pump expression as a response to 
antibiotics produced by a Streptomyces co-cultured competitor (135). This phenomenon 
may happen in the clinic as well as in laboratory co-cultures — competition between co-
evolving Staphylococcus aureus strains has been shown to facilitate the evolution of 
clinically relevant vancomycin resistance (136). While nutrient competition can increase 
resistance evolution, or at least modulate the resistance evolution trajectory, few studies 
have yet specifically tested the impact of cooperative metabolic interactions on 
resistance. 
How does metabolic cross-feeding modulate bacterial responses to antibiotics? 
Antibiotic resistance is a broad field, and as such a myriad of approaches have been 
taken to attempt to mitigate resistance evolution and spread. Significant work has been 
done especially on the cellular and global mechanisms of resistance, as well as their 
associated fitness costs. Additionally, polymicrobial communities are known to facilitate 
tolerance induction and resistance evolution through a variety of interspecies 
interactions including horizontal gene transfer, small molecule signaling, and public-
goods resistance. When looking specifically at metabolic interactions between bacteria, 
however, only competitive interactions have hitherto been explored as potentially 
impacting resistance evolution. To date, only one study - aside from the ones described 
here - has looked specifically at how resistance in microbial communities is impacted by 





communities, including those containing pathogens, it is an important area of research to 
investigate. 
The goal of my thesis work is to draw together hypotheses from many fields described 
above (clinical microbiology, microbial ecology, evolutionary biology, bacterial 
genetics, etc.) to develop a more cohesive understanding of how obligate metabolic 
exchange between bacterial species impacts antibiotic resistance. The main system I 
used to conduct this research is an engineered two– or three– species synthetic 
consortium of Escherichia coli, Salmonella enterica serovar Typhimurium, and 
Methylobacterium extorquens. This system was previously engineered such that any 
species (or combination thereof) can be grown independently, competitively, or in 
obligate cooperation depending on the nutrient sources supplied in minimal medium. 
The E. coli strain is an engineered MG1655 strain containing a clean deletion of metB, a 
cystathionine gamma-synthase required for methionine biosynthesis (137). The S. 
enterica strain was evolved and selected in a two-step process to create a strain which 
excretes methionine at sufficient concentrations to sustain the E. coli auxotroph in 
methionine-free medium. First, S. enterica LT2 was grown on ethionine, a toxic 
methionine analog that represses methionine biosynthesis. Ethionine resistance arose 
through mutations in metJ, a transcriptional repressor of several methionine biosynthesis 
genes (138). The metJ mutants were then plated on lactose minimal medium with E. coli 
methionine auxotrophs. In this environment, S. enterica is unable to grow unless E. coli 
metabolizes lactose to acetate, and E. coli is unable to grow unless S. enterica secretes 
methionine; thus, consortium growth only occurred if a S. enterica methionine-excreting 





(homoserine trans-succinylase) mutation which stabilized enzyme homodimer formation 
(139). This two-species system could then grow independently (E. coli on lactose and 
methionine, S. enterica on acetate or glucose) or in obligate co-culture (in lactose 
medium only). Later, a third species, Methylobacterium extorquens, was added to the 
system. M. extorquens is a model organism for C1 metabolism and produces NH3 from 
single-carbon compounds such as methylamine. To allow for obligate growth in the 
consortium, the hydroxypyruvate reductase gene hprA was deleted; this allowed M. 
extorquens to assimilate nitrogen but not carbon from C1 compounds, forcing it to rely 
on E. coli for carbon in the form of acetate. In return, M. extorquens could provide NH3 
to E. coli and S. enterica (140). This system is unique in that the interactions between 
species can be precisely calibrated by manipulating nutrient availability and serves as a 
useful tool in investigating the impact of interspecies interactions on antibiotic tolerance.  
My thesis focuses on three main questions relating to how microbial communities 
respond to antibiotic pressure. The null hypothesis underlying much of this work is that 
metabolic dependencies determine community survival; that is, the loss of any one 
metabolite producing community member will cause the death of the others. I call this 
the “weakest link” hypothesis— the community is only tolerant of a given selection 
pressure to the point that its weakest member is tolerant. Though there are many factors 
influencing antibiotic tolerance as described above, the weakest link hypothesis is a 
useful entry point into these investigations as it is easily tested in our system. The first 
question I sought to answer is this: can community antibiotic tolerance be predicted by 
weakest link dynamics? Using the above three–species system, I found that this is 





hypothesis to evolutionary timescales to see how weakest link dynamics might impact 
the rate and mechanisms of antibiotic resistance evolution. Again, I found that metabolic 
dependencies slow resistance acquisition, though their impact on mechanism was mixed. 
In chapter 4, I added an additional layer of complexity by asking how drug interactions 
might be modulated by cross-feeding and weakest link dynamics. Here, I found that 
weakest link–based predictions of antibiotic interactions in co-cultures were generally 
correct, and that weakest link dynamics can largely nullify antagonistic or synergistic 
antibiotic interactions which may be present in monoculture. Overall, my work 
demonstrates that metabolic interactions are both an important factor in determining 
community response to antibiotics and represent a potentially untapped tool in research 














Microbes frequently rely on metabolites excreted by other bacterial species, but little is 
known about how this cross-feeding influences the effect of antibiotics. We 
hypothesized that when species rely on each other for essential metabolites, the 
minimum inhibitory concentration (MIC) for all species will drop to that of the "weakest 
link" — the species least resistant in monoculture. We tested this hypothesis in an 
obligate cross-feeding system that was engineered between Escherichia coli, Salmonella 
enterica, and Methylobacterium extorquens. The effect of tetracycline and ampicillin 
were tested on both liquid and solid media. In all cases, resistant species were inhibited 
at significantly lower antibiotic concentrations in the cross-feeding community than in 
monoculture or a competitive community. However, deviation from the "weakest link" 
hypothesis was also observed in cross-feeding communities apparently as result of 
changes in the timing of growth and cross-protection. Comparable results were also 
observed in a clinically relevant system involving facultative cross-feeding between 
Pseudomonas aeruginosa and an anaerobic consortium found in the lungs of cystic 
fibrosis patients. P. aeruginosa was inhibited by lower concentrations of ampicillin 
when cross-feeding than when grown in isolation. These results suggest that cross-






Antibiotic resistant bacteria pose a considerable public health threat worldwide; the 
World Health Organization reports that 25-50% of hospital-acquired pathogens are now 
multiple-drug-resistant (141). Despite extensive research on cellular mechanisms of 
resistance in many bacterial species (142, 143), a growing body of research suggests that 
a single-species view of pathogen response to an antibiotic may be incomplete. Many 
infections are known to involve multiple pathogens (15, 101) or interactions between 
pathogens and commensals, (11, 17, 19). As well, we still have little understanding of 
how interspecies ecological interactions influence the impact of antibiotics on microbial 
communities. 
Growth in a microbial consortium can influence a species’ antibiotic tolerance by 
multiple mechanisms (124, 144, 145). Resistant species can protect more sensitive 
species by degrading antibiotics; for example, production of antibiotic-degrading 
enzymes by one species causes detoxification of shared growth medium (122, 124, 146). 
Additionally, secretions from one species can induce resistance mechanisms in others; 
for example, by activating stress-response pathways (123) or efflux pump expression 
(125). Spatial structure may also play a role in protective interactions; a synthetic 
community of Pseudomonas aeruginosa, Pseudomonas protegens, and Klebsiella 
pneumoniae was found to have greater tobramycin resistance when grown as a 
multispecies biofilm versus single species biofilm or multispecies planktonic culture 
(147). Less directly, community growth may alter antibiotic resistance by inducing 





(148–151). In many cases, however, mechanisms underlying communities' effects on 
resistance remain unclear (15). 
Few studies have investigated how exchange of essential nutrients in a bacterial 
community modulates the impact of antibiotics (55, 152). When metabolites produced 
by one organism are used as a nutrient or energy source by another it is known as cross-
feeding (42, 153). This phenomenon is nearly ubiquitous in microbial communities (41, 
43, 154) and is thought to contribute to our inability to cultivate most bacterial species in 
isolation (155, 156). Cross-feeding has also been shown to play a critical role in the 
human microbiome (20, 157, 158). Given the ubiquity and importance of cross-feeding 
in human-associated microbial communities, greater investigation into how cross-
feeding influences population and community responses to antibiotics is needed.  
Here, we test how cross-feeding changes the effect of antibiotics on bacterial 
communities. We define tolerance as the ability of species to grow in a given antibiotic 
concentration. Tolerance as we define it can change as a function of physiological state 
or environmental conditions, while changes in resistance would require a change in 
DNA sequence (59). We hypothesize that when species depend on one another the 
community tolerance (i.e. the level of antibiotic required to inhibit detectable community 
growth) will be set by the tolerance of the ‘weakest link’ (the least tolerant community 
member). Alternatively, community tolerance may be higher than that of the weakest 
species in monoculture (‘community protection’ hypothesis), or lower (‘community 
sensitivity’ hypothesis). Higher than expected tolerance may occur if one or more 
species in a community excretes a compound which either actively degrades antibiotics 





expression in neighboring species (125, 127). Lower than expected tolerance could 
result if sublethal concentrations of antibiotic, while not sufficient to arrest or kill any 
one species, sufficiently disrupt cross-feeding to inhibit community growth.  
We tested the impact of cross-feeding using an engineered obligate mutualism involving 
Escherichia coli, Salmonella enterica serovar Typhimurium, and Methylobacterium 
extorquens (159). In one minimal medium, these species rely on each other for essential 
metabolites in a cooperative community (Figure 2.1A). However, if essential 
metabolites are provided in the medium, the species can be grown as monocultures, or in 
a competitive community (Figure 2.1B). We compared the tolerance of each species 
grown in monoculture to tolerance in the mutualism, both overall in the community and 
at the species level. Our system is ideal to test our ‘weakest link’ hypothesis because the 
mechanism of dependency between species is known, and the identity of the weakest 
link can be changed by altering the antibiotic used. This system allows us to rigorously 
connect observed changes in tolerance to ecological interactions between species. 
To test the generality of our hypotheses, and to determine conditions under which 
deviation from them might occur, we employed multiple experimental setups. We tested 
two antibiotics with different mechanisms of action— ampicillin is a bactericidal 
inhibitor of cell wall synthesis (124), whereas tetracycline is a bacteriostatic protein 
synthesis inhibitor (61). Additionally, ampicillin resistance commonly arises as a 
function of enzymatic degradation by β-lactamases (61), allowing the potential for cross-
protection of less tolerant species (124). Conversely, tetracycline resistance often 
involves mutations that would only protect the species that possesses them, such as 





enzymes do exist, but are far less common than β-lactamases (160, 161). The impact of 
these antibiotics was tested in both liquid media and on agar plates to test the influence 
of spatial structure. Finally, we investigated the effect of cross-feeding on tolerance in a 
model relevant for cystic fibrosis. This second system involves two components: the 
pathogen Pseudomonas aeruginosa, which grows poorly on mucin, a major carbon 
source in the cystic fibrosis lung; and a previously defined consortium of anaerobic 
bacteria that break down mucin into usable metabolites for P. aeruginosa (18). 
Changing antibiotics, environmental structure, and model systems makes it possible to 
identify both system-specific and general impacts of cross-feeding on antibiotic 
tolerance. 
Across all treatments and both model systems, resistant bacteria were inhibited by lower 
concentrations of antibiotic when cross-feeding than when growing independently. 
However, we found that cross-feeding can conditionally provide protection to less 
tolerant bacteria. For both ampicillin and tetracycline, cases arose in which tolerance 
was higher than predicted based on measurements of tolerance in monoculture. Our 
results demonstrate that metabolic interactions impact antibiotic tolerance in a 
community and suggest that antibiotic-resistant pathogens may be inhibited by targeting 







Bacterial strains and media 
The three-species community contained strains of Escherichia coli, Salmonella enterica 
and Methylobacterium extorquens described previously (53, 159). The E. coli str. K12 
contains a ΔmetB mutation. The S. enterica strain excretes methionine as a result of 
mutations in metA and metJ (137–139). The M. extorquens AM1 ΔhprA mutant is 
unable to assimilate carbon from C1 compounds (162). In lactose minimal medium, the 
species rely on each other for essential metabolites. E. coli secretes acetate byproducts 
which the other species rely on for a carbon source. M. extorquens releases ammonia 
byproducts which provide a source of nitrogen for other species. S. enterica secretes 
methionine, which is essential because our E. coli strain is auxotrophic for this amino 
acid (Figure 2.1). Each species has a fluorescent label integrated into its genome: cyan 
fluorescent protein (CFP) for E. coli, yellow fluorescent protein (YFP) for S. enterica, 
and red fluorescent protein (RFP) for M. extorquens. Bacteria were grown in minimal 
Hypho media (159) containing varying amounts and types of carbon and nitrogen, 
depending on medium type (see Supplementary table S2.1).  
The cross-feeding system of Pseudomonas aeruginosa strain PA14 and a four-species 
consortium of anaerobic mucin-degrading species has also been previously described. 
Briefly, P. aeruginosa monoculture yield on mucin is relatively low due to its inability 
to break down mucin into a usable growth substrate. However, when P. aeruginosa is 
co-cultured on mucin with the anaerobic consortium, the latter degrades mucin into 





Pseudomonas aeruginosa strain PA14 (163) was obtained from D.K. Newman 
(Caltech). The anaerobic consortium (composed primarily of Prevotella sp., Veillonella 
sp., Fusobacterium sp., and Streptococcus sp.) was derived from human saliva using 
porcine gastric mucin enrichment as previously described (18). 
Liquid media experiments 
Bacteria were inoculated along an antibiotic gradient to measure the minimum inhibitory 
concentration (MIC) for monocultures and co-cultures. Each species was grown from 
freezer stocks at 30°C in species-specific monoculture Hypho medium; monocultures 
and communities were inoculated from these same monoculture growth conditions (see 
Supplementary table S2.1). Once cultures reached mid-log phase (OD~0.2-0.3), they 
were diluted 1/200. Cells were inoculated into a 96-well plate, with fresh Hypho and 
varying concentrations of an antibiotic. The inoculate size for a species was kept 
constant at ~104 cells per well in monoculture and community (i.e. community 
treatments started with 3x more total cells than monocultures). Ampicillin was used at 0, 
0.2, 0.5, 1, 2, and 5µg/mL for E. coli, S. enterica, and the communities, and at 0, 2, 5, 
10, 20, and 50µg/mL for M. extorquens; these concentrations provided the best range of 
sublethal to lethal ampicillin concentrations. Tetracycline was used at 0, 1, 2, 3, 5, and 
10µg/mL for E. coli, M. extorquens, and the community, and 0, 10, 20, 30, 50, and 
100µg/mL were used for S. enterica. 96-well plates were placed into a Tecan InfinitePro 
200 at 30°C for 120 hours. Measurements of OD600 were taken every 15 minutes to 
track overall bacterial growth, and fluorescence measurements were taken to track 
growth of individual species. Correlations between colony-forming units (CFU) and 





inhibitory concentration (MIC) was defined as the lowest antibiotic concentration at 
which no growth (as measured by fluorescence) was seen by 3x the time to detectable 
growth of the antibiotic–free control.  
Solid media antibiotic susceptibility experiments 
Resistance on plates was determined by measuring the zone of inhibition diameter 
around an antibiotic containing disk. For monocultures, 150µL of log-phase culture 
(OD= 0.5) was spread on Hypho plates (1% agar) in a lawn; for communities, 150µL of 
culture from each species was mixed, spun down, and re-suspended in 150µL of the 
appropriate community medium before plating onto Hypho plates. Discs of filter paper 
6mm in diameter were inoculated with 25µg antibiotic and left to dry for 10 minutes. 
Discs were applied to the center of plates with bacteria and incubated at 30°C for 48 
hours (E. coli, S. enterica, competitive community) or 72 hours (M. extorquens, 
cooperative community), depending on how long it took for cells outside the zone of 
inhibition to become confluent. Three technical replicates for the zone of clearing were 
measured for each plate and averaged to provide a single plate diameter; at least eight 
biological replicate plates were measured for each condition (see Supplementary tables 
S2.2-S2.3 for summary statistics). 
Fluorescence microscopy 
Fluorescent images were obtained using a Nikon AZ100 Multizoom macroscope with a 
C1si Spectral confocal attachment, 4x objective lens at 3.40x magnification at the 
University of Minnesota Imaging Center. 457nm, 514nm and 561nm argon lasers were 





CFP, 550nm for YFP, and 590nm for RFP. Disc diffusion Petri plates were placed on 
the stage and images from 2x12 fields of view were obtained and stitched together using 
Nikon NIS Elements software. Images for each fluorophore were quantified for 
fluorescence location and overlaid using Fiji image analysis software (164) (see 
Supplementary tables S2.4-S2.5 for summary statistics). 
Testing β-lactamase production  
Nitrocefin discs (Sigma-Aldrich, 49862) were used to determine if M. extorquens was 
producing a β-lactamase. For solid medium, cells were scraped off agar and suspended 
in the appropriate liquid medium; the OD600 of the suspension was then diluted to ~0.5, 
to match the OD600 of liquid cultures. Discs were placed on a microscope slide and 
15µL of liquid culture or diluted solid medium suspension was added to the disc. After 
60 minutes, a color change from yellow to purple/ pink indicated the production of a β-
lactamase that hydrolyzed the nitrocefin in the disc (165). As a positive control, an E. 
coli strain carrying a pBR322 plasmid, which contains a bla β-lactamase gene was also 
tested. Plasmid-free E. coli were used as a negative control.  
Pseudomonas aeruginosa cross-feeding model2 
Antibiotic tolerance assays were performed in minimal medium containing 1 mM 
magnesium sulfate, 60 mM potassium phosphate (pH 7.4), 90 mM sodium chloride, 
trace minerals (166) and supplemented with autoclaved and dialyzed pig gastric mucin 
(30g/L, Sigma-Aldrich) for co-cultures; mucin or glucose (12 mM) was used for P. 
aeruginosa monoculture as indicated. Ampicillin was added at indicated concentrations. 





characterized previously (18) and allowed to grow under anaerobic conditions 
containing carbon dioxide, hydrogen and nitrogen (5:5:90) at 37°C for 48 hrs. For P. 
aeruginosa assays, cultures were inoculated from overnight cultures grown in LB and 
grown aerobically while shaking at 37°C for 16 hrs. Optical densities were determined 
using a Biotek Synergy H1 plate reader and are given as mean and standard deviation of 
three replicates. 
Cross-feeding assays were performed as described previously (18). Briefly, a mucin 
fermenting community from freezer stock was inoculated into the minimal mucin 
medium and allowed to grow for 48 hours anaerobically at 37°C. This culture (OD= 
0.03) was used to inoculate the lower phase (1:100 dilution) which contained 2 mL of 
minimal mucin medium, 1% agar, and supplemented with ampicillin as indicated. After 
solidification of the mucin fermenting agar cultures in 16mm glass culture tubes, P. 
aeruginosa PA14 was added to buffered media containing no mucin and 0.7% agar to 
1/1000 from an LB overnight culture (inoculum CFU/mL approximately 5x107). This 
mixture was then added to the top of the mucin fermenting community and allowed to 
solidify. This allowed oxygen to diffuse to P. aeruginosa from the top of the tube and 
mucin degradation products to diffuse from the anaerobic community below. After 60 
hours at 37OC, the top agar section (containing PA14) was removed, homogenized by 
pipette in sterile saline, serially diluted, and plated on LB agar to enumerate PA14.  
Statistical analyses 
For liquid and solid media assays, at least eight biological replicates of each treatment 





cultures were conducted using a Mann-Whitney U test with an applied Bonferroni 
correction for ten multiple comparisons. For P. aeruginosa cross-feeding assays, 
triplicate experiments were performed for each antibiotic concentration and community 
type. Normalized CFU values were calculated by dividing CFU at each antibiotic 
concentration by the CFU at 0µg/mL ampicillin. Comparisons of normalized values at 
each concentration were performed using a Mann-Whitney U test. Raw data for these 







Obligate cross-feeding in the cooperative community reduces the amount of 
antibiotic necessary to inhibit resistant bacteria in liquid media. 
The minimum inhibitory concentration (MIC) of each species was tested in 
monoculture, cooperative community (cross-feeding), and competitive community. MIC 
was defined as the lowest concentration of antibiotic at which no growth (as measured 
by species-specific fluorescent markers) was detected after 3x the time to detection of 
growth in the relevant antibiotic–free control. This metric was used to take into account 
different growth rates of each of our species, and each growth condition. Media 
compositions and carbon sources for each growth condition can be found in 
Supplementary table S2.1.  
In monoculture experiments, species’ MICs varied widely in the different antibiotics 
tested. When grown in the presence of ampicillin, M. extorquens had a median MIC of 
100µg/ml, which was significantly higher than the 2µg/ml and 1µg/ml necessary to 
inhibit E. coli and S. enterica, respectively (Figure 2.2A, P<0.0001 for each). In 
tetracycline, S. enterica had a median MIC of 50µg/ml (Figure 2.2B). This was 
significantly higher than the median MIC of 5g/ml in M. extorquens (P <0.0001) and 
2µg/ml in E. coli (P <0.0001). We note that the spread in MIC for the most tolerant 
species is in part due to increasing step-size between antibiotic concentrations along the 






Consistent with the weakest link hypothesis, antibiotic concentrations needed to inhibit 
resistant species decreased substantially when bacteria were grown in an obligate 
mutualism rather than in monocultures. Fifty-fold less ampicillin was needed to inhibit 
the cooperative community (1g/mL) than to inhibit M. extorquens in monoculture 
(Figure 2.2A, P < 0.0001). Similarly, the median MIC of tetracycline for S. enterica 
decreased significantly from 50µg/ml in monoculture to 4µg/ml in the cooperative 
community (Figure 2.2B, P <0.0001).  
We next distinguished the effect of species interactions from community complexity by 
measuring the MIC of the bacterial community when species were competing for 
common resources (Figure 2.1B, Figure 2.2). The median MIC for resistant bacteria 
was not significantly different in the competitive community than it was in monoculture 
(for M. extorquens in ampicillin Figure 2.3C, P > 0.90; for S. enterica in tetracycline, 
Figure 2.3E, P= 0.80). Therefore, decreased tolerance of resistant species to these 
antibiotics was a result of metabolic interdependence, rather than simply the presence of 
other species. 
As an additional control, we examined the monoculture and competitive co-culture MIC 
of the three species using carbon sources that matched those that they consume in 
cooperative community (Supplementary figure S2.2). We found that the same 
qualitative patterns were observed, with M. extorquens showing high tolerance to 
ampicillin and S. enterica demonstrating high tolerance to tetracycline in both 






Tolerance to tetracycline was higher than expected in community 
Unexpectedly, we saw a small but significant trend towards protection of E. coli in 
cooperative community in tetracycline. E. coli median monoculture MIC was 2µg/mL 
while median MIC in the cooperative community was 4μg/mL (P= 0.0111, Figure 
2.3D); we expected these MICs to match, as E. coli was the weakest link in tetracycline. 
This effect was not due to higher starting cell density in community, which can increase 
antibiotic tolerance (167) (Supplementary figure S2.3A). As tetracycline is known to 
rapidly photolyse (168), we predicted that its increased time to detectable growth in the 
cooperative community might be protecting E. coli by allowing time for tetracycline to 
break down. Several lines of evidence indicate that tetracycline breakdown is occurring 
as E. coli experiences a delay in nutrient access when obtaining metabolites from cross-
feeding partners instead of growth medium. First, E. coli monoculture MIC increases if 
tetracycline-containing media sits for 20 hours before cells are added (Supplementary 
figure S2.3A). Second, the time to detectable E. coli growth is significantly longer in 
cooperative community than in monoculture (Supplementary figure S2.3B, P < 0.001). 
Third, the MIC of E. coli in monoculture increased if cells sat in tetracycline for 20 
hours before nitrogen and methionine were added to the media (P= 0.001, 
Supplementary figure S2.3A).  
Interspecies competition sets M. extorquens tolerance in tetracycline 
M. extorquens growth in tetracycline also did not follow the hypothesized weakest link 
pattern, though for different reasons than E. coli. In monoculture, tetracycline MIC for 





was not observed even in the absence of antibiotic (Figure 2.3F). M. extorquens was 
able to grow in the ampicillin experiments because it can grow at high ampicillin 
concentrations where its better competitors are antibiotic-inhibited (Supplementary 
figure S2.4). This suggests that growth patterns of M. extorquens in tetracycline are 
governed by competitive ability rather than resistance, while in ampicillin M. extorquens 
experiences competitive release (where removal of a stronger competitor species, in this 
case by antibiotic, allows a weaker competitor to grow). 
Resistant bacteria are also constrained by sensitive partners in structured 
environments 
We next tested whether growth on agar (rather than growth in liquid media) altered the 
impact of species interactions on antibiotic resistance. We hypothesized that spatial 
structure might enhance the ability of resistant bacteria to protect metabolic partners 
from degradable antibiotics like ampicillin, and thereby eliminate reduction of tolerance 
in the cross-feeding system.  
Tolerance patterns on agar largely mirrored results from liquid media. Less antibiotic 
was needed to inhibit resistant bacteria in cooperative community than was needed in 
monoculture (Figure 2.4-2.6). Note that small clearing diameters signify high resistance, 
so relative rankings in Figures 2.4-2.6 are the inverse of Figure 2.2 and 2.3. Ampicillin 
cleared growth of M. extorquens out to a median diameter of 37.2 mm in cooperative 
community, but only 26.55 mm in monoculture (Figure 2.5H, P= 0.0006). Similarly, on 
tetracycline, S. enterica had a median clearing diameter of 8.67mm in monoculture and 





community, zones of clearing matched those of the most resistant monoculture (Figure 
2.4A, M. extorquens vs. competitive community P= 0.999; Figure 2.4B, S. enterica vs. 
competitive community P= 0.4242). As in liquid, M. extorquens is only observed in 
ampicillin competitive community at diameters where it has higher tolerance than E. coli 
and S. enterica (Figure 2.5E), and not at all in in tetracycline competitive community 
(Figure 2.6E, H). Finally, using acetate as the carbon source for S. enterica and M. 
extorquens in monocultures and competitive community again showed qualitatively 
similar results (Supplementary figure S2.5). 
Though M. extorquens had lower tolerance for ampicillin in cooperative community, we 
did observe cross-protection of more sensitive species. The cooperative community 
overall had a significantly smaller zone of inhibition than either S. enterica or E. coli 
monocultures (Figure 2.4A, P <0.0001 for S. enterica and P= 0.01 for E. coli). 
Quantification of fluorescence on these plates indicates that inhibition of both sensitive 
species was reduced in cooperative community (Figure 2.5F, E. coli monoculture vs. 
cooperative community diameter P= 0.0057, and Figure 2.5G, S. enterica monoculture 
vs. cooperative community diameter P= 0.02). This can also be observed qualitatively 
(Figure 2.5, panels A and B vs. D). We found that protection was not due to an increase 
in initial cell density on community versus monoculture plates (Supplementary figure 
S2.6A), and that M. extorquens was responsible for providing protection 
(Supplementary figure S2.6B). Consistent with the observed cross-protection, genes 
encoding ampicillin degrading β-lactamases were found in the genome of M. extorquens. 
Nitrocefin disks were used to demonstrate β-lactamase activity when M. extorquens was 





Metabolic dependency reduces antibiotic tolerance of a pathogen 
To test whether our findings extend to a medically relevant system, we investigated how 
co-culturing influences the effective tolerance of Pseudomonas aeruginosa to ampicillin. 
P. aeruginosa is a leading cause of morbidity and mortality in people with cystic fibrosis 
(169). It was recently demonstrated that P. aeruginosa can cross-feed on carbon 
generated by mucin-degrading anaerobes that are also associated with CF lung disease 
(18). In addition to its medical relevance, this system is distinct from our previous 
system in that cross-feeding is not obligate (P. aeruginosa growth on mucin decreases 
but is not abolished by the absence of anaerobes). We tested how ampicillin influenced 
the growth of P. aeruginosa, when grown alone on mucin versus in a facultative cross-
feeding co-culture. 
Consistent with previous findings (170), P. aeruginosa was highly resistant to ampicillin 
in monoculture (Figure 2.7, Supplementary figure S2.8A). No observable decrease in 
final CFU count was observed across any concentration out to 25g/mL of the drug. In 
contrast, ampicillin inhibited the final density of mucin-degrading anaerobes (as 
measured by OD600), starting at 5g/mL (P= 0.0216) (Figure 2.7, Supplementary 
figure S2.8B). Consistent with expectations, ampicillin also reduced the final CFU of P. 
aeruginosa grown in co-cultures on mucin, starting at 5µg/mL ampicillin (P= 0.0173). 
These data suggest that applying antibiotic to inhibit the growth of cross-feeding 








Our results demonstrate that metabolic dependency between microbial community 
members plays a critical role in mediating the effect of antibiotics. In both mass-action 
(liquid) and structured (solid) environments we observed that bacterial species that show 
high levels of tolerance to a given antibiotic in monoculture are inhibited at much lower 
concentrations in an obligate mutualism. The constraint of cross-feeding on bacterial 
tolerance was consistent across drugs and microbial systems; this was true for two 
antibiotics with different modes of action and extended to a medically relevant system 
with facultative cross-feeding. P. aeruginosa growth was reduced by substantially lower 
concentrations of ampicillin when the pathogen was cross-feeding off of mucin-
degrading anaerobes that were sensitive to the drug.  
We have shown that the ability of a given bacterial species to grow in the presence of an 
antibiotic is a combination of its intrinsic tolerance and the tolerance of species on which 
it relies for metabolites. Dependence on other bacteria reduced the MIC of bacteria with 
high resistance in monoculture, regardless of the antibiotic and mechanism of action. 
This change in MIC was driven by inhibition of a beneficial partner rather than a change 
in the resistance of the focal species. The effective tolerance of a cross-feeding network, 
therefore, is generally set by the ‘weakest link’ species; that is, the species with the 
lowest resistance to the antibiotic, whose tolerance in community usually matches its 
monoculture tolerance. This suggests that antibiotics will often be more effective at 
controlling microbial communities where there is extensive metabolic interdependence, 






Unexpectedly, we did see deviations from our weakest link hypothesis. E. coli had a 
higher tetracycline MIC in the cross-feeding community than in monoculture, suggesting 
some protective effect of cooperative community growth. This slight, but significant, 
increase was likely driven by an increase in time to detectable E. coli growth when 
cross-feeding. Tetracycline breaks down rapidly, so this delay likely allowed E. coli to 
experience reduced antibiotic concentrations. Similar antibiotic dynamics may often 
occur in clinical or environmental settings (168, 171), where metabolically inactive 
"persisters" commonly survive antibiotic treatment by delaying growth (59), particularly 
in the case of bacteriostatic drugs such as tetracycline. Although we have evidence that a 
delay in growth in cooperative community coupled with tetracycline breakdown can 
explain the increased E. coli tolerance to tetracycline, it is important to note that other 
factors may also contribute.  
Community context further altered tolerance by enabling cross-protection of less tolerant 
species by more tolerant partners. On agar with ampicillin, both E. coli and S. enterica 
grew closer to the antibiotic disc in the presence of M. extorquens. This protection was 
likely caused by degradation of the antibiotic due to β-lactamase activity in M. 
extorquens. Our results are consistent with previous observations that spatial structure 
can allow bacteria to lower local antibiotic gradients sufficiently to permit growth of 
sensitive isolates (124). There were limits on the extent of cross-protection in our 
community, however. The cross-feeding community increased tolerance of E. coli and S. 
enterica but, tolerance of M. extorquens was still lower in the cooperative community 
than it was in monoculture. Cross-protection may reduce the magnitude of the 





does not eliminate this constraint. As well, degradative enzymes are not available for all 
antibiotics nor for all bacterial species, limiting the ubiquity of this mechanism. Further 
research is needed on the interaction of cross-protection and cross-feeding, particularly 
in polymicrobial infection contexts, as these studies may help direct antibiotic choice.  
 This study also demonstrates some issues which can arise when measuring the effect of 
antibiotics in microbial communities. It has previously been shown that MIC is a 
problematic metric that can be influenced by factors such as changes in initial microbial 
density, or metabolic state (59, 167). In our study, it was not possible to measure the 
tolerance of M. extorquens to tetracycline in the competitive community, as M. 
extorquens was always outcompeted. The competitive release of M. extorquens in 
ampicillin treated competitive communities again deviates from standard patterns for 
MIC. This may also impact antibiotic choice in polymicrobial infections. If, for 
example, a pathogen grown in monoculture is highly antibiotic-resistant but limited in 
vivo by less tolerant competitors, application of high levels of antibiotic might only 
serve to remove competitor species that would have otherwise kept the pathogen at bay; 
this has been observed in C. difficile infections, which are often precipitated by 
antibiotic-mediated depletion of healthy intestinal microbiome species (36, 172, 173). 
Our results highlight that the community context further complicates challenges 
associated with interpreting MIC measurements. 
The constraint of cross-feeding on antibiotic tolerance also extended to a microbial 
community relevant to cystic fibrosis. It should be noted that this system involved 
facultative cross-feeding, so inhibiting anaerobes only reduced the yield of P. 





elimination of growth in the obligate system, two-fold changes may be medically 
relevant (174–178). More broadly, the constraint in this treatment speaks to the 
generality of our findings. Even in scenarios with less extreme metabolic dependency, 
the impact of antibiotics can be magnified when highly resistant species are cross-
feeding from less resistant species. Given that metabolic interactions are common in 
infection contexts (11, 19), this work suggests that even narrow-spectrum antibiotics, 
designed to target a single species, may have widespread effects throughout a 
metabolically interconnected community. 
Our results highlight that mutualistic networks are highly susceptible to environmental 
change. This result is consistent with work in other ecological systems from plant-
pollinator to insect-symbiont (179–181). Integrating these ecological concepts into a 
microbial perspective may allow greater precision in our medical practices. Broad-
spectrum reductions of bacteria in the gut can cause long-lasting negative health 
outcomes such as facilitating infections by Clostridium difficile (172). To develop 
precision treatments, predicting the impact of a drug on a focal population, and how a 
drug will affect off-target members of a microbial community, is essential. Our work 
highlights that precision microbiome management will require not only improved 
pharmacology but also a more comprehensive understanding of ecological interactions 
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Chapter 2 Figures and Tables 
 
Figure 2.1 Cooperative and competitive model communities. A. Cooperative 
community. Methylamine and lactose are supplied in the growth medium as a nitrogen 
and a carbon source, respectively. E. coli consumes lactose and excretes acetate as a 





methionine auxotroph E. coli. M. extorquens, which has a deletion in hprA which 
renders it unable to assimilate carbon from methylamine, provides nitrogen to the 
community via methylamine breakdown. B. Competitive community. Growth medium 
contains all metabolites necessary for growth of each individual species such that no 







Figure 2.2 Minimum inhibitory concentration (MIC) values for each monoculture and 
community type in ampicillin (A) and tetracycline (B) based on total population OD600. 
The ‘weakest link’ species (i.e. the species with the lowest median MIC in monoculture) 
is indicated on the x-axis. Bars represent median values. MIC is defined as the minimum 





observable growth of the antibiotic free control. Cultures were grown on a Tecan plate 
reader with measurements every 15 minutes. At least eight replicates were performed for 
each species/ antibiotic combination. Pairwise comparisons of median MIC were 
performed using a Mann-Whitney U test, with a Bonferroni correction applied for ten 








Figure 2.3 Species-specific minimum inhibitory concentration (MIC) values in 
monoculture, cooperative community, and competitive community in ampicillin (A-C) 
and tetracycline (D-F). MIC was defined as the minimum concentration of antibiotic 
required to inhibit growth by three times the time to detectable growth of the antibiotic 
free control MICs were calculated based on fluorescence (CFP for E. coli, YFP for S. 
enterica, and RFP for M. extorquens) recorded on a Tecan plate reader with fluorescence 





using a Mann-Whitney U test, with a Bonferroni correction applied for three multiple 






Figure 2.4 Diameters of zones of clearing for ampicillin (A) and tetracycline (B) disc 
diffusion assays. The diameter of the zone of clearing was measured three times for each 
plate and averaged for a single plate measurement. At least eight replicate plates were 
measured for each monoculture and community type. The ‘weakest link’ species (i.e. the 





axis. Pairwise comparisons of the zone of clearing for each monoculture and community 
was performed with a Mann-Whitney U test with Bonferroni adjustment for multiple 
comparisons. Significant differences are noted by different letters above each cluster; 











Figure 2.5 Fluorescent microscopy images of Petri plates with ampicillin antibiotic 
discs. An AZ100 confocal fluorescent macroscope at 3.40x magnification was used to 
image 12x2 fields of view of each Petri plate to visualize E. coli (CFP, in blue), S. 
enterica (YFP, in yellow) or M. extorquens (RFP, red). A-E are representative images of 
E. coli monoculture (A.), S. enterica monoculture (B.), M. extorquens monoculture (C.), 
cooperative community (D.) and competitive community (E.) Quantification of the 
diameter of the species-specific zone of clearing for E. coli (F.), S. enterica (G.), and M. 
extorquens (H.) in each growth condition was performed in Elements software. The 
average of three technical replicate diameters was calculated to obtain a single 
measurement. At least 6 biological replicates were obtained for each species/ growth 
condition. Pairwise comparisons of median diameter of clearing were performed using a 
Mann-Whitney U test, with a Bonferroni correction applied for three multiple 











Figure 2.6 Fluorescent microscopy images of Petri plates with tetracycline antibiotic 
discs. An AZ100 confocal fluorescent macroscope at 3.40x magnification was used to 
image 12x2 fields of view of each Petri plate to visualize E. coli (CFP, in blue), S. 
enterica (YFP, in yellow) or M. extorquens (RFP, red). A-E are representative images of 
E. coli monoculture (A.), S. enterica monoculture (B.), M. extorquens monoculture (C.), 
cooperative community (D.) and competitive community (E.) Quantification of the 
diameter of the species-specific zone of clearing for E. coli (F.), S. enterica (G.), and M. 
extorquens (H.) in each growth condition was performed in Elements software. The 
average of three technical replicate diameters was calculated to obtain a single 
measurement. At least 6 biological replicates were obtained for each species/ growth 
condition, except for M. extorquens in competition in tetracycline, for which no RFP 
signal could be detected. Pairwise comparisons of median diameter of clearing were 
performed using a Mann-Whitney U test, with a Bonferroni correction applied for three 








Figure 2.7 Ampicillin tolerance of Pseudomonas aeruginosa PA14 grown, PA14 cross-
feeding with a mucin-fermenting community, and the mucin-fermenting community 
alone. PA14 colony-forming units (CFUs) from monocultures and co-cultures were 
enumerated by plating cells from each ampicillin concentration on LB agar after 16 
hours of growth. Fermenter community OD600 was measured with a Biotek Synergy H1 
plate reader after 48 hours of growth. Normalized OD600 and colony-forming units 
(CFU) values were calculated for each concentration of ampicillin by dividing raw 
values for the OD600 or CFU value at that concentration by the raw OD600 or CFU 
value of growth at 0µg/mL ampicillin. Each point represents the mean and standard 
deviation of triplicate samples. P-values were calculated using a Kruskal-Wallis test 







Supplementary figure S2.1 Correlations between colony-forming units (CFU) and 
optical density (OD600) for each of E. coli, S. enterica, and M. extorquens (A), between 
CFU and cyan fluorescent protein (B), between CFU and yellow fluorescent protein (C), 
and between CFU and red fluorescent protein (D). Briefly, cultures of each species were 
grown to mid-log phase at 30°C (OD600~0.2), diluted twofold eleven times, and the 
dilutions measured for their OD600 and fluorescence in a Tecan plate reader. Each 
dilution was then plated for CFU and the resulting CFU/mL values were calculated and 











Supplementary figure S2.2 Acetate as the sole carbon source for M. extorquens and S. 
enterica in monoculture and competitive community. A. Competitively grown three-
species community using acetate. Growth medium contains all metabolites necessary for 
the growth of each individual species, with the carbon sources provided matching that of 
the carbon sources available to each species in cooperative community via cross-
feeding. Minimum inhibitory concentrations (MICs) in for ampicillin (B.) and 
tetracycline (C.) were calculated as previously described. At least four replicates were 
performed for each community type. Matching letters represent statistical non-







Supplementary figure S2.3 A Minimum inhibitory concentrations (MICs) of 
tetracycline for E. coli in different growth conditions. MIC was calculated as previously 
described. 3x mono is monoculture E. coli at three times the starting density of 
conventional monocultures. Mono. at 20h is sterile E. coli monoculture medium 
containing antibiotic and incubated for 20 hours prior to E. coli inoculation. Mono. 
starved is E. coli monocultures in which nitrogen and methionine are added 20 hours 
post-E. coli inoculation. B. Time to detectable growth of E. coli in different growth 
conditions. Cyan fluorescent protein (CFP) was used to monitor the growth of E. coli. 
Time to detectable growth was recorded as the first time point in which CFP above 
background levels was detected. In the Mono. at 20h and Mono. starved data, the 20 
hour incubation period is included in the time to detectable growth. Pairwise MIC 
comparisons were performed using a Mann-Whitney U test with Bonferroni adjustment 







Supplementary figure S2.4 Competitive release of M. extorquens at high ampicillin 
concentrations in competitively grown community. Species were grown together in 
competitive Hypho medium at a range of ampicillin concentrations for 72 hours at 30OC. 
A Tecan InfinitePro 200 plate reader was then used to measure OD600 of the entire 
community and fluorescent markers corresponding to individual species. Normalized 
OD600 (A), cyan fluorescent protein to detect E. coli (B), yellow fluorescent protein to 
detect S. enterica (C), and red fluorescent protein to detect M. extorquens (D) were 







Supplementary figure S2.5 Acetate as the sole carbon source for M. extorquens and S. 
enterica in monoculture and competitive community on solid medium. Disc diffusion 
experiments using ampicillin (A.) and tetracycline (B.) were performed and analyzed as 
previously described. The ‘weakest link’ species (i.e. the species with the largest median 
zone of clearing in monoculture) is indicated on the x-axis. At least six replicates were 





were performed using a Mann-Whitney U test with Bonferroni adjustment for ten 
multiple comparisons. Matching letters represent statistical non-significance in medians 







Supplementary figure S2.6 Possible mechanisms of S. enterica and E. coli protection 
from ampicillin in cooperative community on solid medium. The ‘weakest link’ species 
(i.e. the species with the largest median zone of clearing in monoculture) is indicated on 
the x-axis. A. Comparing monocultures and cooperative/ competitive community zones 
of clearing to 3x S. enterica to match total cell density of S. enterica monoculture to 





S. enterica monoculture and cooperative three-species community. Pairwise 
comparisons of median zone of clearing were performed using a Mann-Whitney U test 
with Bonferroni adjustment for fifteen (A.) or ten (B.) multiple comparisons. Matching 







Supplementary figure S2.7 Nitrocefin disc assay for M. extorquens. Nitrocefin discs 
were used to determine if M. extorquens was producing a β-lactamase (indicated by a 
color change from yellow to red/ pink). E. coli containing the plasmid pBR322 was used 
as a control; pBR322 contains a bla selectable marker encoding a β-lactamase. A. M. 
extorquens grown in liquid medium B. M. extorquens grown on solid medium C. E. coli 
with pBR322 on solid medium D. E. coli with pBR322 in liquid medium. For liquid 
cultures, 15µL of liquid medium containing cells was pipetted onto the disc and left at 
room temperature for 15 minutes. For solid cultures, colonies were scraped off plates 
and dissolved in liquid medium, and 15µL was pipetted onto the discs. All cells were 










Supplementary Figure S2.8 Raw colony forming unit (CFU) data for Pseudomonas 
aeruginosa PA14 growth on mucin and glucose (A) and raw OD600 data for the 
anaerobic fermenter community on mucin (B). PA14 CFU grown alone on glucose and 





were obtained by plating cells from each concertation of ampicillin on Luria Broth agar. 
Note that CFU values in 0µg/mL ampicillin are higher on mucin than on glucose 
because of the greater amount of carbon available in 12mM of mucin vs. 12mM of 
glucose. OD600 values were obtained using a Biotek Synergy H1 plate reader. Each 
point represents the mean and standard deviation of triplicate samples. P-values were 











































































































Supplementary table S2.2 Summary statistics for diameters of zones of clearing 
obtained by OD600 in ampicillin 
Species mean std. dev median IQR 
E. coli 38.06668 3.943439 38.33335 5.666698 
S. enterica 42.09259 4.274579 41.66665 7.666698 
M. extorquens 16.66668 2.488071 15.6667 2.6667 
Cooperative 
community 
32.35896 2.551192 32.6667 2.6667 
Competitive 
community 
15.98611 2.801933 16 3.41665 
 
 
Supplementary table S2.3 Summary statistics for diameters of zones of clearing 
obtained by OD600 in tetracycline 
Species mean std. dev median IQR 
E. coli 36.66666 1.972022 37 1.333302 
S. enterica 10.08333 0.8393739 9.916665 1 
M. extorquens 37.63888 3.337767 36.8333 3.833349 
Cooperative 
community 
34.66668 2.400134 33.6667 4 
Competitive 
community 







Supplementary table S2.4 Summary statistics for diameters of zones of clearing 
obtained by fluorescence in ampicillin 
Species Community type mean std. dev median IQR 
E. coli monoculture 45.13889 1.709505 44.65 2.433334 
E. coli cooperative 39.7125 0.907629 39.9 1.316668 
E. coli competitive 46.07667 0.878418 46.26667 0.733334 
S. enterica monoculture 48.48333 0.314643 48.56667 0.433334 
S. enterica cooperative 43.03667 2.219301 42.75 1.333332 
S. enterica competitive 46.04 0.994155 46.36667 1.166664 
M. extorquens monoculture 25.86667 1.787612 26.55 2.566666 
M. extorquens cooperative 36.77667 3.72751 37.23333 2.633335 
M. extorquens competitive 24.12 1.820202 24.53333 1.700001 
 
 
Supplementary table S2.5 Summary statistics for diameters of zones of clearing 
obtained by fluorescence in tetracycline 
Species Community type mean std. dev median IQR 
E. coli monoculture 40.17 1.094143 39.9 2.199997 
E. coli cooperative 40.37 1.607809 40.41667 1.933331 
E. coli competitive 38.84 1.091131 38.66667 0.966667 
S. enterica monoculture 8.733333 0.311111 8.666667 0.366667 
S. enterica cooperative 41.53667 1.334115 41.16667 1.266666 
S. enterica competitive 9.65 0.488447 9.85 0.733333 
M. extorquens monoculture 44.59 0.903772 44.43333 1.666668 
M. extorquens cooperative 31 1.428063 31.16667 2.399999 







Chapter 3. Cross-feeding modulates the rate and 
mechanism of antibiotic resistance evolution in a model 







With antibiotic resistance rates on the rise, novel strategies are needed to understand and 
mitigate resistance evolution. A growing appreciation that most bacteria live in 
multispecies environments, as well as the importance of the interspecies interactions 
therein, offers a possible avenue of targeting resistance evolution. We have previously 
shown that “weakest link” dynamics dominate in communities where species are 
engaged in obligate mutualistic cross-feeding. In these communities, the survival of any 
one species (regardless of its intrinsic resistance) is contingent on the resistance of its 
cross-feeding partners, setting the community antibiotic tolerance at that of the “weakest 
link” species. In this study, we extended that hypothesis to see whether obligate cross-
feeding would limit the extent and mechanisms of antibiotic resistance evolution. Under 
both rifampicin and ampicillin selection, we observed slower rates of resistance 
acquisition in obligate co-cultures of E. coli and S. enterica versus monocultures. These 
results were recapitulated in a mathematical model of our experiments. Further, while 
we observed similar mechanisms of resistance arising under rifampicin selection, 
monocultures and co-cultures under ampicillin selection evolved different resistance 
mechanisms. An ftsI penicillin-binding protein mutation arose in S. enterica only in co-
culture; this mutation was lethal in monoculture unless cells were grown in an acidic 
environment. Using our model, we also showed that adding a growth rate cost to big-
benefit resistance mutations and making big-benefit mutations rarer can also select for 
different mechanisms of resistance. Our results demonstrate that cooperative metabolic 







The seemingly unstoppable ability of pathogens to rapidly evolve antibiotic resistance is 
an increasingly pressing global challenge. While resistance frequently evolves in 
complex microbial communities, relatively little is known about how species 
interactions influence the evolution of antibiotic resistance (182–184). Most of the 
studies that do incorporate multiple species focus on the role of horizontal transfer of 
antibiotic resistance between species, and less on the de novo evolution of resistance 
within genomes (102, 184–187). Additionally, antibiotic resistance studies in 
multispecies systems typically involve unknown interactions between species, with 
some exceptions in modeling (55, 133, 188, 189). The specific role of interspecies 
interactions in the evolution of antibiotic resistance in microbial communities, therefore, 
remains largely unexplored. 
Positive interspecies interactions are common in bacterial communities (43), and 
relatively understudied in terms of their role in modulating the evolution of resistance. 
One such interaction is cross-feeding, wherein two species exchange essential 
metabolites (44). The resilience of metabolically interdependent microbial systems to 
environmental disturbances is a growing field of study, with research being conducted 
into how these systems resist invasion (190, 191) and respond to abiotic environmental 
changes (45, 55, 120, 192). Over short time-scales (e.g. within a single growth curve), 
we previously showed that obligate cross-feeding produces “weakest link” dynamics 
(120), wherein the least resistant member of an obligate cross-feeding community 
constrains the ability of more resistant community members to grow at high antibiotic 





grow at higher antibiotic concentrations) did not change for each species, but the 
tolerance (a phenotypic trait describing their ability to grow at high antibiotic 
concentrations) was limited by the dependence on the least resistant species. This idea 
has also been demonstrated by others through modeling approaches (55).  
We hypothesize that the weakest link pattern described above should also hold over 
evolutionary timescales; that is, at any given point during the evolution of resistance in a 
metabolically interdependent community, one “weakest link” species should set the 
tolerance of the whole community. The obligate cross-feeding interactions would then 
require that each individual species develop its own resistance mechanism before the 
tolerance of the community can increase. We therefore hypothesize that metabolically 
interdependent communities will be slower to adapt to rising antibiotic levels than their 
single-species counterparts, leading to higher rates of extinction in these communities. 
We also hypothesize that weakest link dynamics should affect the mechanisms of 
resistance evolution. For example, the evolution of some shared resistance mechanism 
such as an antibiotic-degrading enzyme (121, 122, 184) or an induction of tolerance 
mechanism in a partner species (123, 125) could be uniquely selected for in co-culture. 
Cross-feeding may also limit the types of resistance mutations available to mutualistic 
networks of bacteria; for example, cross-feeding could make some resistance 
mechanisms more costly. Evolution of resistance by altering cell wall permeability may 
be particularly maladaptive in cross-feeding communities, where exchanged nutrients 
will typically be at low concentrations (40, 47, 193). Finally, a reduction in the rate of 
adaptation may drive different mechanisms of resistance to evolve. Varying the rate at 





trajectories (23-28). More rapid changes in antibiotic concentration tend to select for 
mutations with larger effects that are more costly (23-28). These big–effect mutations 
can trap populations on sub-optimal fitness peaks (67). We therefore hypothesize that we 
will see different mechanisms of resistance evolve in co-culture vs. monoculture, though 
the exact nature of these differences is unclear. 
We sought to investigate whether obligate cross-feeding altered the rate and mechanism 
of antibiotic resistance evolution. We used a previously engineered two-species system 
of E. coli and S. enterica, wherein E. coli consumes lactose and excretes acetate for S. 
enterica to use as a carbon and energy source, and S. enterica overproduces methionine 
for the methionine-auxotrophic E. coli. We evolved six replicate populations of each 
species growing in monoculture (providing E. coli with lactose and methionine, and S. 
enterica with glucose) and in obligately cross-feeding co-culture (providing both species 
with lactose only, hereafter referred to as ‘co-culture’) along increasing antibiotic 
gradients of rifampicin or ampicillin for 20 (rifampicin) or 10 (ampicillin) passages of 
48 hours each. At each passage, the MIC (minimum inhibitory concentration, the lowest 
concentration of antibiotic at which 90% of growth was inhibited relative to the 
antibiotic–free control) was assessed. We also constructed a mathematical model of 
resistance evolution in monoculture versus co-culture populations and used it to predict 
some mechanistic differences that might explain the differences in rate of resistance 
acquisition that we observed in monoculture versus co-culture populations. Our results 
show that growth in an obligate co-culture slows the rate of adaptation, and sometimes 







Bacterial Strains and media 
The Escherichia coli and Salmonella enterica strains used in this study have been 
described previously (159). Briefly, the E. coli str. K12 was the ΔmetB strain from the 
Keio collection (194) that was mated with an Hfr line to reinsert the lac operon (29). The 
S. enterica LT2 mutant was selected and engineered to excrete methionine (137). Each 
strain is fluorescently labelled with a genomic integration of a fluorophore; E. coli is 
labelled with cyan fluorescent protein (CFP) and S. enterica is labelled with yellow 
fluorescent protein (YFP). Bacteria were grown in minimal Hypho medium containing 
phosphate and varying amounts and types of carbon and nitrogen as previously 
described (159). Co-culture media contained 2.78mM of lactose, E. coli monoculture 
medium contained 2.78mM of lactose and 0.020mM of methionine, and S. enterica 
medium contained 5.55mM of glucose. 
Experimental Evolution1 
Three different culture conditions (E. coli monoculture, S. enterica monoculture, and 
obligate co-culture) were each evolved across two antibiotic gradients (rifampicin, 
Chem-Impex International Inc. 00260, and ampicillin, Fisher BP1760). Six replicate 
populations were evolved for each antibiotic/ culture condition combination. Each 
antibiotic gradient began with an antibiotic–free control well and increased twofold with 
each subsequent well, starting at 0.25µg/mL and ending at 64µg/mL. When populations 
evolved to grow at 64µg/mL, the upper end of the gradient was increased to 1024µg/mL 





between passages caused by pipetting errors, stocks of antibiotic gradients were 
prepared in advance and diluted such that 2µL of stock constituted the desired 
concentration when diluted 1/100 in the bacterial growth plate. Fresh antibiotic stocks 
were prepared and filter-sterilized immediately before the experiment began.  
Initial bacterial cultures were inoculated from DMSO freezer stocks in 10mL of 
monoculture minimal Hypho medium for approximately 48 hours at 30OC, to stationary 
phase (OD~0.4). Cells were then distributed into 96 well cell culture plates. For 
monocultures, 2µl of bacterial cells (~2x105 cells) were inoculated into 196µl of the 
appropriate monoculture medium with 2µL of antibiotic stock. In co-cultures plates, 1µl 
of E. coli and 1µl of S. enterica were inoculated into 196µL medium. The plates were 
then incubated for 48 hours at 30°C with shaking at 450 rpm. After each growth phase, 
cells were then transferred to a new 96-well plate with fresh media. 1µL cells were 
transferred to a new well with the same antibiotic concentration, and 1µL cells were 
transferred to a new well that was one step higher on the antibiotic gradient (see Figure 
3.1). This regimen challenged bacterial populations with increasing antibiotic 
concentrations at each transfer, but also allowed for populations to be maintained 
throughout the experiment if resistance was not acquired during a given transfer. The 
96-well plate from each growth phase was frozen down in 10% DMSO for future 
analysis. After each 48-hour growth period, each plate was also placed onto a Tecan 
InfinitePro 200 plate reader where OD600 and species-specific fluorescence 
measurements were obtained. These readings were used to calculate the 90% minimum 
inhibitory concentration (MIC90) for each replicate; growth at a given antibiotic 





antibiotic–free control well for a given replicate. Statistical analysis of rate of resistance 
evolution between monocultures and obligate co-cultures for each antibiotic was 
performed in R. A linear mixed-effects model with a random slope for each replicate 
within a treatment group was used to test the relationship between MIC and transfer, 
culture type (monoculture or co-culture), and a transfer-culture type interaction.  
Sequencing 
To identify mutations which conferred antibiotic resistance in each evolved population, 
the most resistant population of each replicate in each antibiotic-growth condition 
combination was whole-genome sequenced. Two antibiotic–free populations per 
antibiotic-growth condition combination were also sequenced to identify any mutations 
which may have arisen during passaging but are not related to antibiotic resistance. Each 
population to be sequenced was scraped from 10% DMSO freezer stock and grown up in 
10mL Hypho at the appropriate antibiotic concentration for 48 hours at 30OC. gDNA 
was then extracted from each population using Zymo Quick-gDNA Miniprep Kit (Zymo 
11-317C). The gDNA was then used to prepare Illumina sequencing libraries according 
to the Nextera XT DNA Library Prep Kit protocol. Libraries were submitted to the 
University of Minnesota Genomics Center for QC analysis and sequenced on an 
Illumina Hi-Seq with 125bp paired-end reads.  
Sequence analysis was performed using BreSeq (195) to align Illumina reads to 
reference E. coli and S. enterica genomes as previously described (196). Briefly, 
mutation lists for resistant populations were filtered such that variation between our 





which also arose in the antibiotic–free populations. Mutation lists were then assembled 
for each population (Supplementary table S3.1) and any known functions described 
(Supplementary table S3.2). Mutations which rose to above 80% frequency (for 
rifampicin) or above 50% frequency (in ampicillin, due to the fewer number of transfers) 
were examined for their possible role in conferring antibiotic resistance (Table 3.1). 
Isolation and phenotyping of isolates 
Obtaining isolates 
At the final transfer of each evolution experiment, the well in each replicate displaying 
growth at the highest antibiotic concentration, according the MIC90, was identified as the 
“resistant population”. These resistant populations, as well as the corresponding 
antibiotic–free control populations from each replicate, were plated onto minimal Hypho 
medium containing X-Gal (5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside, 
Teknova X1220), which allowed us to differentiate between β-galactosidase-positive E. 
coli and β-galactosidase-negative S. enterica through a colorimetric change. Three 
isolates of each species each from the resistant and antibiotic–free wells were selected 
from these plates and frozen down in 10% DMSO for further analysis.  
For ampicillin-evolved populations in which we were unable to obtain S. enterica 
isolates on pH neutral medium, we prepared acidic Hypho plates by adding 6M HCl to 
the growth medium until the pH reached ~4.7. Growth medium was then autoclaved, and 
X-gal was added as described above. For growth of these isolates in liquid medium, 6M 







Isolate growth rates and yields 
Evolved isolates were scraped from DMSO freezer stocks onto solid agar plates and 
grown up overnight, then inoculated into 96-well plates containing the appropriate 
species-specific Hypho and grown at 30°C for 48 hours at 450rpm to acclimatize them 
to minimal media growth and standardize cell density. 2µL of stationary-phase cells was 
then used to inoculate a new 96-well plate containing 198µL monoculture growth 
medium. These plates were then placed in a Tecan InfinitePro 200 for 48 hours at 30°C 
with shaking at 300rpm; OD600, CFP, and YFP were measured every 20 minutes. After 
48 hours, 1µL from the wells of monoculture isolate plates were transferred to new 96-
well plates. These plates contained 198µL of fresh co-culture Hypho medium and 1µL 
of either ancestor strain of E. coli or S. enterica. If the monoculture isolate was E. coli, 
the ancestor strain of S. enterica was added, and vice-versa. The plates were then placed 
into a Tecan InfinitePro 200 for 48 hours at 30°C, and OD600 and florescent data was 
obtained every 20 minutes. Growth rates and yields were then calculated using Baranyi 
curves in R software using an in-house script. Statistical analyses and graphs were 
prepared in Stata version 14.  
Isolate Minimum Inhibitory Concentrations (MICs) 
Evolved isolates were prepared for inoculation as described above for beginning 
monoculture growth rate experiments. Based on the MIC90 of the population from which 
they originated, 2µL of each isolate culture was then inoculated across an antibiotic 





middle of the gradient. An antibiotic–free control well was also included for each 
gradient. If the gradient used was insufficient to calculate MIC (e.g. cells grew at all 
concentrations, or at none of them), the experiment was repeated with the antibiotic 
gradient shifted up or down as necessary. MIC of isolates was determined using MIC90 
as described above. Statistical analyses and graphs were prepared in Stata version 14.  
Evolution Model2 
We used an evolution simulation to examine the rate at which antibiotic resistance 
evolved as a function of the number of interdependent species and other variables. There 
were two timescales in this model; the “within-transfer” timescale, and the “between-
transfer” timescale.  
Within a transfer, evolution was simulated in any given “well” using a modified haploid 
Wright-Fisher simulation with selection. A well was initiated with N individuals (default 
N = 1000). If this was the first transfer, these individuals were clones of a genotype with 
growth rate (s) = 1 and MIC = 0. Each well had a pre-determined antibiotic 
concentration. Evolution occurred over a predetermined number of generations. Each 
generation, the population was fully replaced. The new population was picked from the 
previous generation depending on the frequency of each genotype and its growth rate. 
The unscaled fitness of individual i was determined by 𝑤𝑖 =  𝑠𝑖/ ∑ 𝑠𝑗
𝑁
𝑗=1 . This was 
scaled to get expected frequency 𝑤𝑖 =  𝑤𝑖/ ∑ 𝑤𝑗
𝑁
𝑗=1 . In other words, ∑ 𝑤𝑗
𝑁
𝑗=1 = 1. The 
next generation was then created by generating N random numbers from a uniform 
distribution on [0,1] and choosing genotypes from the previous generation based on their 





concentration in the well. If the genotype’s MIC was less than the antibiotic 
concentration, its 𝑠 = 0 for the fitness calculation.  
Once the new population was generated, some of the new individuals may be mutated. 
Each simulation used a pre-determined mutation rate 𝑢 (default = 0.001 mutations per 
individual per generation). We generated N random numbers from a uniform distribution 
on [0,1]. Any random numbers less than 𝑢 meant those individuals gained a mutation. In 
all cases, mutations could be either a growth rate mutation or an MIC mutation with a 
50:50 chance. Growth rate mutations were simulated by adding a random number from a 
normal distribution with mean 0 and standard deviation 0.1 to the current growth rate 
(i.e. deleterious growth rate mutations were equally as likely as advantageous). MIC 
mutations altered either the MIC of the individual alone or both the MIC and the growth 
rate, as described in the results. We tracked the genealogy of all individuals.  
To simulate interdependence, we simulated >1 species per well. Each species had N 
individuals, and the dynamics of each species were independent of the other species, 
except that there must be individuals of all species with an MIC > the antibiotic 
concentration for any species to grow.  
The second time scale—the transfer scale—was simulated to approximate the wet-lab 
experiments. Individuals were transferred from one well to two wells: the same 
antibiotic concentration, and the next higher antibiotic concentration. Therefore, wells 
received individuals from two wells. If there were surviving species in both source 
wells, N/2 individuals were randomly chosen from each well to populate the new well. If 





from that well to the new well. If no source wells had surviving species, the destination 
well was sterile. Simulations were conducted in R.  
Statistical analyses of the simulation data were performed as follows. We analyzed the 
rate of evolution of antibiotic tolerance as was done in the wet-lab experiments. To 
examine the effect of mutation rate or population size on antibiotic tolerance, we 
measured the maximum tolerance observed (highest antibiotic concentration survivable) 
at the final transfer for each replicate. This response variable was predicted using 
mutation rate or population size as categorical independent variables, crossed with the 
number of species, in a two-way analysis of variance. A one-way analysis of variance 
tested the amount of mutations observed in the most-tolerant population, with an 
independent variable of the # of interdependent species. To calculate the relative 
tolerance of two-species simulations versus one-species simulations (Figure 3.5B, C), 
we first found the mean and standard error in the tolerance in each set of simulations. 
Then, the mean of the two-species community was divided by the mean of the one-
species community. The error was propagated using 
(mean_relative_tolerance)*sqrt((SEM[two species]/mean_tolerance[two_species])^2 + 
(SEM[one species]/mean_tolerance[one_species])^2). The average MIC mutation size 
was the (Figure 3.6D) was average MIC in a surviving population divided by the 
average number of mutations in that population. In all cases, since species were 
functionally equivalent, we arbitrarily chose one species to assess. Statistics were 







Antibiotic resistance evolves more quickly in monoculture than in obligate co-
culture 
First, we tested the rate at which antibiotic resistance evolved in monocultures of E. coli 
and S. enterica as well as obligate co-cultures of the two species. We established six 
replicate cultures of each monoculture, and the co-culture. Each culture was distributed 
along an antibiotic gradient of either ampicillin or rifampicin. After 48 hours of growth, 
we transferred cells in a 1/200 dilution to fresh medium in the same antibiotic 
concentration, as well as double that concentration (Figure 3.1A). We transferred 
populations for 20 transfers (approximately 180 generations) in rifampicin, and 10 
transfers (approximately 90 generations) in ampicillin. At each transfer, we measured 
total population density spectrophotometrically (by OD600) and calculated MIC90 based 
on the density in wells along each gradient. After the final transfer, three colonies of 
each species were isolated from each replicate population and their MIC90 values 
measured. Due to contamination, we removed one replicate of rifampicin-evolved S. 
enterica in monoculture.  
In rifampicin, we found that resistance evolved more quickly in monoculture 
populations than in co-cultures (Figure 3.2A,B). For E. coli, growth in monoculture vs. 
co-culture was associated with a 1.06µg/mL greater increase in MIC per passage (+/- 
SEM of 1.02, t(df = 11) = 2.431, P= 0.0328). There was also a significant, positive 
effect of growing in monoculture vs. obligate co-culture, as monoculture–evolved E. coli 





3.2A, see Supplementary table S3.3 for all statistical results). Similarly, for S. enterica, 
growth in monoculture was associated with a significantly higher increase in MIC per 
passage versus growth in co-culture (1.09 +/- 1.02µg/mL, t(df=11) =3.08, P= 0.01). 
However, the difference in monoculture vs co-culture MIC was not significant (1.22 +/- 
1.13µg/mL, df=207, t=1.63, P= 0.1054). In ampicillin, monoculture resistance in both 
species also rose more quickly than co-culture resistance, even over just ten transfers. 
The per-passage increase in MIC of both monocultures was higher than that of co-
cultures (P= 0.007 for E. coli, P= 0.0272 for S. enterica) (Figure 3.2B). Growth in 
monoculture was also associated with a significantly higher MIC overall than co-culture 
for E. coli (P= 0.0001), but not S. enterica (P= 0.4942).  
Similar mechanisms of rifampicin resistance evolve in monoculture and obligate 
co-culture  
Given the consistently lower average MIC in co-culture–evolved populations than in 
monoculture–evolved populations, we hypothesized that these differences might be due 
to a difference in time under selection of species grown alone vs. cooperatively (Figure 
3.1B-D). To identify whether cross-feeding selected for different resistance mechanisms 
we sequenced resistant populations at transfer 10 (ampicillin) and 20 (rifampicin). 
Genomic DNA was extracted from the well that grew at the highest concentration of 
antibiotic for each replicate population. For each resistant population we created a list of 
mutations excluding any mutations also observed in antibiotic free controls 
(Supplementary Tables S3.1 and S3.2). For further analysis, we focused on genes that 
acquired mutations multiple times within a treatment, as parallel evolution is a signature 





rifampicin selection and those which rose above 50% frequency under ampicillin 
selection (with the lower threshold for the latter due to the fewer number of transfers 
occurring under the latter). We hypothesized that, if time under selection were sufficient 
to explain differences in mutational spectra between monoculture and co-culture–
evolved lines, we should see more mutations arising in monoculture, and co-culture 
mutations would largely be a subset of monoculture–evolved mutations. If, however, 
different mechanisms of resistance were arising in monoculture vs. co-culture, these 
different mechanisms might also be driving the different levels of resistance we 
observed.  
Under rifampicin pressure, the genes that acquired mutations in co-culture were a subset 
of those that acquired mutations in monoculture for both species (Figure 3.3A,B). The 
most clearly identifiable resistance-associated mutation was rpoB, a component of RNA 
polymerase and the most common mutational target for rifampicin resistance (103). 
Mutations in this gene arose in four out of the six replicates each in monoculture and co-
culture (Figure 3.3A) and were strongly tied to higher levels of resistance (Figure 
3.3C,D). A mutation in a prophage tail-specific protein, prc, was also repeatedly 
observed in both monoculture and co-culture (Supplementary figure S3.1). The overlap 
in mutations suggest that co-cultures and monocultures are evolving along similar 
adaptive trajectories. 
Monoculture lines also evolved more mutations than co-culture lines in rifampicin. 
Mutations in mdoG and mdoH were only observed in monocultures of E. coli and S. 
enterica. Both mdoG and mdoH likely influence cell membrane permeability. mdoG, 





FtsZ-mediated assembly of the divisome in rich growth medium (198). mdoH (or opgH) 
encodes a membrane-bound glycosyltransferase that functions in synthesis of 
membrane-derived oligosaccharides (199). However, we found no changes in 
monoculture or co-culture growth rate associated with these mutations (Supplementary 
figure S3.2). Taken together, the pattern of rifampicin resistance mutations suggests that 
populations were moving along the same evolutionary trajectory in monoculture and co-
culture but reached further along that trajectory in monocultures. 
Different mechanisms of ampicillin resistance arise in monocultures vs. obligate co-
cultures 
In contrast to our results from rifampicin, the mutational spectra that we obtained from 
sequencing ampicillin-resistant populations suggests different resistance mechanisms 
arose in monoculture vs. co-culture. We observed more mutations in ampicillin than in 
rifampicin due to our lowered threshold for inclusion (above 50% frequency, versus 
above 80% in ampicillin); we used this cut-off to be able to detect resistance mutational 
signatures even with the fewer number of transfers in ampicillin. We had fewer transfers 
in ampicillin due to contamination in transfers 13 and beyond. Nevertheless, we 
observed distinct mutational signatures in both E. coli and S. enterica monocultures and 
co-cultures.  
Very few genes acquired mutations more than once in the E. coli replicates. Two co-
culture replicates evolved mutations in proQ, a regulator of efflux pumps (200) (Figure 
3.4A). In monoculture, resistance evolution repeatedly involved in a gene associated 





weak signature of differential resistance mechanisms evolving in E. coli in monoculture 
and co-culture.  
The evidence for differential mechanisms of resistance was stronger in S. enterica, 
despite more overlap in mutated genes (Figure 3.4B). Mutations in efflux pump genes 
(acrB, ramR), and an unnamed dehydratase, arose in S. enterica monoculture but not in 
co-culture. Mutations in some genes associated with cell membrane permeability (envZ, 
ompR) were also observed exclusively in monoculture. None of these mutations were 
associated with a significant increase in resistance except for ramR, wherein mutants had 
a higher median MIC than wild-type isolates (P= 0.0491, Supplementary figure S3.3). 
Conversely, mutations in ftsI, a penicillin-binding protein, was only observed in co-
culture. ftsI is an essential gene and encodes a penicillin-binding protein (PBP3) which 
is known to be a target site for β-lactam antibiotics (201). Interestingly, the mutations we 
observed in ftsI in our whole-genome sequencing were a combination of point mutations 
(D534Y at 75% frequency in rMM158) and mutations which should have ablated gene 
function (+A at 100% frequency in rMM127 and Q142* in rMM158). While we were 
able to identify these mutations from whole-genome sequencing of co-cultures, we were 
unable to identify them from S. enterica isolates from these populations (see Methods 
for information on how isolates were obtained). S. enterica isolates were difficult to 
obtain from these populations in general, and isolates which we did manage to isolate 
either did not contain the +A or Q142* mutations, or had a suppressor mutation in the 
same codon as the Q142* mutation site which eliminated the stop codon 





Castanheira et al. recently demonstrated that the lethality associated with ftsI loss in S. 
enterica could be mitigated by growing S. enterica under acidic conditions (pH<5.8); 
under these conditions, a second PBP3, which they called PBP3SAL, is expressed (202). 
Considering this, we plated co-culture populations containing Q142* or +A mutations in 
ftsI on LB of pH 4.7. We were able to obtain S. enterica isolates at roughly equal 
frequencies to what we would expect in the population, and Sanger sequencing 
demonstrated that these isolates did contain the loss-of-function Q142* or +A mutations. 
These isolates did not show detectable growth in monoculture unless the growth medium 
was acidified (Figure 3.4C) and were associated with increased MICs versus isolates 
with wild-type ftsI, though this difference was not statistically significant (Figure 3.4D, 
P= 0.0603). Interestingly, ftsI mutant isolates had co-culture growth rates comparable to 
wild-type when paired with an E. coli ancestor (Supplementary figure S3.4). This 
suggests that ftsI knockout mutations were non-viable in monoculture but conferred little 
cost in co-culture.  
An evolutionary model suggests that differences in time under selection for 
monocultures vs. co-cultures is sufficient to explain differences in evolved 
resistance  
To test the effect of interdependence on evolution of antibiotic resistance in the absence 
of species-specific biological details, we developed a simple model. The model is based 
upon the haploid Wright-Fisher model with selection, but populations at a fixed density 
evolved with a transfer regimen similar to the evolution experiments above. Individuals 
had two genes containing positive real numbers: a growth rate and an MIC, both of 





determined whether an individual could reproduce at all in a well with a given antibiotic 
concentration. When simulations had more than one species, they were interdependent, 
such that a species was unable to grow if there were no viable individuals of the other 
species (see Methods for details).  
We first examined the relationship between the number of interdependent species and 
the rate of evolution of antibiotic resistance. Here, MIC–increasing mutations were free 
of cost, and were pulled from a uniform distribution ranging from zero to 1.1 (with 1 
being the step size at which antibiotic concentration increased across wells). One 
thousand individuals of each species were simulated per well. Ten generations occurred 
within a transfer, and we conduced nine transfers. Mutations occurred at a rate of 𝑢 =
0.001 per individual per generation. Thirty-five replicates were simulated. We found 
that antibiotic tolerance (the highest antibiotic concentration at which a species grew) 
evolved more slowly as more interdependent species were simulated (Figure 3.5A). We 
also observed that increasing the mutation rate (Figure 3.5B) or the population size 
(Figure 3.5C) increased the difference in antibiotic tolerance at the final transfer 
between monocultures and co-cultures (mutation rate, main effect of u: F(2,204) = 
62.88, P < 1e-10; main effect of # species: F(1,204) = 49.06, P < 1e-10; interaction: 
F(2,204) = 10.52, P= 4.49e-5; population size, main effect of N: F(2,204) = 39.9, P < 
1e-10; main effect of # species: F(1,204) = 47.6, p < 1e-10; interaction: F(2,204) = 5.48, 
P= 0.0048). Additionally, we showed that more mutations accumulated in the population 
with highest antibiotic tolerance when there were fewer species present 
(Supplementary figure S3.5A, F(2,102) = 20.98, P < 1e-7); this parallels what we 





MIC-increasing mutations are unlikely to be drawn from a uniform distribution and have 
no pleiotropy. Therefore, we wondered about the rate of evolution of antibiotic 
resistance when either (1) big-benefit mutations were less common, or (2) incurred a 
growth rate cost. To that end, we tested two additional situations: one, “nexp,” in which 
big-benefit mutation were rarer, and two, “tradeoff,” in which all MIC mutations were 
equally likely, but greater changes to MIC incurred a disproportionally larger growth 
rate cost (Figure 3.6A). Either constraint reduced the tolerance achieved through time 
by one or two species communities (Figure 3.6B). Interestingly, not only were the 
absolute tolerances altered, but so were the relative tolerances: tolerance developed 
proportionally more slowly in the “nexp” or “tradeoff” model than in the “null” model 
(Figure 3.6C). Finally, in any model, the average size of an MIC-changing mutation 
was smaller when there were more species (Figure 3.6D, main effect in two-way 
ANOVA, F(1,572) = 119.7, P < 1e-10; main effect of mutant function, and interaction, 
were also significant). Overall, our model showed that cross-feeding (i.e. dependence on 
another species for growth) is sufficient to slow the rate of resistance evolution versus 
monoculture, and that adding a cost to resistance (tradeoff) or making big-benefit 







Our results demonstrate that obligate cross-feeding changes the rate and mechanisms of 
resistance evolution relative to that of monoculture. We showed that the obligate 
interspecies interactions resulted in a slower rate of adaptation to two different drugs and 
in an evolution model unbounded by species–specific details. In rifampicin, the 
resistance mechanisms remained similar between monoculture and co-culture–evolved 
lines; genes that acquired resistance mutations in co-culture were a subset of the genes 
involved in adaptation in monoculture. In ampicillin, in contrast, we observed different 
resistance mechanisms arising in monoculture and in co-culture, likely due in part to 
different costs of resistance mutations in monoculture and co-culture. We showed that 
ftsI mutations provide high levels of ampicillin resistance, but are only selected for in 
co-culture. In this environment, we expect that a second acid–induced penicillin binding 
protein is induced and can compensate for the loss of the essential ftsI gene. Overall, the 
fact that monocultures evolved more resistance than co-cultures, irrespective of species 
and antibiotic identity, suggests that slower resistance evolution in cross-feeding co-
cultures is a general phenomenon. 
Our results demonstrate that mutualistic interactions between species can result in 
slower evolution of antibiotic resistance and, in the case of ampicillin, the selection of 
different antibiotic resistance mechanisms altogether. This emphasizes the importance of 
taking ecological context into account when studying antibiotic resistance and suggests 
that species interactions may play an important role in shaping resistance evolution 
trajectories. Interestingly, the most significant impact that cross-feeding appears to have 





community requires two mutations in two different species, it makes sense that 
resistance evolution would be slowed. This phenomenon depends on the interactions 
between species being obligate, which is unlikely in nature; however, this does provide a 
novel possible strategy for slowing the evolution of resistance— namely, using a broad-
spectrum antibiotic that targets both a pathogen and its cross-feeding partners.  
Our findings that rpoB mutations confer resistance to rifampicin in both monocultures 
and co-cultures are not unexpected; indeed, there is an extensive field of research solely 
focusing on this topic (67, 103, 203–205). However, it is worth noting that there was a 
separation of the specific rpoB mutations which arose in monoculture vs. co-culture. 
S547Y arose in three co-culture E. coli populations, and I572N arose in one; neither of 
these mutations were observed in monoculture, though an I572L mutation did arise in 
one monoculture population. A previous study showed that I572L conferred high levels 
of rifampicin resistance, whereas I572N conferred only a moderate increase in resistance 
(203); this supports our hypothesis that high-level resistance is more commonly selected 
for in monoculture (Figure 3.6D). It is interesting that all of our rpoB mutations 
identified in Lindsey et al. 2013 are associated with gradual or moderate rifampicin 
exposure, rather than sudden exposure. This may explain the high level of variation in 
growth rate among replicate populations in our study; Lindsey et al also found that 
populations evolved under gradual and moderate rifampicin exposure had a greater 
diversity of growth rates and rpoB mutations than populations evolved under sudden 
antibiotic exposure (67). Similarly, in S. enterica, the mutations which arose in 
monoculture differed from those which arose in co-culture (Supplementary table S3.1). 





but it is possible that some aspect of co-culture vs. monoculture growth may be driving 
these differences in specific rpoB mutations. Given that rpoB mutations generally up-
regulate the production of central metabolism enzymes, detoxification pathways, and 
cell membrane processes (132), the need to maintain cross-feeding and/or the different 
physiological states of cross-feeding vs. monoculture cells may be changing the fitness 
landscape of rpoB mutations in these cells. 
One resistance mechanism that consistently arose in our evolved lines was modulation 
of cell wall permeability, either through changes in cell membrane composition or 
mutations affecting porin and efflux pump expression/regulation. Cell membrane 
composition changes are expected to be particularly relevant for hydrophobic antibiotics, 
such as erythromycin, aminoglycosides, and rifampicin; hydrophilic antibiotics such as 
β-lactams are more likely to use porins as entry points into the cell (206, 207). The 
resistance mechanisms which arose during our experimental evolution reflect this; 
mutations in ompR and ompF only arose under ampicillin selection, whereas mutations 
in mdoG and mdoH, which alter membrane biochemical composition, only arose under 
rifampicin selection. Similarly, changes in membrane phospholipid composition was 
recently shown to increase Staphylococcus aureus resistance to daptomycin (208), and 
changes in LPS biosynthesis in E. coli increased sensitivity to bacitracin and rifampicin 
(199). While modulation of cell wall permeability through changes in porin regulation 
(65, 207) and expression of efflux pumps (209) are well-established resistance 
mechanisms, less is known about how modification of cell membrane biochemistry 
affects resistance. The potential cross–resistance provided by each of these mutations 





It is worth noting that the ftsI mutation we identified in S. enterica only arose in co-
culture environments, despite being associated with increased ampicillin resistance 
(albeit non-significantly). This raises an interesting possible evolutionary conflict for S. 
enterica in its role as a facultative intracellular pathogen. Our study demonstrated that 
mutations in ftsI confer high-level resistance (Figure 3.4B); however, this mutation is 
lethal outside of an acidic environment. A previous study identified a compensatory 
penicillin-binding protein, called PBP3Sal, which is induced in acidic environments such 
as macrophages (202). Loss of ftsI might provide high-level resistance but prevent S. 
enterica from reproducing outside the acidic macrophage environment, making S. 
enterica into an obligate intracellular pathogen. Antibiotic pressure in a patient might 
therefore select for antibiotic-resistant ftsI mutants which are unable to spread. Other 
studies have demonstrated that resistance mutations have associated fitness costs in 
specific environments (210, 211). However, further research is needed into how these 
context-dependent costly mutations might be disproportionately selected for in 
multispecies environments where those costs are not realized until an infection situation.  
Our mathematical model identified the same difference in rate of resistance acquisition 
between monocultures and co-cultures as did our experimental results. This shows that 
our experimental findings were not driven by system–specific parameters such as 
species identity, differences in carbon source between monocultures and co-cultures, or 
population size. This is particularly important given that Zampieri et al have previously 
shown that growth on different carbon sources (such as glucose in our S. enterica 
monoculture vs. acetate in the co-culture) can select for different resistance mechanisms 





evolution may therefore be widely generalizable. Additionally, the model offers a 
generalized framework with which to investigate the impact of parameters such as 
mutation effect size, mutation rate, and population size, which may be difficult to 
modulate experimentally. Unexpectedly, the addition of a cost to resistance (tradeoff 
model) or a mutation distribution where large-effect mutations were rarer (nexp model) 
did not affect the pattern of monocultures evolving resistance more quickly. In all cases, 
monocultures also evolved more big benefit mutations than co-cultures, even when there 
was not an associated increase in cost. This suggests that bacteria engaged in mutualisms 
likely evolve resistance via many small-step mutations, rather than fewer large-step 
mutations. We are currently investigating this hypothesis in our system by engineering 
the evolved resistance mutations into the ancestral strain and testing the individual MIC 
benefits of each resistance mutation. We predict that single monoculture–evolved 
mutations will confer higher resistance than single co-culture–evolved mutations. 
Studying how mutualisms evolve resistance to environmental stresses has significant 
implications not only for the evolution of antibiotic resistance in microbial communities, 
but also for the impact of climate change on symbiotic relationships at the macroscopic 
level. For example, the relationships between arbuscular mycorrhizal fungi (AMF) and 
wine grapevines is likely to be modified by climate change via AMF-mediated changes 
in grapevine metabolism and subsequent changes in grape quality. Understanding the 
nature of these interactions, and developing a better framework to predict the effects of 
climate change on them, will be essential in maintaining grape quality under changing 
climatic conditions (213). Climate change may also result in asynchronicity of plant 





partners that may affect the stability of the mutualism. This is particularly likely if 
environmental changes in temperature, precipitation, and interactions with other species 
disproportionately and/or differentially affect one mutualistic partner over another (214). 
Microbial communities offer an intermediate between theoretical models and long-term 
macroscopic mutualism studies, which allow us to test the predictions made by models 
in a more reasonable time frame and potentially develop a predictive framework for the 







1Experiments were performed in conjunction with Michaela Muza 












Figure 3.1 A. Schematic of evolution experiment setup. Monocultures of E. coli and S. 
enterica, as well as cross-feeding co-cultures, were distributed in six replicate 
populations along an antibiotic gradient. The antibiotics tested included rifampicin and 
ampicillin, and the concentration of antibiotic increased twofold at each well. 96-well 
plates were incubated with shaking at 30°C for 48 hours, then cells were transferred to 
fresh medium and antibiotic in a new plate. The passaging regimen was to transfer 1µL 
of culture to a fresh well containing the same concentration of antibiotic at which it had 
previously grown, and 1µL to a fresh well containing one concentration step higher 
antibiotic. At each passage, the OD600 of the plate was measured, as well as species-
specific fluorescence (CFP for E. coli, YFP for S. enterica). B-D. Hypothesis on why 
time under selection may be sufficient to explain MIC differences between monocultures 
and co-cultures. B. In monoculture, each species is under selection at every time step, 
thus selecting for increasing resistance with each passage. C. In obligate co-culture, only 
the more antibiotic-sensitive species is under selection at a given time, and effective co-
culture resistance requires an increase in MIC in both species. This leads to the slower 







Figure 3.2. Resistance evolves more slowly, and to a lesser extent, in co-culture–
evolved populations vs. monoculture–evolved populations. Six replicate populations 
each of monocultures and co-cultures were evolved along a Rifampicin gradient (A-B) 
or an Ampicillin gradient (C-D). Population MICs for each species (E. coli A, C; S. 
enterica B, D) were measured each passage and the resulting MICs plotted (rifampicin 
A, B; ampicillin C, D). Statistical analysis was performed using a mixed-effects model 
with a randomized slope for each replicate within a culture type. P-values are for the 









Figure 3.3 Resistance– associated mutations in rifampicin-resistant evolved populations 
A-B. Venn diagrams of mutations which arose in E. coli (A) or S. enterica (B) 
monoculture only, co-culture only, or both. Putative resistance mutations which arise in 
more than one population are are named; other mutations may be found in 
Supplementary table 1. Rifampicin MICs of isolates with wild-type vs. mutant rpoB 
genes in E. coli (C) and S. enterica (D). Isolates were obtained from passage 20 
populations by streaking onto selective medium and picking isolated colonies. MIC90 
values for isolates were defined as the lowest concentration of antibiotic which 
decreased growth by greater than 90% by 48 hours at 30OC. Each point represents the 







Figure 3.4 Resistance– associated mutations in ampicillin-resistant evolved populations. 
Venn diagrams of mutations which arose in E. coli (A) or S. enterica (B) monoculture 
only, co-culture only, or both. Mutation descriptions may be found in Supplementary 
table 1-2. C. Image of co-culture populations containing ftsI mutations on Petri plates 
with LB pH= 7 (left) and pH= 4.7 (right). Blue colonies are E. coli which metabolize X-
gal to a blue color; white colonies are S. enterica. D. MICs of isolates from libraries 
containing ftsI mutations in pH= 7 or pH= 4.7 medium. Isolates were obtained from 
passage 10 populations by streaking onto selective medium and picking isolated 
colonies. MIC90 values were defined as the lowest concentration of antibiotic which 
decreased growth by greater than 90% by 48 hours at 30OC. Each point represents the 






Figure 3.5 Simulation model of the evolution of antibiotic resistance in single-species 
vs. multispecies obligately dependent communities. A. A 9-season simulated evolution 
experiment with 35 replicate populations shows that increasing the number of 
interdependent species in a consortium results in a slower increase in the average MIC 
over time. B, C. Effect of mutation rate and population size on resistance evolution in 
model. B. As mutation rates increase in our model, the difference between average MIC 
of monoculture–evolved vs. co-culture–evolved populations also increase. C. As 
population size increases, the difference between average MIC of monoculture–evolved 










Figure 3.6. Effect of different mutation distributions on the rate of evolution of 
antibiotic resistance. Tradeoff mutation models in evolution simulation. A. (left) 
Distributions from which MIC-altering mutations were randomly pulled. The x-axis is 
relative to the maximum MIC change possible in one mutation. Both the “null” and the 
“tradeoff” model used uniform distributions. The “nexp” used a truncated negative 
exponential distribution with rate parameter 2.3, which kept 90% of random numbers 
less than the max MIC change of 1.0. During simulations, random pulls higher than this 
value were resampled (right). In the trade-off model, mutations which altered MIC had 
a deterministic cost to growth rate, using the function 0.75*(MIC change)^2, meaning 
larger mutations were disproportionally more costly, and the maximum cost to growth 
rate was 0.75, B. The absolute increase in antibiotic tolerance for each mutation 
distribution, simulated for one or two species communities and using 100 replicates per 
treatment. Points are mean +/- SEM. C. The tolerance achieved by two-species 
communities divided by the tolerance achieved by one-species communities, using the 
data from B. D. The average change in MIC for any mutation as a function of the 






















BA010 E. coli rpoB → 
DNA-directed RNA 
polymerase subunit beta 




BA017 E. coli rpoB → 
DNA-directed RNA 
polymerase subunit beta 




BA030 E. coli mdoG → 
glucan biosynthesis protein 
G mdoG → 




BA030 E. coli rpoB → 
DNA-directed RNA 
polymerase subunit beta 




BA036 E. coli glpA → 
anaerobic 
glycerol-3-phosphate 
dehydrogenase subunit A 




BA036 E. coli mdoG → 
glucan biosynthesis protein 
G mdoG → 








BA049 E. coli mdoG → 
glucan biosynthesis protein 
G mdoG → 




BA049 E. coli rpoB → 
DNA-directed RNA 
polymerase subunit beta 















BA067 S. enterica mdoH → 
gucans biosynthesis 
glucosyltransferase H 




BA067 S. enterica rpoB → 
DNA-directed RNA 
polymerase subunit beta 












BA079 S. enterica mdoH → 
gucans biosynthesis 
glucosyltransferase H 




BA079 S. enterica rpoB → 
DNA-directed RNA 
polymerase subunit beta 








BA098 S. enterica mdoH → 
gucans biosynthesis 
glucosyltransferase H 




BA098 S. enterica rpoB → 
DNA-directed RNA 
polymerase subunit beta 




BA108 S. enterica rpoB → 
DNA-directed RNA 
polymerase subunit beta 




BA108 S. enterica rpoB → 
DNA-directed RNA 
polymerase subunit beta 











BA115 S. enterica mdoH → 
glucans biosynthesis 
glucosyltransferase H 




BA115 S. enterica rpoB → 
DNA-directed RNA 
polymerase subunit beta 
C→T 4,367,504 100% 
Rif Co-culture BA125 E. coli pnp ← 
polyribonucleotide 
nucleotidyltransferase 
+G 3,303,449:1 90.10% 
Rif Co-culture BA125 E. coli rpoB → 
DNA-directed RNA 
polymerase subunit betat 
T→A 4,172,887 100% 
Rif Co-culture BA139 E. coli rfaQ ← 
LPS core heptosyltransferase 
RfaQ 
Δ1 bp 3,800,489 100% 
Rif Co-culture BA139 E. coli rpoB → 
DNA-directed RNA 
polymerase subunit beta 
C→A 4,172,893 100% 
Rif Co-culture BA139 S. enterica rpoB → 
DNA-directed RNA 
polymerase subunit beta 
A→G 4,366,350 100% 
Rif Co-culture BA145 E. coli prc ← tail-specific protease Δ2 bp 1,908,859 100% 
Rif Co-culture BA145 E. coli prs ← 
ribose-phosphate 
pyrophosphokinase 
A→T 1,256,880 100% 
Rif Co-culture BA145 E. coli rpoB → 
DNA-directed RNA 
polymerase subunit beta 
C→A 4,172,893 100% 
Rif Co-culture BA155 E. coli prc ← tail-specific protease Δ10 bp 1,907,831 64.40% 
Rif Co-culture BA165 E. coli rplK → 50S ribosomal protein L11 C→T 4,168,451 100% 
Rif Co-culture BA165 E. coli rpoB → 
DNA-directed RNA 
polymerase subunit beta 
C→A 4,172,893 92.80% 
Rif Co-culture BA165 E. coli 
BW25113_R
S13710 ← 
CP4-57 defective prophage, 
DUF4297/DUF1837 






polymorphic toxin family 
protein/hypothetical protein 
Rif Co-culture BA176 E. coli prc ← tail-specific protease Δ11 bp 1,908,656 100% 
Rif Co-culture BA176 S. enterica rpoB → 
DNA-directed RNA 
polymerase subunit beta 




rMM010 E. coli acrB ← 
multidrug efflux RND 
transporter permease subunit 




rMM010 E. coli rne ← ribonuclease E 






rMM020 E. coli envZ ← 
two-component sensor 
histidine kinase 








rMM049 E. coli ilvN ← 
acetolactate synthase 
isozyme 1 small subunit 




rMM060 E. coli eda ← 
2-keto-3-deoxy-L-rhamnona
te aldolase 








rMM060 E. coli prlF → antitoxin PrlF 
repeat_region (–





rMM060 E. coli rne ← ribonuclease E 






rMM067 S. enterica ompF/IS10 
outer membrane protein F/ 
repeat region 










rMM078 S. enterica ompF/IS10 
outer membrane protein F/ 
repeat region 











rMM078 S. enterica 
STM2273/ 
IS10 







rMM090 S. enterica acrB ← 
RND family acridine efflux 
pump 




rMM090 S. enterica ompR ← 
osmolarity response 
regulator OmpR 








rMM090 S. enterica 
STM2273/ 
IS10 











rMM098 S. enterica 
STM2273/ 
IS10 







rMM108 S. enterica ompF/IS10 
outer membrane protein F/ 
repeat region 







rMM108 S. enterica 
STM2273/ 
IS10 














rMM119 S. enterica acrB ← 
RND family acridine efflux 
pump 




rMM119 S. enterica ompR ← 
osmolarity response 
regulator OmpR 
R210L (CGT→CTT) 3,659,697 100% 
Amp Co-culture rMM127 S. enterica ahpF → 
alkyl hydroperoxide 
reductase subunit F 
G→A 672,700 94.60% 
Amp Co-culture rMM127 S. enterica amn ← AMP nucleosidase T→C 2,092,111 100% 
Amp Co-culture rMM127 S. enterica dnaQ → 
DNA polymerase III subunit 
epsilon 
T→A 303,499 100% 
Amp Co-culture rMM127 S. enterica envZ ← 
osmolarity sensor protein 
EnvZ 
A→G 3,659,359 100% 
Amp Co-culture rMM127 S. enterica ftsI → peptidoglycan synthase FtsI +A 143,219:1 100% 
Amp Co-culture rMM127 S. enterica ftsZ → cell division protein FtsZ C→T 155,877 100% 
Amp Co-culture rMM127 S. enterica 




G→A 3,694,118 94.40% 
Amp Co-culture rMM127 S. enterica metL → 
bifunctional aspartate kinase 
II/ homoserine 
dehydrogenase II 
G→A 4,312,839 100% 
Amp Co-culture rMM127 S. enterica rtn → 
lambda/N4 phages resistance 
membrane protein 
T→C 2,315,609 92.40% 
Amp Co-culture rMM127 S. enterica sppA ← protease 4 G→A 1,373,495 54.20% 
Amp Co-culture rMM127 S. enterica STM0019 → hydroxymethyltransferase A→G 20,208 100% 




Amp Co-culture rMM127 S. enterica 
STM1552 →




A→G 1,629,730 100% 
Amp Co-culture rMM127 S. enterica STM2179 ← sugar transporter T→C 2,275,700 93.00% 
Amp Co-culture rMM127 S. enterica STM2700 ← phage tail fiber-like protein T→C 2,850,036 94.00% 
Amp Co-culture rMM127 S. enterica STM2739 → phage tail-like protein C→A 2,877,206 100% 
Amp Co-culture rMM127 S. enterica STM2756 ← 
sugar phosphate 
aminotransferase 
C→T 2,894,787 100% 
Amp Co-culture rMM127 S. enterica STM3052 ← outer membrane protein T→C 3,211,576 94.00% 
Amp Co-culture rMM127 S. enterica STM3631 ← xanthine permease T→C 3,817,700 94.60% 
Amp Co-culture rMM127 S. enterica 
STM3653 ←
 / ← glyS 
acetyltransferase/glycine--tR
NA ligase subunit beta 
A→G 3,839,640 100% 
Amp Co-culture rMM127 S. enterica STM4419 → sugar transporter C→T 4,662,084 100% 
Amp Co-culture rMM127 S. enterica 
xylA ← / → 
xylR 
xylose isomerase/xylose 
operon regulatory protein 
T→C 3,848,052 100% 
Amp Co-culture rMM127 S. enterica yeaQ → inner membrane protein T→C 1,353,286 54.60% 
Amp Co-culture rMM127 S. enterica yhiP → 
dipeptide/tripeptide 
permease B 
C→T 3,762,685 52.60% 
Amp Co-culture rMM137 E. coli proQ ← RNA chaperone ProQ Δ5 bp 1,909,389 19.70% 
Amp Co-culture rMM137 S. enterica metL → 
bifunctional aspartate kinase 
II/ homoserine 
dehydrogenase II 
Δ4 bp 4,311,847 59.20% 
Amp Co-culture rMM146 S. enterica ompF ← outer membrane protein F Δ116 bp 1,090,110 64.50% 




Amp Co-culture rMM158 S. enterica ftsI → peptidoglycan synthase FtsI G→T 143,325 75.30% 










Supplementary table S3.2 Functions of genes mutated under antibiotic selection. 
Gene Mutated in Description Function 
fre → E. coli: BA056 NAD(P)H-flavin reductase 
May be involved in iron homeostasis and 
oxidative stress response (UniProt) 
rpoB → 
E. coli: BA010, BA017, 
BA030, BA049, BA125, 
BA139, BA145, BA165 
S. enterica: BA067, BA079, 
BA098, BA108, BA115, 
BA139, BA176 
DNA-directed RNA polymerase subunit 
beta 
RNA polymerase beta subunit; commonly 
mutated in rifampicin-resistant lines (215) 
prc ← 
E. coli: BA010, BA036, 
BA145, BA155, BA176 
tail-specific protease 
Cleaves precursor to form a functional PBP3; 
involved in thermal and osmotic stress 
response (216); mutations lead to increased 
antibiotic susceptibility (217) 
mdoH → 
E. coli: BA010, BA056, 
rMM039 
S. enterica: BA067, BA079, 
BA098, BA115 
glucosyltransferase 
Also called mdoH/opgH; involved in 
regulating cell wall osmolarity and likely 
modulates cellular penetration of rifampicin 
(199) 
mdoG → 
E. coli: BA030, BA036, 
BA049 
glucan biosynthesis protein G MdoG → 
Required for the synthesis of osmoregulated 
periplasmic glucans; may function in biofilm 
formation (218) 
glpA → E. coli: BA036 
anaerobic glycerol-3-phosphate 
dehydrogenase subunit A 
Involved in utilization of glycerol as a carbon 
source; deletions lead to decreased persister 
formation (219) 
pnp ← E. coli: BA125 polyribonucleotide nucleotidyltransferase 
Involved in mRNA degradation and tRNA 
processing; contributes to rRNA quality 
control during steady-state growth (220) 
rfaQ ← E. coli: BA139 LPS core heptosyltransferase RfaQ 
Also called waaQ; involved in LPS 
biosynthesis (UniProt) 
prs ← E. coli: BA145 ribose-phosphate pyrophosphokinase Involved in central metabolism (UniProt) 
BW25113_RS13710 ← 
/ ← BW25113_RS13715 
E. coli: BA165 
CP4-57 defective prophage, 
DUF4297/DUF1837 polymorphic toxin 





rplK → E. coli: BA165 50S ribosomal protein L11 
Regulator of the stringent response and signals 
increased ppGpp production, which increases 
antibiotic tolerance (221) 
rne ← E. coli: rMM010, rMM060 ribonuclease E 
Small regulatory RNA that functions in SOS 
initiation (222) 
acrB ← 
E. coli: rMM010 
S. enterica: rMM090, 
rMM119 
multidrug efflux RND transporter 
permease subunit 
Efflux transporter protein component of the 
TolC-AcrAB multidrug efflux pump (223) 
envZ ← 
E. coli: rMM020 
S. enterica: rMM127 
two-component sensor histidine kinase 
Sensor kinase in two-component signalling 
control of ompF/ompC expression regulation 
(223) 
ilvN ← E. coli: rMM049 
acetolactate synthase isozyme 1 small 
subunit 
Catalyzes the first step in valine biosynthesis 
and the second step in isoleucine biosynthesis 
(UniProt) 
eda ← E. coli: rMM060 2-keto-3-deoxy-L-rhamnonate aldolase 
Involved in glucose degradation through the 
Entner-Doudoroff pathway (UniProt) 
prlF → E. coli: rMM060 antitoxin PrlF 
Antitoxin component of an mRNA 
degradation toxin system (224) 
ompF ← 
E. coli: rMM060 
S. enterica: rMM146 
outer membrane protein F 
Classic trimeric porin commonly lost in beta-
lactam resistant strains (225) 
proQ ← E. coli: rMM137, rMM158 RNA chaperone ProQ 
Small regulatory RNA that controls efflux 
pump expression (200) 
ispD ← S. enterica: BA079 
2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase 
Functions in isoprene biosynthesis (UniProt) 
STM4466 ← S. enterica: BA079 carbamate kinase 
Functions in the arginine deaminase pathway 
(UniProt) 
ramR ← 
S. enterica: BA108, 
rMM078, rMM090 
regulatory protein 
Negative repressor of ramA, which positively 
regulates acrAB expression- knockouts result 
in constitutive acrAB expression (226) 
ompF/IS10 
S. enterica: rMM067, 
rMM078, rMM108 
outer membrane protein F/ repeat region 
Classic trimeric porin commonly lost in beta-
lactam resistant strains (225) 
STM2273/ IS10 
S. enterica: rMM078, 
rMM090, rMM098, 
rMM108 
dehydratase/ repeat region - 
yoaE 
S. enterica: rMM090, 
rMM108, rMM167 
inner membrane protein 






S. enterica: rMM090, 
rMM119 
osmolarity response regulator OmpR 
Response regulator in two-component 
signalling of ompF/ompC expression (223) 
ahpF → S. enterica: rMM127 alkyl hydroperoxide reductase subunit F 
Functions in protecting cells from hydrogen 
peroxide toxicity (227) 
amn ← S. enterica: rMM127 AMP nucleosidase 
Loss of function mutations allow greater cold 
tolerance in E. coli (228) 
dnaQ → S. enterica: rMM127 DNA polymerase III subunit epsilon 
Encodes proofreading DNA polymerase III; 
mutations lead to high mutation rates and are 
often observed under antibiotic selection (229) 
ftsZ → S. enterica: rMM127 cell division protein FtsZ 
Essential component of cell division (forms 
septum Z-ring); target of antimicrobial 
development (230) 




rtn → S. enterica: rMM127 
lambda/N4 phages resistance membrane 
protein 
- 
sppA ← S. enterica: rMM127 protease 4 Signal peptide peptidase (UniProt) 
STM0019 → S. enterica: rMM127 hydroxymethyltransferase - 
STM0566 → S. enterica: rMM127 inner membrane protein - 
STM1552 → / ← STM05155 S. enterica: rMM127 cytoplasmic protein/hypothetical protein - 
STM2179 ← S. enterica: rMM127 sugar transporter 4-hydroxybenzoate transporter (UniProt) 
STM2700 ← S. enterica: rMM127 phage tail fiber-like protein - 
STM2739 → S. enterica: rMM127 phage tail-like protein Putative integrase (UniProt) 
STM2756 ← S. enterica: rMM127 sugar phosphate aminotransferase - 
STM3052 ← S. enterica: rMM127 outer membrane protein 
May be involved in phenol degradation 
(UniProt) 
STM3631 ← S. enterica: rMM127 xanthine permease - 




STM4419 → S. enterica: rMM127 sugar transporter Carbohydrate/proton symporter (UniProt) 
xylA ← / → xylR S. enterica: rMM127 
xylose isomerase/xylose operon regulatory 
protein 
- 




yhiP → S. enterica: rMM127 dipeptide/tripeptide permease B Putative transporter (UniProt) 
metL → 
S. enterica: rMM127, 
rMM137 
bifunctional aspartate kinase II/homoserine 
dehydrogenase II 
Catalyzes the first step in lysine/homoserine 
biosynthesis, the last step in homoserine 
biosynthesis, and indirectly functions in 
methionine and threonine biosynthesis 
(UniProt) 
ftsI → 
S. enterica: rMM127, 
rMM158 
peptidoglycan synthase FtsI 
Penicillin-binding protein 3 (PBP3); mutations 





Supplementary table S3.3. Statistics for mixed–effects model analyzing rate of MIC 
increase over 20 rifampicin passages and 10 ampicillin passages.  
E. coli in Rifampicin 
  
 Estimate Std. Error df t value 
(Intercept) 0.77227 1.05741 226 -4.63 6.2E-06 
evol_condition 1.067 1.08214 226 0.822 0.41221 
passage 1.09838 1.01694 11.2929 5.584 0.00015 
evol_condition: passage 1.05947 1.02405 11.2929 2.431 0.03285 
S. enterica in Rifampicin  
 Estimate Std. Error df t value 
(Intercept) 0.90274 1.08656 207 -1.232 0.21921 
evol_condition 1.22175 1.13104 207 1.626 0.10537 
passage 1.08845 1.01818 11.4501 4.705 0.00058 
evol_condition: passage 1.08584 1.02707 11.4501 3.082 0.00998 
E. coli in Ampicillin  
 Estimate Std. Error df t value 
(Intercept) 1.8614 1.12912 106 5.116 1.4E-06 
evol_condition 1.97848 1.18738 106 3.973 0.00013 
passage 1.11823 1.02495 36.0446 4.535 6.1E-05 
evol_condition: passage 1.10477 1.03546 36.0446 2.859 0.00701 
S. enterica in Ampicillin  
 Estimate Std. Error df t value 
(Intercept) 2.39983 1.12832 106 7.251 7.1E-11 
evol_condition 0.88947 1.18617 106 -0.686 0.49417 
passage 1.08302 1.02837 25.1259 2.851 0.00859 









Supplementary figure S3.1 A. MICs of monoculture– and co-culture– evolved E. coli 
isolates containing wild-type or mutant prc. B. Monoculture and co-culture growth rates 
of monoculture–evolved E. coli isolates containing wild-type or mutant prc. C. 
Monoculture and co-culture growth rates of co-culture–evolved E. coli isolates 
containing wild-type or mutant prc. All p-values based on Mann-Whitney U tests. Points 









Supplementary figure S3.2 Impact of mdoG and mdoH mutations on MICs and growth 
rates in rifampicin-resistant evolved E. coli and S. enterica. A. MIC of mdoG wild-type 
vs. mutant E. coli isolates, averaged by population (three isolates per population were 
used). B. Monoculture and co-culture growth rates of mdoG wild-type vs. mutant E. coli 
isolates. C. MIC of mdoH wild-type vs. mutant E. coli isolates. D. Monoculture and co-
culture growth rates of mdoH wild-type vs. mutant E. coli isolates. E. MIC of mdoH 
wild-type vs. mutant S. enterica isolates. F. Monoculture and co-culture growth rates of 










Supplementary figure S3.3 Effect of other mutations on MICs of ampicillin-evolved 
isolates. A. MICs of wild-type vs. mutant E. coli with mutations in rne (monoculture–
evolved, in blue) and proQ (co-culture–evolved, in green). B. MICs of wild-type vs. 
mutant S. enterica with mutations in acrB/ompR, ramR, an unnamed dehydratase (all 
evolved in monoculture only), and metL (evolved in co-culture only). C. MICs of wild-
type vs. mutant S. enterica with mutations in ompF evolved in monoculture (gold) or co-
culture (green). D. MICs of wild-type vs. mutant S. enterica with mutations in yoaE 








Supplementary figure S3.4 Monoculture and co-culture growth rates of ftsI mutant 
isolates in pH=4.7 growth medium. P= 0.0614 for monocultures, P= 0.3545 for co-






Supplementary figure S3.5 Number of mutations in monoculture vs. co-culture in 
simulation and in experimental evolution. A. The number of mutations (mean + SEM) 
accumulated in a species in simulations with one-three interdependent species. B. 
Experimental data showing the total number of unique mutations which arose in six 
replicate populations of each monocultures and co-cultures under rifampicin (left) and 




Chapter 4. Weakest link dynamics predict apparent 






With the growing global threat of antimicrobial resistance, novel strategies are required 
for combatting resistant pathogens. Combination therapy, wherein multiple drugs are 
used to treat an infection, has proven highly successful in the treatment of cancer and 
HIV. However, this practice has proven challenging for the treatment of bacterial 
infections due to difficulties in selecting the correct combinations and dosages. An 
additional challenge in infection treatment is the polymicrobial nature of many 
infections, which may respond to antibiotics differently than a monoculture pathogen. 
This study tests whether patterns of antibiotic interactions (synergy, antagonism, or 
independence/additivity) in monoculture can be used to predict antibiotic interactions in 
an obligate cross-feeding co-culture. Using our previously described weakest link 
hypothesis, we hypothesized antibiotic interactions in co-culture based on the 
interactions we observed in monoculture. We then compared our predictions to observed 
antibiotic interactions in co-culture. We tested the interactions between ten previously 
identified antibiotic combinations using checkerboard assays. Although our antibiotic 
combinations interacted differently than predicted in our monocultures, our monoculture 
results were generally sufficient to predict co-culture patterns based solely on the 
weakest link hypothesis. These results suggest that combination therapy for cross-
feeding multispecies infections may be successfully designed based on antibiotic 







Antibiotic resistance is a growing global threat. It is estimated that, by 2050, 10 million 
deaths per year worldwide will be attributable to antibiotic-resistant infections (58). 
Many previously treatable infections, such as tuberculosis (231), urinary tract infections 
(232), and even Staphylococcus-mediated skin infections (233) now require higher doses 
of more powerful antibiotics. More concerning is that the patients most at risk for 
multidrug resistant infections are those with complex medical histories and increased 
risk of side effects (89). This arms race against pathogens by clinicians is proving a 
losing battle, as resistance is acquired rapidly, and the development of novel 
antimicrobials is limited (88, 90). The demand for novel treatment strategies is, 
therefore, an ever–increasing issue. 
One treatment strategy that has proven particularly successful in the treatment of viral 
infections is the use of drug combinations. The best example of this is perhaps in HIV, 
where the advent of highly active antiretroviral therapy (HAART) dramatically 
improved the longevity and quality of life for HIV patients (234). The theory behind this 
treatment is based on simple probability — even in a highly mutable and therefore rapid 
resistance-acquiring virus such as HIV, it is much less likely that a viral population will 
acquire resistance to multiple antivirals than a single one, assuming an independent 
mutation is required for resistance to each drug (235). In line with this theory, HAART 
regimens typically involve drugs targeting different viral targets, including the HIV 
protease required for virion maturation, the reverse transcriptase required for replication, 
and the integrase required for viral insertion into the host genome (234). This approach, 




chemotherapy to manage drug-resistant and genetically heterogeneous tumors (236). For 
example, treatment for metastatic colon cancer may involve a growth factor inhibitor to 
block cell division signals, a nucleoside analog to induce hypermutation and apoptosis of 
cancer cells, and a topoisomerase inhibitor to inhibit DNA replication (237).  
The success of combination therapy is affected by interactions between drugs, wherein 
the activity and effectiveness of one drug is impacted by the presence or absence of 
another (238). There are several mechanisms by which antibiotics may synergize (work 
more effectively or at lower doses together than separately) or antagonize (work less 
effectively or at higher doses together than separately). Antibiotic interactions may arise 
as a result of chemical interactions (e.g. two similar drugs compete for the same 
enzymatic target) (238), or biological constraints (e.g. bacteriostatic drugs slow cellular 
growth sufficiently for cells to become transiently tolerant to bactericidal drugs) (239). 
While the precise nature of these interactions depends on the drugs and the bacterial 
species being targeted, some general mechanisms have been described for different 
classes of antibiotics (240). For example, cell wall inhibitors such as β-lactam antibiotics 
may synergize with aminoglycosides by permeabilizing the cell membrane, thus 
allowing increased aminoglycoside penetration (241, 242) or co-inducing cell envelope 
stress (243). Co-administration of β-lactam antibiotics and ̫β-lactamase inhibitors such 
as tazobactam maintains β-lactam efficacy even in β-lactamase–containing pathogens 
(244). Antibiotics targeting similar cellular processes or pathways may also synergize 
(245, 246). Conversely, antagonism may occur when the cellular response to one 
antibiotic involves induction of tolerance or resistance mechanisms to another (240, 247, 




response to a second drug, leading to antagonistic interactions (249). These are general 
trends only, however, and many species– and drug – specific exceptions apply, making 
it challenging to predict drug interactions a priori in new systems.  
In cases of bacterial infections, multidrug therapy has been adopted only in a few 
specific infections. Standard treatment for drug–sensitive tuberculosis, for example, 
includes two months of isoniazid, rifampicin, pyrazinamide, and ethambutol, followed 
by four months of isoniazid and rifampicin (231). However, clinical trials of 
combination therapy in the treatment of bacterial infections in patients have been limited 
for a few reasons (240). One is that combination therapy is most useful in infections 
which do not respond to single drugs at tolerable concentrations; many bacterial 
infections are still treatable by single antibiotics at non– or minimally toxic doses (86). 
Another is the inherent difficulty in choosing the correct antibiotic combinations and 
doses for a specific infection (86, 250). Perhaps most importantly, however, is that the 
evidence for the effectiveness of multidrug treatment regimens, particularly for Gram-
negative pathogens, is mixed at best and leads to increased side effects in several cases 
(87). However, there has been some evidence that combination therapy is effective at 
reducing mortality for septic patients, possibly due to increased likelihood of 
administering the correct antibiotic to treat a pathogen(s) whose resistance profile is 
unknown (251). Further research into the precise mechanisms of bacterial suppression in 
combination therapy may therefore have clinical impacts in cases of severe bacteremia.  
Another increasingly appreciated feature of bacterial infections is their polymicrobial 
nature. Numerous clinically relevant infections are now known to involve multiple 




infecting pathogens (11, 12). Polymicrobial infections have been observed to have worse 
clinical outcomes in some cases (115–117), though these results are mixed (252, 253). 
The metabolic interactions (both positive and negative) among these species have been 
demonstrated to impact antibiotic response. For example, in a co-culture model of 
Candida albicans and Candida glabrata, competition for glucose changes the ability of 
each species to survive and invade a community during antifungal treatment (134). 
While negative interactions such as resource competition might be more common in 
infection scenarios, where a pathogen (or pathogens) is likely to be invading an 
established community, positive ecological interactions may also be occurring. One such 
interaction is cross-feeding, wherein one species produces an essential metabolite for 
another; this also occurs in infection contexts (13). For example, in a cystic fibrosis 
model where the pathogen Pseudomonas aeruginosa depends on the mucin degradation 
products supplied by a community of anaerobic commensals, antibiotics specifically 
targeting the anaerobes decreased P. aeruginosa abundance despite its intrinsic 
resistance to the antibiotic (120). Treatment regimens might, therefore, be more effective 
if metabolic interactions among species are taken into account; however, little research 
has been done on how cross-feeding might impact combination therapy.  
To this end, we aimed to test whether cross-feeding interactions in a model bacterial 
community might influence antibiotic interactions. We selected ten combinations of six 
antibiotics based on the work of Yeh et al. (238); this study quantitatively tested the 
pairwise interactions between 21 different antibiotics which altered E. coli growth rate. 
Yeh et al then developed a drug interaction network wherein interactions were found to 




mechanistic framework for future interaction studies. Three of the combinations we 
selected from this study were predicted to synergize (greater antibiotic efficacy in 
combination than alone); three were predicted to antagonize (lower antibiotic efficacy in 
combination than alone), and four to interact additively or independently in E. coli 
monoculture. Our model system, consisting of an E. coli methionine auxotroph strain 
that produces acetate from lactose, and an S. enterica that produces methionine, has been 
previously described (120, 137, 159).We first tested each of these combinations for their 
drug interactions in E. coli and S. enterica monoculture, and used fractional inhibitory 
concentration indices (FICIs) to identify any drug interactions. We then used our 
“weakest link” hypothesis to predict the growth patterns of the co-culture and the 
subsequent antibiotic interactions. Briefly, the weakest link hypothesis states that the 
“weakest link” species in an obligate cross-feeding community will define the tolerance 
(i.e. the ability to grow at high antibiotic concentrations) of the entire community. The 
weakest link species is defined as the species with the lowest antibiotic tolerance in 
monoculture. We previously showed that this hypothesis holds true for different 
individual drugs in our system and others (120). In this study, we found that only three 
antibiotic combinations showed non-additive interactions, likely due to the different 
antibiotic interaction metrics that we used versus those used by Yeh et al. (238). 
However, in  those non-additive combinations, weakest link dynamics successfully 
predicted co-culture growth and antibiotic interactions. While more antibiotic 
combinations need to be explored, these results suggest that the responses of individual 
community members to combination therapy might be sufficient to predict the antibiotic 





Our model microbial community has been previously described (137). Briefly, our 
system consists of an E. coli methionine auxotroph, and an S. enterica strain which has 
been evolved to secrete excess methionine. In a lactose environment, E. coli metabolizes 
lactose to produce acetate for S. enterica, which in turn supplies methionine for E. coli. 
Each species can also be grown in monoculture by supplying E. coli with methionine 
and lactose, and S. enterica with acetate.  
We performed checkerboard assays (described below) with six antibiotics in ten 
different combinations predicted to synergize (3), antagonize (3), or not interact (4)— 
see Table 4.1 for these combinations. For each drug combination, we tested E. coli and 
S. enterica in monocultures, and the two-species in obligate co-culture. Each antibiotic 
combination/culture type was tested in triplicate. Seven two-fold dilutions of each 
antibiotic, along with an antibiotic–free control for each, were used in orthogonal 
gradients on a 96-well plate such that the antibiotic concentrations increased from left-
to-right and top-to-bottom. The first row and column of each plate were antibiotic–free 
wells for the vertically– and horizontally– distributed antibiotics, respectively. The 
minimum inhibitory concentrations (MICs) for each antibiotic were determined in the 
absence of the other antibiotic. Mid-log–phase cells (OD~0.4) were grown up on the day 
of the experiment in species–specific Hypho growth medium (120) and 2µL was 
inoculated into 194µL fresh species-specific Hypho. Antibiotic stocks were prepared 
within two days of the experiment such that 2µL of stock could be added to each well to 
achieve the desired gradient concentrations. Plates were then incubated at 30°C with 




species-specific fluorescence (CFP for E. coli and YFP for S. enterica). The 90% 
minimum inhibitory concentration (MIC90) was then used to establish which wells 
showed growth. Any well that had an OD600 or fluorescent protein value above 10% of 
the highest plate value was considered growth. We used the highest plate value rather 
than the antibiotic–free well because we consistently saw a slight increase in OD600 in 
the co-cultures at sublethal concentrations, possibly due to a low level of cell lysis and 
subsequent boost for the cross-feeding partner (196, 254).  
We used the Loewe additivity method to identify the nature of our antibiotic interactions 
as previously described (88). Briefly, we calculated the fractional inhibitory 
concentration (FIC) for antibiotics A and B as follows: FICA = (MICA in combination / MICA 
alone), and FICB = (MICB in combination / MICB alone). FIC values were obtained for each well 
at the edge of growth, as shown in Figure 4.1. The FICI is the sum of FICA and FICB 
(255). As there are multiple FICI values per plate, we chose to report the median FICI 
value as the plate value. We did not use the minimum or maximum FICI value so that 
we would not over-interpret synergy or antagonism results, respectively (256). 
Minimum FICI values can be found in Supplementary table S4.3. Our cut-off values 
were designed as follows: FICI < 0.8 represents synergy; FICI between 0.8 and 2 
represent additive interactions, FICI between 1 and 2 represent independent interactions, 
and FICI ≥ 2 represents antagonism (255–258). Isobolograms were generated by plotting 
the FICA and FICB values as x,y coordinates. A straight line connecting the FIC values 





Based on observed monoculture growth patterns (MICs and FICs in each antibiotic 
combination), we predicted co-culture growth patterns assuming weakest link dynamics; 
that is, co-cultures should only grow at concentrations of both antibiotics where both 
species are able to grow in monoculture. We then calculated FICs and FICIs for these 
predicted co-culture plates and compared them to our observed data. We then used a 






Based on previous results in E. coli (238), we tested ten combinations of six antibiotics 
for synergy or antagonism in E. coli and S. enterica monocultures (Table 4.1). The 
mechanism of action for each of these antibiotics can be found in Supplementary table 
S4.1. Each combination was tested in triplicate and minimum inhibitory concentrations 
(MICs), fractional inhibitory concentrations (FICs) and fractional inhibitory 
concentration indices (FICIs) were obtained after 48 hours of growth at 30°C (Figure 
4.1). To avoid over– or under– interpretation of the antibiotic interactions, we used the 
median FICI value for each plate and the mean value from each of the three replicate 
plates for each antibiotic combination. 
Previous work from our lab has shown that co-culture growth in the presence of 
antibiotics is dependent on weakest link dynamics (120). This hypothesis predicts that 
the MIC of an obligately cross-feeding co-culture is set by the MIC of the least tolerant 
species in the community. This phenomenon allows us to determine how antibiotics 
should interact in co-culture based on how they interact in each monoculture. A sample 
of these predictions are detailed in Figure 4.2. In brief, the co-culture is predicted to 
grow only where both species can grow individually (see plate diagrams). The impact of 
weakest link dynamics on antibiotic interactions depends on whether the weakest link 
species is the same or different in both antibiotics, and how the antibiotics interact with 
each species. In scenario 1, the weakest link species differs in each antibiotic, but in both 
species the antibiotic effects are independent of each other; therefore, the antibiotics 
should also be independent in co-culture. This is seen in the FICI plots (where the 




line). In scenario 2, the antibiotics synergize in both species, but because weakest link 
species differs in each antibiotic, the synergism is weakened (though still present) in co-
culture. In scenario 3, the antibiotics antagonize in both species. However, in E. coli, 
antibiotic B antagonizes antibiotic A (i.e. as the concentration of B increases, the MIC of 
A also increases), but not vice versa (i.e. the MIC of B does not change as the 
concentration of A increases). In S. enterica, antibiotic A antagonizes antibiotic B but 
not vice versa. This leads to a ‘cancelling out’ of the antagonistic interactions in co-
culture and causes the antibiotics to interact independently. In scenario 4, E. coli is the 
weakest link species in both antibiotics. Therefore, the co-culture antibiotic interaction 
pattern exactly matches that of E. coli.  
We first tested whether the antibiotic combinations we selected would interact as 
predicted in the literature in our monocultures. We tested each antibiotic combination in 
triplicate for E. coli and S. enterica, then calculated the median FICI value for each plate 
and combination (Figure 4.3). Our categories were designated as follows: FICI < 0.8 
represents synergy; FICI between 0.8 and 2 represent additive interactions, FICI 
between 1 and 2 represent independent interactions, and FICI ≥ 2 represents antagonism. 
These are less stringent than other FICI results, as we chose median values to minimize 
the impact of plate-to-plate variation, which tends to bias FICI results towards additive 
or independent interactions. We also looked at isobolograms (Figure 3.4) of each 
antibiotic combination for each species, to get a more visual/qualitative examination of 
interactions between antibiotics. Supplementary tables S4.2 and S4.3 contain raw 




Interestingly, we did see some deviations from our prediction. Nalidixic acid/bleomycin 
and streptomycin/ciprofloxacin were predicted to synergize; however, our FICI and 
isobologram data show additive/independent interactions for these antibiotics in both 
species. Nalidixic acid and streptomycin did synergize as predicted in E. coli, but not in 
S. enterica. Of the three pairs of antibiotics predicted to antagonize (nalidixic acid/ 
spectinomycin, nalidixic acid/doxycycline, and spectinomycin/streptomycin), only the 
last showed potentially antagonistic interactions; the others all interacted independently. 
Finally, we observed some unexpected synergy in our antibiotic pairs which were 
predicted to interact additively/independently. Ciprofloxacin/bleomycin synergized in E. 
coli, and spectinomycin/doxycycline synergized in both species; however, this is more 
evident in the FICI data than in the isobolograms. The isobolograms suggest that low 
concentrations of doxycyline decrease the MIC of spectinomycin, but not vice versa; 
that is, doxycyline synergizes with spectinomycin to increase the latter’s potency, but 
spectinomycin does not change the effect of doxycycline.  
Based on our results from monoculture and our weakest link hypothesis, we then 
predicted the antibiotic interactions which would arise in obligate cross-feeding co-
culture. To generate these predictions, we examined the monoculture growth patterns in 
each antibiotic combination (i.e. at which concentrations of each antibiotic monoculture 
growth occurred). We then generated a predicted growth pattern for the co-culture 
wherein growth would only occur at antibiotic concentrations where both species could 
grow. From this predicted growth pattern, we calculated FICIs and generated 
isobolograms; these can be seen in Figure 4.5 and 4.6, respectively. An example of how 




According to our predictions, if one species is the weakest link (i.e. the least tolerant) in 
both antibiotics, the co-culture interaction typically matched that of the weakest link 
monoculture. This is the case for nalidixic acid/bleomycin and nalidixic 
acid/ciprofloxacin (where S. enterica is the weakest link), and for 
streptomycin/ciprofloxacin, spectinomycin/streptomycin, streptomycin/doxycyline, and 
spectinomycin/doxycycline (where E. coli is the weakest link). Co-culture predictions 
were somewhat more complicated for the other combinations (nalidixic acid/ 
streptomycin, nalidixic acid/spectinomycin, nalidixic acid/doxycycline, and 
ciprofloxacin/ bleomycin), where each species is the weakest link in a different 
antibiotic. We were particularly interested in nalidixic acid/streptomycin, as these 
antibiotics synergize in E. coli (which is the weakest link in streptomycin) and interact 
independently in S. enterica (which is the weakest link in nalidixic acid). Based on the 
differences in MIC in these species in each antibiotic (see Supplementary table S4.4), 
we predicted an independent interaction in co-culture. Similarly, in the ciprofloxacin/ 
bleomycin combination, the antibiotics verged on antagonizing in E. coli and interacted 
independently in S. enterica; however, their MICs were similar in both antibiotics. This 
provided an opportunity to examine interactions in co-culture where weakest link 
dynamics might play less of a role.  
After generating predicted FICIs based on our monoculture results and weakest link 
dynamics, we tested antibiotic interactions in co-culture. We then compared our 
predicted FICIs to those observed experimentally for each antibiotic combination. 
Qualitatively, our predictions based on weakest link were accurate — the antibiotic 




matched the interaction category identified by the observed FICIs (Figure 4.5, see 
Supplementary Table S4.5 for raw FICI data). This supports our hypothesis that 
weakest-link dynamics can be used to predict antibiotic interaction categories in co-
culture. The one exception to this was in the spectinomycin/ streptomycin combination. 
While there was no statistical significance in this difference, (P= 0.37), we predicted an 
independent interaction and observed an antagonistic interaction. Interestingly, the 
isobologram suggested that antibiotics antagonized much more in co-culture than we 
predicted. This suggests that weakest-link dynamics may not always predict co-culture 
outcomes and that some other factor may be determining antibiotic interactions in this 
case. Quantitatively, our FICI predictions also matched that of our observed data (see 
Supplementary Table S4.6 for all P-values), with one exception. The predicted FICI 
for the nalidixic acid/ spectinomycin combination was significantly higher than 
predicted (P= 0.037), but this difference still resulted in independent interactions and so 
is likely not biologically significant. Overall, weakest-link dynamics were generally 






The goal of this work was to identify whether our previously identified weakest link 
hypothesis, wherein the antibiotic tolerance of a mutualistic co-culture is set by the 
weakest link species, could change drug interaction patterns in antibiotic combinations. 
We tested previously identified antibiotic combinations in each of our monocultures. 
Few of the predicted interactions applied to our monocultures, possibly for reasons 
discussed below. However, we then used the interactions we identified in monoculture, 
as well as our knowledge of weakest link dynamics, to predict how each set of 
antibiotics would interact in co-culture. We found that our predictions were qualitatively 
correct, with predicted and observed FICIs and isobolograms falling into the same 
antibiotic interaction category (synergistic, additive, independent, or antagonistic). The 
one exception to this was the spectinomycin/streptomycin combination, which 
antagonized more strongly in co-culture than we predicted from monoculture.  
Our findings demonstrate an important and hitherto unexplored explanation for why in 
vivo antibiotic interactions do not match in vitro assay predictions. Many infections are 
now known to be polymicrobial (11–14) and likely involve some form of cooperative 
metabolite exchange. These ecological interactions may be at least partially responsible 
for the difficulty in finding a successful synergistic antibiotic treatment. Indeed, our 
results suggest that cross-feeding generally ablates any antagonistic/ synergistic 
antibiotic interactions unless one partner is the weakest link in every antibiotic (Figure 
4.2); whether or not this is the case in natural microbial communities is unknown. 
Helpfully, our results suggest that the antibiotic interactions at the community level are 




interaction patterns are known for each species in the community, the antibiotic 
interaction pattern is generally predictable based on weakest link dynamics. This adds 
further weight to the argument that microbial ecology must be considered when treating 
bacterial infections in the clinic.  
Unexpectedly, the antibiotic interactions that we observed in our monocultures did not 
match the interactions that Yeh et al. had previously observed (238). The most likely 
reason for this is their use of a growth rate-based measurement method, a dose-response 
curve (86), versus our yield-based checkerboard assay. We elected to do a yield-based 
method because it allowed us to more highly parallelize our experiments and decrease 
plate-to-plate variation in cell density and growth phase, both of which are known to 
significantly impact antibiotic tolerance (81, 259, 260). Much research has been done on 
the best method for assessing antibiotic synergy/antagonism (86, 92, 239); we selected 
the checkerboard method also because of its widespread use and ease of interpretation. 
Future experiments using dose-response curves might be particularly important for 
cross-feeding systems such as ours, as cross-feeding is known to alter growth rates of 
member species (140, 261).  
An additional challenge in interpreting antibiotic interactions in multispecies contexts is 
the possibility of antibiotic interactions changing depending on which species is the 
weakest link at a given combination of antibiotic combinations. Taking the largest FICI 
value from a plate biases results towards antagonism and taking the smallest value biases 
towards synergy. Therefore, the median value is useful in avoiding overinterpretation of 
data; however, it obscures any concentration-specific changes in interactions which 




provide more information as to how the antibiotics are interacting at different 
concentration combinations than FICIs. The isobologram of nalidixic acid/bleomycin in 
Figure 4.6 provides a good example of this. The predicted co-culture isobole showed 
additive-synergistic interactions; however, the observed co-culture isobole showed 
synergistic interactions at low bleomycin FIC values. A similar pattern is seen with 
ciprofloxacin/bleomycin in the same figure. While these patterns may be artifacts of our 
system, it remains possible that checkerboard assays involving multiple species may 
produce isobologram patterns which deviate from the typical convex/concave, 
antagonism/synergy pattern seen in monocultures. Mathematical modeling of how 
different antibiotic interactions and MICs in each species impact co-culture antibiotic 
interactions may be a useful way to explore this possibility.  
The one drug interaction in our study where weakest link dynamics appeared insufficient 
to predict co-culture interactions was the streptomycin/spectinomycin combination. 
These drugs were predicted to antagonize in E. coli; though they have similar 
mechanisms of action, spectinomycin ionically inhibits entry of streptomycin into the 
cell (262). Given that E. coli was the weakest link in both antibiotics, we predicted 
similar dynamics in co-cultures; additive interactions bordering on antagonism (i.e. 
FICIs between 1.5 and 2). However, the degree of antagonism that we observed was 
much higher than predicted. There could be several reasons for this. Given that 
disruptions in protein biosynthesis have pleiotropic effects on cell physiology and 
metabolism (263), the application of both drugs might have sufficiently disrupted the 
cross-feeding between our species such that they starved at otherwise sublethal 




change metabolic profile (266, 267) of cells is well known; what is less clear is how this 
might impact metabolite exchange in antibiotic-exposed natural microbial communities. 
The complex and often non-obligate metabolite exchange food webs in natural 
communities (268, 269) might make this question difficult to answer, but our study 
suggests that weakest link dynamics are a useful null hypothesis starting point. 
Though much research has been done in vitro on antibiotic synergy/antagonism, it 
remains unclear what the biological/clinical relevance of any of these interactions truly 
are. With a few exceptions (90, 231), antibiotic synergy has yet to be adopted as a 
clinically important treatment strategy due to a variety of factors. Differences in drug 
half-life and bioavailability can impact effective dosages in vivo (270), and strain-
specific resistance profiles make assessment of antibiotic synergy challenging in the 
clinic (86). However, antibiotic combinations may become an increasingly critical 
clinical tool as resistance continues to rise (250). Further research is therefore required 
not just on how antibiotics interact in vitro, but how they interact in natural 










Chapter 4 Figures and Tables 
Table 4.1 Antibiotic combinations used in the study and their predicted interactions in 
E. coli based on Yeh et al. 2006. 
Synergy Antagonism Additive 
Nalidixic acid and 
streptomycin 
Nalidixic acid and 
spectinomycin 
Nalidixic acid and 
ciprofloxacin 
Nalidixic acid and 
bleomycin 






















Figure 4.1 Antibiotic interaction experimental setup and hypotheses. A. The two-species 
obligate cross-feeding system. When lactose is supplied, E. coli uses it to produce 
acetate for S. enterica, which produces methionine for E. coli. Each species can be 
grown in co-culture or monoculture, depending on the metabolites supplied. B. Setup for 
checkerboard assays. Seven antibiotic concentrations plus one antibiotic–free well were 
developed for each antibiotic/ species combination, with the MIC approximately in the 
middle of the gradient. Mid-log phase cells were inoculated into plates containing 
species-specific growth medium and antibiotic at twofold dilutions. Cells were allowed 
to grow for 48 hours at 30°C with shaking, and a Tecan plate reader was used to 
measure growth at OD600. Growth was defined as an OD600 above 10% of the 
maximum OD600 obtained on each plate. Three replicates of each antibiotic/ culture 
condition were obtained. C. Table of calculations for fractional inhibitory concentrations 





 Plate diagram FICI plots Isobolograms 
Scenario 1:  
• Species-level: 
independent interactions 
• Community level: 
independent interactions 
• Each species has a 
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Scenario 2:  
• Species-level: synergistic 
interactions 
• Community level: 
independent interactions 
• Each species has a 
different MIC in each 
antibiotic 
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Scenario 3:  
• Species-level: 
antagonistic interactions 
• Community level: 
independent interactions 
• Each species has a 
different MIC in each 
antibiotic and direction of 
antagonism differs for 
each species 
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Scenario 4:  
• Species-level: synergistic 
interactions in E. coli, 
independent interactions 
in S. enterica 
• Community level: 
synergistic interactions 
• E. coli has the lowest 
MIC in each antibiotic 
 
  0 0.5 1 2 4 8 16 32 
0                 
0.5                 
1                 
2                 
4                 
8                 
16                 





























































Figure 4.2 Antibiotic interactions at the species level versus the co-culture level. In the plate diagrams (simulated data), blue cells 
represent concentrations where only E. coli can grow; yellow cells represent concentrations where only S. enterica can grow, and 
green cells represent concentrations where the co-culture can grow (i.e. concentrations where both monocultures can grow). 
Antibiotic A is on the y-axis and antibiotic B is on the X-axis. Points that fall below the red dotted line on FICI plots represent 
synergistic interactions; points that fall above the green dotted line represent antagonistic interactions. FICI plots and isobolograms 








Figure 4.3 Fractional inhibitory concentration index (FICI) plots of E. coli and S. 
enterica monocultures across ten antibiotic combinations. Each point represents the 
mean +/-SE of three replicate FICI values from three biological replicates. FICIs on each 
plate represent the median FICI value from the plate. Antibiotic abbreviations: Nalx= 
nalidixic acid; strep= streptomycin; bleo= bleomycin; cipro= ciprofloxacin; spx= 





































E. coli S. enterica
Points below the red line represent synergy
Points above the green line represent antagonism










Figure 4.4 Representative isobolograms of E. coli and S. enterica monoculture 
fractional inhibitory concentrations (FICs) across ten antibiotic combinations. FICs were 
calculated based on 48 hours of 30°C growth, and growth was identified as any well 
which had an OD600 at least 10% of the highest OD600 well on each plate. Each axis 
corresponds to a fractional inhibitory concentration (FIC) for the antibiotic pair. The 
black 1-1 line represent a perfectly independent interaction; a concave line towards the 
origin represents a synergistic interaction, and a convex line away from the origin 







Figure 4.5 Fractional inhibitory concentration index (FICI) plots of predicted and actual 
co-cultures across ten antibiotic combinations. Each point represents the mean +/-SE of 
three replicate FICI values from three biological replicates. FICIs on each plate represent 
the median FICI value from the plate. Asterisks represent P < 0.05 for predicted versus 
observed ES co-culture FICs were compared with a Mann-Whitney U test. P-values can 
be found in Supplementary table S4.6. Antibiotic abbreviations: Nalx= nalidixic acid; 











Figure 4.6 Representative isobolograms of predicted and observed co-culture fractional 
inhibitory concentrations (FICs) across ten antibiotic combinations. Predicted FICs were 
determined based on monoculture FICs and hypothesized weakest link dynamics (i.e. 
co-culture growth could only occur at concentrations of both antibiotics where both 
species could grow alone). Observed co-culture FICs were calculated based on 48 hours 
of 30°C growth, and growth was identified as any well which had an OD600 at least 






Supplementary table S4.1 Mechanism of action of antibiotics used in this study. 
Antibiotic Mechanism 
Bleomycin Induces DNA breaks; may inhibit thymidine incorporation into DNA 
Ciprofloxacin Fluoroquinolone: binds DNA gyrase and topoisomerase IV 
Nalidixic acid Naphthyridone: binds DNA gyrase and topoisomerase IV 
Doxycycline Binds 30s ribosomal subunit to prevent protein biosynthesis 
Spectinomycin Binds 30s ribosomal subunit to prevent protein biosynthesis 






Supplementary table S4.2 Median FICIs for E. coli and S. enterica in monoculture 
across ten antibiotic combinations and three replicates. FICIs for each replicate are the 
median FICI value per plate. FICI values below 0.8 are considered synergy; FICIs 
between 0.8 and 1 are additive interactions, FICIs between 1 and 2 are independent 
interactions, and FICIs above 2 are antagonistic interactions.  








0.75 0.625 0.8828125 
Nalidixic acid/ bleomycin 0.6875 0.75 1.125 
Streptomycin/ 
ciprofloxacin 
1.125 0.625 1.0625 
Nalidixic acid/ 
spectinomycin 
1.0625 0.75 1.375 
Nalidixic acid/ doxycyline 1.25 1.1875 1.375 
Spectinomycin/ 
streptomycin 
2.5 1.5 1.5 
Nalidixic acid/ 
ciprofloxacin 
1.0625 1.0234375 1.0625 
Ciprofloxacin/ bleomycin 0.546875 0.5625 1.03125 
Streptomycin/ doxycyline 1 1.046875 1.1875 
Spectinomycin/ 
doxycycline 







1.1875 1.015625 1.0625 
Nalidixic acid/ bleomycin 1.1875 0.75 1.0625 
Streptomycin/ 
ciprofloxacin 
1.125 0.75 1.03125 
Nalidixic acid/ 
spectinomycin 
1.25 1.125 1.125 






1.25 0.875 1.09375 
Nalidixic acid/ 
ciprofloxacin 
1.1875 1.09375 1.03125 
Ciprofloxacin/ bleomycin 1.1875 1.03125 1.0625 
Streptomycin/ doxycyline 1.1875 1.09375 1.03125 
Spectinomycin/ 
doxycycline 






Supplementary table S4.3 Minimum FICIs for E. coli and S. enterica in monoculture 
across ten antibiotic combinations and three replicates. FICIs for each replicate are the 
minimum FICI value per plate. FICI values below 0.8 are considered synergy; FICIs 
between 0.5 and 1 are additive interactions, FICIs between 1 and 2 are independent 
interactions, and FICIs above 2 are antagonistic interactions.  








0.5625 0.5 0.5625 
Nalidixic acid/ bleomycin 0.5625 0.5 1.015625 
Streptomycin/ 
ciprofloxacin 
1 0.5 1 
Nalidixic acid/ 
spectinomycin 
0.625 0.53125 1 
Nalidixic acid/ doxycyline 1.0625 1.03125 1.0625 
Spectinomycin/ 
streptomycin 
1.0625 1.015625 1.015625 
Nalidixic acid/ 
ciprofloxacin 
0.75 0.625 0.75 
Ciprofloxacin/ bleomycin 0.375 0.375 0.5 
Streptomycin/ doxycyline 0.625 1 1.03125 
Spectinomycin/ 
doxycycline 







1.0625 0.5625 1 
Nalidixic acid/ bleomycin 1.0625 0.5625 0.75 
Streptomycin/ 
ciprofloxacin 
1 0.5625 0.625 
Nalidixic acid/ 
spectinomycin 
1.0625 1 1 






1 0.53125 1 
Nalidixic acid/ 
ciprofloxacin 
1.0625 1 0.625 
Ciprofloxacin/ bleomycin 1.0625 0.625 0.75 
Streptomycin/ doxycyline 1.03125 1 0.75 
Spectinomycin/ 
doxycycline 
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Supplementary figure S4.1 Example of developing predicted FICIs from replicate 1 of 
nalidixic acid/ spectinomycin combination. Growth patterns of E. coli (A) and S. 
enterica (B)monocultures were used to predict growth patterns for the co-culture (C). 
FICIs and isobolograms were developed from this predicted data as previously 
described, and these were compared to real data obtained from co-cultures (D). 
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Supplementary table S4.4 Minimum inhibitory concentrations (MICs) of each species 
in each antibiotic, predictions for co-cultures based on weakest link, and actual co-
culture MICs. MICs were defined as the lowest concentration of antibiotic required to 
inhibit growth below 10% of the densest well (by OD600) within a plate. Medians and 
ranges are displayed. Predicted co-culture MICs are based on weakest link hypothesis 
(i.e. the co-culture will be limited by the least resistant monoculture).  
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Supplementary table S4.5 Observed fractional inhibitory concentration indices (FICIs) 
for each antibiotic combination in monoculture and co-culture, and predicted co-culture 
FICIs based on weakest link. FICIs are median values from three biological replicates 
each. Red cells represent synergistic interactions (median FICI<0.8); green cells 













0.75 1.06 1.13 1.13 
Nalidixic acid/ 
bleomycin 
0.75 1.06 1.06 0.88 
Streptomycin/ 
ciprofloxacin 
1.06 1.03 1.06 1.05 
Nalidixic acid/ 
spectinomycin 
1.06 1.13 1.13 1.25 
Nalidixic acid/ 
doxycyline 
1.25 1.03 1.19 1.38 
Spectinomycin/ 
streptomycin 
1.50 1.09 1.50 2.13 
Nalidixic acid/ 
ciprofloxacin 
1.06 1.09 1.13 1.25 
Ciprofloxacin/ 
bleomycin 
0.56 1.06 1.05 1.06 
Streptomycin/ 
doxycyline 
1.05 1.09 1.05 0.88 
Spectinomycin/ 
doxycycline 






Supplementary table S4.6 Mann-Whitney U statistical test results for predicted vs. 
observed FICI results.  
Antibiotic combination P-value for predicted vs. observed FICI 
Nalidixic acid/ streptomycin 0.49 
Nalidixic acid/ bleomycin 0.66 
Streptomycin/ ciprofloxacin 0.50 
Nalidixic acid/ spectinomycin 0.037 
Nalidixic acid/ doxycyline 0.50 
Spectinomycin/ streptomycin 0.37 
Nalidixic acid/ ciprofloxacin 0.18 
Ciprofloxacin/ bleomycin 0.10 
Streptomycin/ doxycyline 0.51 












Cross-feeding and antibiotics: more questions raised than answered 
Overall, my thesis focused on how obligate metabolic cross-feeding modulates the 
impact of antibiotics on bacterial communities. Using a model obligate cross-feeding 
bacterial community, I approached this question in three main ways. First, I examined 
the ecological impact of cross-feeding; that is, how do monocultures versus communities 
respond to antibiotics over a single growth phase? I found that community antibiotic 
tolerance (the ability to grow at a given antibiotic concentration) is generally set by the 
‘weakest link’ species— the most antibiotic-sensitive species in monoculture. Highly 
resistant species have lowered tolerance in cross-feeding contexts due to their 
dependence on more sensitive cross-feeding partners. Second, I asked whether the rate 
and mechanism of resistance evolution could be impacted by cross-feeding. I found that 
cross-feeding communities evolved resistance more slowly than monocultures (both in 
wet-lab and modeling experiments) and that mechanisms of resistance may differ 
between the two. Excitingly, under ampicillin selection, I found that loss-of-function 
mutations in the penicillin-binding protein ftsI only evolved in co-culture due to its 
conditional lethality in monoculture at neutral pH. Third, I examined how antibiotic 
synergy/ antagonism might be impacted by cross-feeding interactions using 
checkerboard assays. I found that weakest link dynamics also generally explained 
antibiotic interactions in cross-feeding communities, and that this abrogated synergistic 
or antagonistic interactions unless one species was the weakest link in both antibiotics. 
This research adds to an already dense body of literature on antibiotic resistance ecology 
and evolution but makes critical contributions in the often-overlooked impact of 




Despite the plethora of research on antibiotic resistance, and even antibiotic resistance in 
multispecies contexts, many aspects of this field remain understudied. Even in my own 
research, there are several outstanding questions that have arisen over the course of my 
studies which warrant further investigation. Many of these pertain to the evolved 
mechanisms of resistance which I began investigating in chapter 3, and to how the work 
in chapters 3 and 4 might be combined to investigate the evolution of broad-spectrum 
resistance in cross-feeding communities. I also discuss other avenues of research which 
seem important next steps based on my work, including the impacts of sublethal 
antibiotic concentrations, mutator strains, the role of competitive interactions on 
resistance evolution, and some specific antibiotics which should have particularly strong 
effects in cross-feeding communities. Finally, I discuss possible extensions of my 
findings into clinical settings and ecological studies on mutualism stability.  
Defining resistance in microbial communities: MIC is insufficient 
Perhaps the most useful concept that I have taken away from my thesis work is that 
metrics that purport to measure antibiotic resistance/ tolerance only do so within a 
narrow set of biological parameters. An MIC, for example, is not actually an objective 
measure of antibiotic resistance. Rather, it measures the ability of a specific bacterial 
strain of a specific population size at a specific growth phase to grow to an arbitrary 
density or within an arbitrary time point, in the presence of an antibiotic that may or may 
not be at the predicted concentration, depending on whether it degrades over time. The 
growth rate dependence proved particularly problematic in my experiments in chapter 2 
and necessitated the development of a novel MIC metric to contend with the differences 




are well-established even in monoculture studies (110, 271); this will only get worse as 
resistance studies begin to include more polymicrobial communities. The definition of 
resistance/ tolerance, as my research shows, is dependent on how one tests it. P. 
aeruginosa is highly ampicillin-resistant when grown alone in glucose, but highly 
ampicillin-sensitive when grown on mucin with its cross-feeding partners (chapter 2). 
Synergy testing is likely to be similarly affected by this issue, particularly synergy 
assays such as the checkerboard assay which rely on MICs. Our current methodologies 
for assessing resistance barely consider induced tolerance mechanisms like changes in 
growth rate or cellular permeability; they are certainly not designed to appropriately 
assess community resistance.  
Ecological theory and experiments on community resistance and resilience may provide 
some useful alternative ways to describe the impact of abiotic selection pressures on 
microbial communities. Resistance is defined as the ability of a community to remain 
unchanged in the face of a disturbance (such as antibiotic administration), whereas 
resilience describes the ability of a community to return to its pre-disturbance state (52, 
272). Both these descriptors are clinically relevant— antibiotics should both eliminate a 
pathogen (or pathogenic community) and prevent it from recurring. However, 
prioritizing antibiotic therapy which targets resistance rather than resilience can result in 
recurring infections which have low resistance but high resilience— for example, due to 
persister formation of a small percentage of the population. Resilience must therefore 
also be taken into account when assessing clinical resistance— possibly by redefining 
MIC as the concentration of antibiotic required to suppress growth of a population and 




remains much work to be done on determining the appropriate way to define and 
measure antibiotic resistance, particularly in multispecies communities where 
interspecies interactions, fitness effects, and many other factors may influence the ability 
of the pathogen(s) to grow and cause disease.  
My finding that ftsI mutations only arose in a co-culture study also raises some questions 
regarding the accurate identification of antibiotic resistance genes (ARGs) from 
environmental metagenome data. ARGs are typically defined based on monoculture 
studies and/ or sequence similarity to previously identified ARGs (273). If cross-feeding 
selects for unique ARGs not found in monoculture studies but ubiquitous in 
environmental communities where cross-feeding is common, it is likely that such 
resistance genes will be overlooked in these studies. It is also possible that mutations 
identified in metagenomic sequence data do confer antibiotic resistance, but only in the 
context of the whole microbial community; for example, if the ARG/ mutation had high 
costs in monoculture that were reduced by polyculture growth. If these mutations were 
investigated in laboratory monocultures, they would likely be missed— possibly because 
of their different costs/ benefits in monoculture vs. polyculture, as was the case with the 
ftsI mutations we evolved. Future studies investigating novel resistance mechanisms in 
ARGs might therefore benefit from studying resistance in the context of a microbial 
ecosystem to better understand how metabolic interactions drive the selection of 






Extensions of the antibiotic resistance evolution experiments  
One drawback to my experiments in chapter 3 is the lack of molecular biology 
experiments and data to back up any conclusions that a given mutation confers 
resistance. The ability to move mutations between the evolved resistant and ancestral 
strains would facilitate a plethora of future experiments, particularly related to fitness 
costs and benefits of resistance. I observed many mutations arising in only the resistant 
populations which, based on their function, seem to have little to do with resistance (the 
mdoG and mdoH mutations in monoculture–evolved rifampicin-resistant populations, 
for example). It would be informative to engineer these mutations into a clean genetic 
background and test the fitness and growth rate effects of mdoG mutants alone versus 
mdoG/ rpoB double mutants. I predict that mdoG mutations themselves do not confer 
high-level resistance, but that they synergize with rpoB mutations to decrease the cost of 
resistance. However, there is some evidence that mdoG/ mdoH mutations do contribute 
to resistance directly. Previous work in E. coli has shown that premature stop codon 
mutations in mdoH (opgH) led to increased resistance to rifampicin, increased mucoidy 
(though this was not related to the increased tolerance), and reduced cell size (199). In 
Pseudomonas aeruginosa, the opgGH operon is induced under low osmotic conditions 
and likely contributes to proper cell envelope organization, but does not play a role in 
resistance to tobramycin (274); however, other periplasmic glucans have been shown to 
directly interact with and inhibit tobramycin in P. aeruginosa biofilms (275, 276). In 
Salmonella enterica and Shigella flexneri, deletion of opgGH abolished osmoregulated 
periplasmic glucan (OPG) biosynthesis, increased the lag time of bacterial growth in 




possible that mdoH and mdoG mutations are providing resistance, but we were unable to 
detect it due to a lack of statistical power and/ or the overwhelming effect of rpoB 
mutations. The generation of a mutant with wild-type rpoB and mutant mdoG would 
answer this question.  
An additional utility of a mutation-moving system would be to track individual 
genotypes (such as isogenic strains with wild type vs. putative resistance mutations) 
using different fluorescent markers. This would allow me to perform competition 
experiments, both in co-culture and monocultures, to test some hypotheses about the 
differential fitness costs of resistance mutations in monoculture vs. co-culture (97). For 
example, I would be particularly interested in whether the different ftsI mutants from 
chapter 3 (the knockout Q142* or the +A frameshift) are more fit than the D534Y 
mutant. The latter is still able to grow in monoculture at pH 7, unlike the other two 
mutants which require pH 4.7 to grow in monoculture— this suggests that the D534Y 
mutant still produces at least some functional ftsI protein, and the other mutants do not. 
In one replicate population of the co-culture evolved under ampicillin, the D534Y 
mutation was at 75% frequency, while the Q142* mutation was at 9% (and the two did 
not co-occur in any of the isolates that I sequenced). However, by passage 20 (which 
was not reported due to contamination issues), the Q142* mutation had swept to fixation 
and the D534Y mutation had been lost. This suggests that a complete loss-of-function in 
ftsI either is required to provide higher-level resistance, or the loss-of-function mutation 
is more fit, or additional mutations were evolved between passage 10 and 20 that 




mutants and a way to fluorescently track them individually would allow me to compete 
them in co-culture in the presence or absence of ampicillin to test these possibilities.  
A persistent issue that I encountered when testing the fitness effects of different 
resistance-associated mutations in this study was the inability to test the fitness of these 
mutants in the environment in which they evolved. Ideally, to measure the fitness of an 
antibiotic-resistant mutant, I would measure its growth rate at the concentration of 
antibiotic at which it was obtained from the evolution experiment (97). However, the 
appropriate control in this experiment is unclear. An ancestral strain would be ideal, but 
the antibiotic concentrations at which I obtained my resistant isolates did not allow for 
any wild-type growth. Another option is using an ancestral strain carrying a resistance 
plasmid, but that itself likely has fitness costs that would be difficult to control for. 
Competition experiments between ancestral and evolved resistant isolates pose a similar 
problem, in addition to the issue of not being able to distinguish different genotypes 
without screening possibly hundreds of colonies. The best option in this case may be to 
compete different resistant genotypes and describe their relative fitness, rather than the 
fitness of the evolved resistant genotype versus that of the ancestor.  
During the evolution experiment described in chapter 3, I froze down populations of 
cells at each passage for further analysis. Though I sequenced the most resistant and 
antibiotic–free lines at the final passage (10 for ampicillin, 20 for rifampicin), there 
remains several generations’ worth of un-sequenced evolutionary history in populations 
from earlier passages. Numerous experiments could be done on these, including ones 
testing the evolution of sublethal resistance as described above. Another, related 




order do resistance-associated mutations arise in these populations? In an evolution 
experiment to identify determinants of carbapenem resistance, Adler et al. (279) 
identified ompR or envZ as the first-step mutations conferring resistance. Presumed loss-
of-function mutations in ompR conferred the highest levels of resistance, and envZ point 
mutations conferred lower levels of resistance. Second-step mutations to resistance in 
ompR mutant backgrounds tended to be in ompF, whereas mutations in envZ 
backgrounds tended to be in ompC. (279). I observed many of these mutations in the 
ampicillin-evolved populations— sequencing the most resistant population from each 
replicate at each passage, and perhaps testing isolate growth rates, would be one way to 
identify similar patterns. It would also be interesting to test whether epistatic patterns are 
similar in monocultures or co-cultures, as the costs of different mutations (and the 
associated fitness landscape) might change with the addition of a cross-feeding partner.  
Evolution of resistance to multiple drugs: collateral sensitivity and resistance 
An important next step in this research will be to combine the work done in chapters 3 
and 4 and examine how co-cultures evolve resistance to multiple antibiotics at once. In 
theory, combination therapy offers a useful tool for limiting the evolution of resistance 
in bacteria. Combination therapy is based on the assumption that it is more challenging/ 
less likely that bacteria will evolve resistance to two antibiotics with two different 
mechanisms of action, thereby necessitating two resistance mutations, than to evolve 
resistance to a single antibiotic (93). Additionally, the decrease in antibiotic dosages 
required when antibiotics synergize has obvious advantages in decreasing the 
evolutionary pressure on bacteria to evolve high-level resistance (88). This approach has 




which are known for rapid drug resistance evolution. However, some research suggests 
that antibiotics which synergize in the short term may actually facilitate the evolution of 
resistance, while antagonistic interactions suppress resistance evolution (88, 280, 281). 
Additionally, multidrug efflux pumps present a unique problem in employing this 
strategy in bacteria. Many efflux pumps are able to export a variety of structurally 
unrelated antibiotics and are easily transferred among diverse bacterial species on 
resistance plasmids (63, 282). Thus, a single mutation in a regulatory region, or 
acquisition of a plasmid containing a single efflux pump, might confer resistance to 
multiple drugs at once. The utility of combination therapy, and its potential for treating 
infections and limiting the evolution of resistance, therefore, remains unclear.  
A growing body of research suggests that collateral sensitivity (wherein evolution of 
high-level resistance to one antibiotic leads to enhanced sensitivity to others) and 
negative hysteresis (an induced hypersensitivity to one antibiotic induced by pre-
exposure to another without an associated genetic change) are common outcomes during 
multiple antibiotic treatment (104, 283, 284). An example of this is the evolution of 
hypersensitivity in E. coli by Lázár et al. They found that evolution of aminoglycoside 
resistance involved a decrease in proton motive force (PMF) across the cell membrane. 
This diminished the effectiveness of PMF-dependent efflux pumps, causing 
hypersensitivity to other antibiotics applied to aminoglycoside-resistant strains (285). 
Clinically, the use of antibiotic cycling protocols which involve sequential or alternating 
administration of different antibiotics have proven highly successful in treating resistant 
infections (106, 286), though whether cycling or mixing (administration of multiple 




Some of this mixed success may have to do with the fact that antibiotic order, type, 
dosage, and cycling time strongly influences collateral sensitivity success (290–292); in 
one study in P. aeruginosa, short cycling times selected against resistance whereas 
longer treatments with each antibiotic selected for high-levels of resistance (293). 
Given the already complex and unclear context-dependence of collateral resistance 
versus sensitivity arising, adding bacterial community context into the mix at first seems 
unreasonable. If combination therapy success is already challenging to predict in 
monocultures, how can adding an additional layer of complexity and unpredictability aid 
in elucidating collateral resistance/ sensitivity research? My results from chapter 4, 
however, suggest that recognizing and appreciating the community context and 
metabolic partners of a focal species can inform predictions about antibiotic synergy and 
antagonism. It is possible that part of the difficulty in determining a single successful 
multidrug treatment for a given pathogen, for example, is due at least in part to the 
different commensal species that it interacts with. Studying the evolution of collateral 
resistance/ sensitivity in vitro using not only single species, but species consortia, might 
produce more reliable predictions for which antibiotic combinations most successfully 
synergize and/ or limit resistance evolution in vivo. Choosing the correct level at which 
to study the form and function of bacteria in communities remains an open question 
(294, 295), but in this case the added complexity of a multispecies system may help 
clarify the variation in efficacy of combination therapy in the clinic. Synergistic 
interactions among bacterial species may, for example, modulate synergy of antibiotics 





Sublethal antibiotic resistance 
The impacts of sublethal antibiotic exposure, while not explored in the research 
described above, is an essential part of understanding resistance evolution in cross-
feeding communities. In natural environments such as soil, selection at sublethal levels 
of antibiotic may be a more realistic scenario as bacteria are exposed to antibiotic runoff 
from agricultural, industrial, and waste-water treatment runoff , as well as natural 
production from soil microbes such as Streptomycetes (297). More specific to my 
research, the existence of a weakest link species by extension assumes that there are 
other, more resistant species in the community. In the presence of antibiotic 
concentrations which permit community survival, these non-weakest link species must 
then be growing and surviving at sublethal antibiotic concentrations. In the resistance 
evolution experiments outlined in chapter 3, the species with the higher resistance in the 
cross-feeding system is effectively experiencing selection at sublethal antibiotic levels, 
which has been shown by several groups to confer high levels of resistance (110, 187). 
This is supported by data showing that individual species-level resistance evolved 
beyond that of the level of community tolerance in our evolved resistant co-cultures 
(Figure 5.1). Thus, I would hypothesize that the mutants which we observed at passage 
20 are most likely mutations which have arisen at sublethal concentrations in prior 
passages and have moved to the ‘most resistant’ front well via passaging, rather than 
mutants which arose and remained at the ‘front’, as these are mutants which evolved at 
high antibiotic concentrations and are therefore likely to be less fit. Further studies 
examining the antibiotic concentration and time point at which these resistance 




Sublethal concentrations of antibiotics have been shown to select for resistance 
mutations with a lower fitness cost, as their more-fit, susceptible competitors are not 
killed at sublethal concentrations as they are at near-MIC concentrations (110). 
Sublethal concentrations of antibiotics also increase mutation rates via induction of the 
SOS response; not only does this increase the likelihood of a resistance mutation arising 
in the exposed population (via increased mutation rates and/ or mobilization of 
transmissible resistance elements), but it also increases the mutation pool available for 
compensatory mutations to arise (298). In the case of human pathogens, these 
compensatory mutations might specifically increase survival within the human host, 
allowing them to outcompete commensal human microbes and transmit more effectively 
between hosts (102). Sublethal concentrations of antibiotics can also themselves increase 
the rate/ frequency of resistance acquisition by HGT and mutation (recombination and 
mutagenesis) (60). This may be a mechanism of niche adaptation, particularly in soil 
environments; the increased mutation rates and increased expression of efflux pumps 
may allow bacterial communities to adapt more quickly to changing environments (102). 
Sublethal antibiotic concentrations can select for resistance mutations which confer 
similar levels of resistance to lethal antibiotic concentration selection, but also conferred 
greater levels of cross-resistance; lethal-selected mutations tended to be in antibiotic-
specific pathways as well (299). 
Evolution at sublethal concentrations has also been shown to change the resistance 
mechanisms evolved (300); this may also partially explain why co-culture–evolved 
ampicillin-resistant S. enterica evolved different resistance mechanisms than in 




antibiotic concentrations and intensities, such as those done by Lindsey et al. (67), will 
help answer this question. Given that resistance mutations evolved at sublethal 
concentrations tend to have a lower fitness cost than those evolved at high antibiotic 
concentrations, I would predict that the difference between rate of resistance evolution in 
monocultures and co-cultures would decrease in an environment where sublethal 
antibiotics were applied. 
Mutator strains 
An additional feature which I did not explore in chapter 3 was the appearance of mutator 
strains in our ampicillin-evolved S. enterica. Recurring antibiotic pressure is known to 
select for mutator strains because the increased mutation rates in these strains lead to an 
increased likelihood that a rare resistant mutant will arise (60). Because sublethal 
antibiotic concentrations favor resistance evolution via many small-step mutations, 
mutator strains (which have mutations in DNA repair genes and therefore have greatly 
increased mutation rates) are enriched for in these environments (297). Interestingly, a 
recent study showed that mutator strains have a similar rate of resistance acquisition to 
their non-mutator counterparts; the mutator strain had higher overall numbers of 
mutations, but the non-mutators showed a stronger bias towards coding (and therefore 
likely adaptive) mutations (229). These strains are clinically problematic; mutator strains 
of Pseudomonas aeruginosa identified in cystic fibrosis patient lungs were associated 
with a threefold increase in the rate of antibiotic resistance acquisition and the 
deterioration of patient lung function (301). Mutator strains also show a lower cost of 
resistance for some antibiotics (302), likely because compensatory mutations arise 




E. coli mutator strains evolved similar mechanisms of resistance as non-mutators, but 
they did so more quickly and to a higher level with little fitness cost (303); similar 
results were found in P. aeruginosa (304). While mutator phenotypes may prove useful 
during short-term pulses of environmental stress (such as a course of antibiotics), they 
are not a viable long-term evolutionary strategy as high mutation rates necessarily lead 
to high rates of death and accumulation of deleterious mutations (305). 
The impact of mutator strains on interspecies interactions remains understudied. One 
group found that mutS– deficient P. aeruginosa outcompeted wild-type strains in biofilm 
formation but not planktonic growth. This success was driven largely by enhanced 
phenotypic diversification of the mutator strain in biofilms, which the authors suggest 
led to greater niche expansion and a more specialized set of biofilm functions (306). 
This result could also apply in multispecies systems, particularly in colonization 
scenarios. Mutator genotypes may give some species a competitive edge as they attempt 
to colonize a new environment with a new carbon source, for example. They might also 
be able to more effectively evolve resistance to antimicrobials produced by competitor 
species. An analysis of wild-type versus mutator strain growth rates on rich versus 
minimal media showed that mutators incur a much greater growth deficit on minimal 
media than wild-type strains (307). This suggests that one of the consequences of the 
mutator phenotype is a dependence on a rich nutrient environment to compensate for the 
deleterious effects of an increased mutation rate. Based on this result, I would predict 
that mutator strains would fare poorly in cooperative communities, where nutrient access 
is limited to that which a metabolic partner can provide. A spatially structured 




concentration of nutrient exchange in these environments might allow mutator strains to 
survive. However, the greater evolvability of mutator strains also increases the 
likelihood that cheaters will arise, as was observed in a study of cooperative siderophore 
production in P. aeruginosa (308). Similarly, cheaters evolved more frequently in a 
mutator population of P. aeruginosa infecting a caterpillar, as did increased virulence 
and growth rate (309). Again, this suggests that mutator strains should fare poorly in 
metabolically cooperative communities. I suspect that they arose in our evolution 
experiments as a response to antibiotic pressure, and that if I were to continue evolving 
the mutator-containing co-cultures in the absence of antibiotic, they would quickly 
collapse or lose the mutator genotype.  
Competition as a driver of resistance ecology and evolution 
Some research has been conducted on how inter– and intraspecies interactions, 
particularly competitive interactions, impact microbial populations. Resource 
competition decreases the frequency of resistant genotypes within a population in the 
absence of antibiotic pressure, particularly when resistant genotypes have a fitness cost 
(133, 188). Additionally, competitors can slow the evolution of resistance within a 
population simply by reducing population size (133, 188, 310), though competition 
between co-evolving Staphylococcus aureus strains was shown to facilitate the evolution 
of clinically relevant vancomycin resistance (136). In contrast, competitors that produce 
antibiotics can increase selection for resistance within a population (20). Nutrient 
availability and antibiotic concentration can also modulate competitive fitness and 
species frequencies, as recently demonstrated in a competitive two-species community 




C. glabrata was outcompeted in the absence of fluconazole as expected; however, when 
glucose concentrations were increased, C. glabrata dominated the community even in 
the absence of antifungals (134). The presence of the blue-green alga Scenedesmus 
obliquus was also shown to increase the susceptibility of the primary producer 
cyanobacterium Microcystis aeruginosa to the antibiotic enrofloxacin (311). Changes in 
carbon source have also been shown to modulate the mechanism and level of resistance 
evolution (212). This suggests that nutrient exchange and availability may modulate 
resistance in microbial communities, and that looking at cooperative species interactions 
may be particularly relevant for resistance studies.  
While competitive/ independent microbial communities were addressed somewhat in 
chapter 2, most of my work has solely focused on obligate cross-feeding interactions. 
However, in natural microbial communities, and even in our model community, 
competitive interactions are occurring alongside, and likely more frequently, than 
cooperative ones (26, 268, 312, 313). Recent work from our lab has illustrated how 
scaling between cooperative and competitive interactions between our species can 
change ecological dynamics and even community survival (192). A common mechanism 
of interference competition that arises in bacteria is antibiotic production (26, 314, 315); 
what happens when this arises in the context of cross-feeding? An informative 
experiment could be done wherein two species, cross-feeding for some nutrients (for 
example, amino acids) and competing for another (for example, carbon) are mixed 
together. One species produces an antibiotic; the other is susceptible. The stability of this 
co-culture (in terms of maintaining species ratios) would be contingent on a number of 




the sensitive species; the relative growth rates of each species and their uptake rates for 
the carbon source (192); and the fitness costs and benefits of antibiotic production (314). 
A model such as that described in Kosakowski et al. (316), which involved an antibiotic 
producer, a cheater, and a sensitive strain, might be easily modified to test this 
possibility. A cross-feeding interaction between the producer/ cheater species and the 
sensitive species could be engineered, for example, and the ratio of producer to cheater 
examined over time. Given the complex and environmentally dependent nature of 
microbial interactions, it is easy to see this scenario arising in, for example, a soil 
bacterial community where Streptomyces species produce a wide array of antibiotics 
(317, 318) but also frequently exchange metabolites with surrounding species (319, 
320). Understanding how these different selection pressures interact, therefore, might 
have important implications for the discovery of new antibiotics and their effects on 
microbial communities. 
In addition to the monoculture and obligate cooperative co-culture lines in chapter 3, I 
also evolved a competitive community of E. coli and S. enterica grown in glucose and 
methionine. In this experiment, E. coli and S. enterica competed for both nitrogen and 
carbon, although nitrogen is not limiting in our growth medium. I performed the 
evolution experiments but have not yet performed any analyses of these populations; 
identifying the relative rates of resistance evolution in competitive versus monoculture 
communities will investigate whether competition increases or decreases rate and level 
of resistance acquisition. Additionally, sequencing of the resistance mutations in these 
populations will prove informative for identifying whether different resistance mutations 




Antibiotics with disproportionate impacts on cross-feeding communities 
The concept of shared/ public-goods resistance, which arose in spatially structured 
communities in chapter 2, offers some interesting evolutionary dynamics questions in 
cross-feeding systems. While it is well-established that shared resistance can protect 
sensitive species in various contexts (120–122, 146, 321–323), the additional influence 
of metabolic interactions has yet to be explored. In the scenarios cited above, antibiotic 
degradation can be thought of as a public good, where the producer (the β-lactamase– 
producing species, say) provides a benefit to other species. This is a cheater scenario, as 
the producer carries a production cost while likely competing with non-producers for 
resources. Even if degradation selectively benefits the producer over the non-producer 
species, as is likely the case where the β-lactamase or other degradation enzymes are 
confined to the periplasm, the benefits of antibiotic degradation is not limited to the 
producer species (324). However, β-lactamase production is known to have a high 
fitness cost, possibly due to its impacts on peptitoglycan metabolism (325–327). What 
impact might this have on a cross-feeding community, where the non-producer species 
receive a protective benefit in terms of the β-lactamase, but may be harmed if β-
lactamase production disrupts metabolite exchange from the producer species? 
Alternatively, how might the presence of an obligate cross-feeding partner impact the 
selection pressure on which resistance mechanisms arise over time? I predict that the 
metabolic costs of losing a cross-feeding partner would outweigh the fitness costs of 
producing high quantities of a public-goods resistance mechanism. An experimental 
evolution study in a cross-feeding community where at least one species has the genetic 




Methylobacterium extorquens, which I have shown can produce a β-lactamase) would 
shed light on this question.  
In terms of testing the impact of antibiotic combinations in situations where antibiotic 
degradation occurs, a checkerboard assay may prove insufficient to detect degradation. 
Another method worth exploring is the E-test method, which involves laying filter paper 
strips containing gradients of antibiotics at right angles on bacteria growing on Petri 
plates (258, 328). Particularly in cases where resistant species may produce an 
antibiotic-degrading enzyme such as a β-lactamase, the least resistant species gains a 
protective effect from community growth in a spatially structured environment (124, 
329). We observed that β-lactamase– based protection of E.coli and S. enterica by M. 
extorquens only occurred in spatially structured environments, not in liquid (120); others 
have observed this as well (55). This may also be the case in an E-test scenario, where 
spatial structure and publicly available resistance might shift the antibiotic interaction 
towards the resistance-producing species and away from the weakest link species. As 
many bacterial infections exist in a spatially structured environment (e.g. biofilms), this 
is an important avenue of research to pursue.  
The phenotypic or genetic disruption of metabolism by antibiotics and antibiotic 
resistance mutations, respectively, is another unexplored area where metabolically 
interconnected community antibiotic responses might differ from those in monoculture. 
Sulfa drugs, such as trimethoprim, interfere with folate biosynthesis and resistance to 
these is often achieved through a metabolic workaround. Cells may acquire mutations in 
folate biosynthesis gene promoters that increases expression of folate biosynthesis 




to allow for uptake and utilization of exogenous folate sources (61). Either of these 
changes could potentially change cross-feeding interactions, though whether the 
interactions are broken or strengthened is an open question. One species might gain an 
efflux pump resistance mutation to trimethoprim, for example, and might subsequently 
evolve folate excretion to preserve its sensitive partner. Or, the upregulation of folate 
biosynthesis machinery in one species might decrease the amount of cross-fed nutrient it 
is able to provide its partner, leading to a decrease in community productivity. These 
disruptions are difficult to predict in monoculture, let alone in multispecies cross-feeding 
systems. However, one study combined metabolic models of C. difficile with 
transcriptomic data from several environments, including exposure to sublethal 
antibiotics, to predict therapeutic targets that would disrupt C. difficile metabolism 
(330). A similar approach could be used for a defined cross-feeding community such as 
ours, where the transcriptome of each species could be measured in the presence of 
sublethal antibiotic concentrations and added to our established metabolic models as 
described in the above study. I could then use Computation of Microbial Ecosystems in 
Time and Space (COMETS), a multispecies metabolic modeling platform (159), to 
predict the metabolic impacts of antibiotics on an obligate co-culture.  
Clinical relevance 
One of the main challenges (and indeed, one of the main weaknesses of this work that 
has often been pointed out to me) is that its clinical relevance is unclear due to the model 
nature of our experimental system. My research assumes and depends on cross-feeding 
interactions between bacterial species being identified both in terms of their obligacy 




a rare case of a well-characterized clinically relevant cross-feeding interaction; other 
examples may be found in dental plaque and Pseudomonas-Staphylococcus interactions 
in skin infections (20), but these are rare. Far more common is a scenario where an 
infection may be associated with multiple species of bacteria, but the nature of their 
interaction is either unknown or more complex than metabolic cross-feeding (e.g. 
involves horizontal gene transfer, toxin production, quorum sensing and quenching, 
etc.). It is unclear how the weakest link hypothesis would generalize to such a system, 
where bacteria are likely to be both helping and harming each other. What is clear from 
my work is that antibiotic pressure has the potential (though not the guarantee) of 
impacting microbial communities indirectly, particularly when key species in microbial 
food webs are disrupted. Further research into the microbial ecology of infections might 
then be informed by my research as to which keystone species would be most effectively 
targeted to disrupt the community.  
An additional layer of complexity in natural systems as opposed to our model 
community is that of the nutrient environment, which may affect both the obligacy and 
the stability of cross-feeding interactions. Previous work from our lab has shown that 
nutrient addition can break even obligate metabolic dependencies under certain 
conditions (192); therefore, nutrient disruption of the system could nullify weakest link 
responses to antibiotics. Fortunately, many infection contexts in particular are known to 
be nutrient-limited environments (331–334); however, in a site such as the human gut, 
nutrient influxes are likely to be constantly changing metabolic interactions between 
species (335, 336). This raises the possibility of using prebiotics in combination with 




as a means to selectively boost growth of beneficial bacteria (337, 338), and some 
studies have found this to be effective at ameliorating dysbioses in human-associated 
microbial communities such as the gut and the oral cavity (339–341). However, they 
might also be useful in boosting particular keystone species or altering the metabolic 
environment of the gut such that pathogens become dependent on cross-fed versus 
environmentally derived nutrients (as Pseudomonas is in the human CF lung), antibiotic-
mediated targeting of the pathogen’s cross-feeding partner may become much more 
effective. However, this approach again makes several assumptions that are unlikely to 
hold true. First, it assumes that the cross-feeding interactions involved in the infection 
are well-known, which is unlikely; second, it assumes that addition of a prebiotic will 
sufficiently alter the nutrient environment to affect a shift in cross-feeding interactions, 
which is unknown; third, it again relies on a narrow-spectrum antibiotic that will target 
only the pathogen’s cross-feeder and not disrupt the rest of the community, which is also 
unlikely; and fourth, it assumes a single pathogen is solely responsible for causing the 
disease state, which is may or may not be accurate.  
So what, then, can be derived from my research in terms of its application to the clinic? 
First, in the rare cases where cross-feeding interactions are known in an infection, the 
weakest link hypothesis at least provides an additional antibiotic target. If a pathogen is 
difficult to treat due to resistance or drug toxicity, targeting a cross-feeding partner may 
allow a lower dose or a less toxic antibiotic to be administered successfully. This may be 
particularly useful in cases where bacterial load is highly predictive of patient outcomes 
(342–344), or in cases where multiple antibiotics are administered, as shown in chapter 




relevant microbes and will hopefully motivate further research in the area. Third, it may 
serve as a useful null hypothesis during infection ecology research— if weakest link 
eco-evolutionary dynamics are not arising in these systems upon antibiotic application, 
other factors such as antibiotic breakdown (chapter 2), sublethal resistance evolution 
(chapter 3), or other factors such as partner-mediated tolerance induction (123, 124) 
might be useful, testable explanations.  
An alternative clinical approach suggested by my research is the development of 
metabolite exchange inhibitors as antibiotic adjuvants. Indeed, this approach has been 
suggested as a way to treat Pseudomonas aeruginosa infections— blocking species 
specific central metabolism genes with small-molecule inhibitors might force the 
pathogen into a more antibiotic-sensitive metabolic state, or kill it outright (345). 
Metabolic inhibitors might also serve to disrupt the ability of a pathogen to obtain 
essential metabolites from neighboring species, without the slash-and-burn approach of 
antibiotics that is known to disrupt microbial community structure (346–351). Amino 
acid transporters might be a particularly useful target, as amino acids are commonly 
exchanged in natural microbial communities and amino acid auxotrophies are commonly 
found in metagenomic studies (44, 352, 353). Metabolic model building with whole-
genome sequences from pathogens would allow identification of missing amino acid 
biosynthesis pathways in specific pathogens; inhibitors could then be designed that 
prevent uptake of that metabolite in the pathogen (if the import protein is known), or 
excretion of that metabolite in the neighboring community (again, if known).  
While metabolite exchange inhibitors are an intriguing possibility, the substantial 




suggests a related but more immediately available approach might prove more useful. 
While my research has not specifically tested or shown this, it is possible that the 
stability of our cross-feeding system in the face of antibiotic pressure is dependent on 
the maintenance of a metabolic state wherein the necessary metabolites can be supplied 
to each species. It stands to reason that, if an antibiotic were to sufficiently shift cellular 
metabolism away from production and export of these metabolites without killing the 
producer or receiver species, it is possible that sublethal antibiotic concentrations would 
be sufficient to disrupt a pathogenic microbial community. Sulfa drugs and other 
antibiotics known to disrupt microbial metabolism might be particularly useful in this 
regard, as described above. The advantage of this approach is that the precise nature of 
the metabolic interaction need not be known, only the direction— possibly making the 
implementation of this approach more clinically useful.  
Despite the strong influence of environmental context on resistance mutation fitness 
costs, laboratory studies of fitness costs do appear to have clinical relevance as the 
selected resistance alleles in lab studies are also observed in clinical cases. However, it 
is less clear whether quantification of resistance, such as by MIC, can be extrapolated 
from the lab to the clinic (60). This may be for a number of reasons, such as host 
microenvironments, which are often acidic (pH~5.5), altering the tolerance of 
pathogenic bacteria to a variety of antibiotics (354), differences in nutrient availability in 
lab vs. host environments (355), and other in vivo pharmacokinetic considerations in 
drug solubility, metabolism, and excretion (356–358). The evolution of compensatory 
mutations which decrease the fitness costs of resistance mutations has proven 




clinic. If treatment regimens are too long, resistant mutants are able to reach large 
population sizes, which increases the likelihood of compensatory mutations arising 
which offset the costs of resistance. This is difficult to study in the lab, however, as 
different compensatory mutations are known to evolve in lab vs. clinical environments 
(60). A notable example of this is fluoroquinolone resistance in E. coli clinical isolates. 
The most common first resistance mutation is rare (small target size in gyrA) but has the 
largest MIC increase with the smallest fitness cost. The second resistance mutation 
differs in vitro vs. in clinical isolates; in the former, a mutation in an efflux pump (which 
is more common but more costly) is selected, whereas in the latter, a mutation in another 
topoisomerase (which is rarer but less costly) is selected (68). Whether the microbial 
community context has an impact in these cases remains to be seen but may be worth 
exploring as a way to better predict and screen for resistance mutations in clinical 
isolates.  
Ecological implications  
One interesting extension of our weakest link hypothesis is how it might inform the 
impact of climate change or other abiotic disturbances on symbioses in macroecological 
contexts. Predicting the effects of climate change on global ecological systems has 
proven challenging, often because the direct and indirect effects of climate change on 
mutualistic interactions and the species therein remain unclear (359). Microbes are 
frequently used as model systems in evolutionary biology because of their large 
population sizes, rapid generation time, and relative ease of manipulability. Our system, 
therefore, might be considered as a model for how symbioses respond to abiotic 




study on antibiotic resistance in pathogenic bacteria. Based on my results, I would 
predict that the mutualism members which are most sensitive to abiotic environmental 
fluctuations (such as changes in temperature, humidity, etc.) will define whether the 
mutualism survives a given abiotic disturbance. It would be interesting to examine 
mechanisms of cross-protection in macroscopic mutualisms that mirror antibiotic 
degradation in bacterial communities, for example. Mutualists which are able to protect 
their sensitive partners from environmental changes should be more stable than those 
without such collective resistance mechanisms. 
Northfield and Ives (2002) modelled the effects of climate change/ environmental 
stresses on mutualistic, competitive, and predator-prey relationships. Their model was 
able to tune how a trait value of one species impacted the fitness of the other, either 
detrimentally (conflicting co-evolution) or non-detrimentally (non-conflicting co-
evolution). They showed that, under conflicting co-evolution parameters, the impact of 
environmental change on species densities is decreased. This is because the fitness 
decrease in species B caused by the change in the species A trait leads species B to 
evolve to be less invested in the mutualism. In contrast, under nonconflicting co-
evolution, the benefits that a change in the species A trait confers on species B leads 
species B to be more invested in the mutualism. This suggests that, in mutualisms where 
trait changes caused by climate change have a positive impact on the secondary species, 
the mutualism will become more susceptible to environmental change due to increased 
investment in the mutualism by species B (359). I could test this hypothesis by co-
evolving our system under different antibiotic selection regimes which selectively target 




lactam antibiotics whereas the other two species are highly sensitive, and S. enterica is 
highly resistant to tetracycline. I could also use our system to study how increases in 
temperature (as a proxy to increasing global temperatures) might affect mutualisms. M. 
extorquens is unable to grow above 30OC, but E. coli and S. enterica grow optimally at 
37OC. An evolution experiment examining the stability of the mutualism in response to 
rising growth temperatures should yield some interesting insights that could be 
extrapolated to macroscopic mutualisms wherein partners have discordant temperature 
sensitivities.  
My weakest link hypothesis, in conjunction with the Harcombe lab model microbial 
system, might also be a useful tool in empirically testing the insurance hypothesis. This 
theory states that increases in species diversity in an ecosystem should ‘insure’ 
ecosystem function against environmental disturbances and prevent ecosystem collapse. 
This is because a greater number of species increases the likelihood that loss of one 
species due to the environmental disturbance will be compensated for by another (360–
362). While this hypothesis has been tested (and upheld) in numerous microbial 
communities (52, 363–366), it has yet to be tested in a cooperative microbial 
community. Cooperation is expected to stabilise species ratios (53, 192), whereas 
competition is expected to stabilize biomass, as predicted in the insurance hypothesis. 
An important corollary of the insurance hypothesis is that community biomass is 
expected to be stabilized along an environmental stressor gradient; species ratios should 
fluctuate along this gradient as per their individual resistances to the stressor, but total 
biomass should remain constant provided the species have sufficiently different 




therefore, might involve growing our community in obligate versus competitive co-
culture along opposing antibiotic gradients. I would predict that the competitive co-
culture would maintain total biomass but potentially lose species as the concentration of 
some antibiotic rose above its tolerance. However, in cooperative co-culture, weakest 
link dynamics should prevent much growth at all, since scaling across two antibiotic 
gradients may change the identity of the weakest link species but not the impact of the 
weakest link on community antibiotic tolerance. Finally, it would be interesting to scale 
between mutualistic, facilitative, and competitive interactions as described by 
Hammarlund et al. (192), to see how modulating interspecies interactions influences 
tolerance to opposing antibiotic gradients. A facilitative community, wherein cross-
feeding occurs but is not required for survival, should be able to maintain species 
richness and biomass most effectively. This community is not constrained by weakest 
link dynamics but also contains positive interactions, which have been shown to aid in 
maintenance of biodiversity, particularly in harsh environments (368–370).  
Final Thoughts 
The challenges of predicting and mitigating the evolution of antibiotic resistance, as well 
as coping with already resistant bacteria, remains a formidable and imposing problem. 
The role of interspecies interactions in modulating resistance ecology and evolution, 
therefore, is increasingly pressing— particularly as the role of microbial communities in 
human health is growing as well. My research sheds light on how cooperative metabolic 
interactions might change how bacteria respond to antibiotics, both in the short term and 
over evolutionary time. Crucially, the existence of weakest link dynamics, wherein the 




community to antibiotics, offers a novel target in developing more effective antibiotic 
treatment strategies. While this body of work represents a critical step forward in this 
field, there remains much work to be done if we are to avoid returning to a world where 





Chapter 5 Figures 
 
Figure 5.1 Log2MICs of populations vs. isolates from each population evolved under 
rifampicin selection in E. coli– S. enterica obligate co-culture. Population MICs were re-
measured from passage 20 isolates frozen and re-grown along a rifampicin gradient for 
48 hours with shaking at 30OC. Isolates of each species were also isolated from these 
populations and their individual MICs measured as above. Colors represent different 
populations, and shapes represent different culture types (triangle for populations, circle 
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